WO2000055375A1

WO2000055375A1 - Secreted proteins and polynucleotides encoding them

Info

Publication number: WO2000055375A1
Application number: PCT/US2000/007285
Authority: WO
Inventors: Dario Valenzuela; Olive Yuan; Heidi Hoffman; Jeff Hall; Peter Rapiejko
Original assignee: Alphagene, Inc.
Priority date: 1999-03-17
Filing date: 2000-03-17
Publication date: 2000-09-21
Also published as: AU3899700A

Abstract

Novel polynucleotides and the proteins encoded thereby are disclosed.

Description

SECRETED PROTEINS AND POLYNUCLEOTIDES ENCODING THEM

This application is a continuation-in-part of the following applications:

(1) provisional application Ser. No. 60/124,916, filed March 17, 1999;

(2) provisional application Ser. No. 60/124,808, filed March 17, 1999;

(3) provisional application Ser. No. 60/149,639, filed August 17, 1999;

(4) provisional application Ser. No. 60/157,247, filed October 1, 1999; (5) provisional application Ser. No. 60/167,824, filed November 29, 1999; (6) provisional application Ser. No. 60/182,711 , filed February 15, 2000; all of which are incorporated by reference herein.

FIELD OF THE INVENTION The present invention provides novel polynucleotides and proteins encoded by such polynucleotides, along with therapeutic, diagnostic and research utilities for these polynucleotides and proteins.

BACKGROUND OF THE INVENTION Technology aimed at the discovery of protein factors (including e.g., cytokines, such as lymphokines, interferons, CSFs and interleukins) has matured rapidly over the past decade. The now routine hybridization cloning and expression cloning techniques clone novel polynucleotides "directly" in the sense that they rely on information directly related to the discovered protein (i.e., partial DNA amino acid sequence ofthe protein in the case of hybridization cloning; activity of the protein in the case of expression cloning). More recent "indirect" cloning techniques such as signal sequence cloning, which isolates DNA sequences based on the presence of a now well-recognized secretory leader sequence motif, as well as various PCR-based or low stringency hybridization cloning techniques, have advanced the state ofthe art by making available large numbers of DNA/amino acid sequences for proteins that are known to have biological activity by virtue of their secreted nature in the case of leader sequence cloning, or by virtue of the cell or tissue source in the case of PCR-based techniques. It is to these proteins and the polynucleotides encoding them that the present invention is directed. SUMMARY OF THE INVENTION In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NOJ;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 1 from nucleotide 27 to nucleotide 260;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 1 from nucleotide 72 to nucleotide 260; (d) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone vc62_l deposited with the ATCC under accession number 207114;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vc62_l deposited with the ATCC under accession number 207114;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vc62_l deposited with the ATCC under accession number 207114;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vc62_l deposited with the ATCC under accession number 207114;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:2;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:2;

(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; (1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NOJ.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NOJ from nucleotide 27 to nucleotide 260 ; the nucleotide sequence ofSEQIDNOJ from nucleotide 72 to nucleotide 260; the nucleotide sequence ofthe full-length protein coding sequence of clone vc62_l deposited with the ATCC under accession number 207114; or the nucleotide sequence of a mature protein coding sequence of clone vc62_l deposited with the ATCC under accession number 207114. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDN A insert of clone vc62_l deposited with the ATCC under accession number 207114. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 2 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:2, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment comprising the amino acid sequence from amino acid 34 to amino acid 43 of SEQ ID NO:2.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NOJ.

Further embodiments ofthe invention provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO: 1 , but excluding the poly(A) tail at the 3' end of SEQ ID NOJ; and

(ab) the nucleotide sequence of the cDN A insert of clone vc62_l deposited with the ATCC under accession number 207114;

(ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of: (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NOJ , but excluding the poly (A) tail at the 3' end of SEQ ID NOJ; and (bb) the nucleotide sequence of the cDN A insert of clone vc62_l deposited with the ATCC under accession number 207114; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 1 , and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO: 1 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO: 1 , but excluding the poly(A) tail at the 3' end of SEQ ID NO: 1. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 1 from nucleotide 27 to nucleotide 260, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NOJ from nucleotide 27 to nucleotide 260, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NOJ from nucleotide 27 to nucleotide 260. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NOJ from nucleotide 72 to nucleotide 260, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO: 1 from nucleotide 72 to nucleotide 260JO a nucleotide sequence corresponding to the 3 ' end of said sequence of SEQ ID NO: 1 from nucleotide 72 to nucleotide 260. In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:2; (b) a fragment of the amino acid sequence of SEQ ID NO:2, the fragment comprising eight contiguous amino acids of SEQ ID NO:2; and

(c) the amino acid sequence encoded by the cDNA insert of clone vc62_l deposited with the ATCC under accession number 207114; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:2. In further preferred embodiments, the present invention provides a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:2 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:2, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment comprising the amino acid sequence from amino acid 34 to amino acid 43 of SEQ ID NO:2.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 3 from nucleotide 6 to nucleotide 1325;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3 from nucleotide 99 to nucleotide 1325; (d) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone vplO_l deposited with the ATCC under accession number 207114;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vpl0_l deposited with the ATCC under accession number 207114; (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vpl0_l deposited with the ATCC under accession number 207114;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vpl0_l deposited with the ATCC under accession number 207114;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:4;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:4;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; (1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:3. Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID

NO:3 from nucleotide 6 to nucleotide 1325; the nucleotide sequence of SEQ ID NO:3 from nucleotide 99 to nucleotide 1325; the nucleotide sequence ofthe full-length protein coding sequence of clone vpl0_l deposited with the ATCC under accession number 207114; or the nucleotide sequence of a mature protein coding sequence of clone vpl0_l deposited with the ATCC under accession number 207114. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vpl0_l deposited with the ATCC under accession number 207114. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NOJ, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NOJ having biological activity, the fragment comprising the amino acid sequence from amino acid 215 to amino acid 224 of SEQ ID NO:4.

Other embodiments provide the gene corresponding to the cDN A sequence of SEQ ID NO:3. Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of:

(aa) SEQ ID NO:3, but excluding the poly(A) tail at the 3' end of SEQ ID NO:3; and

(ab) the nucleotide sequence ofthe cDNA insert of clone vp 10_1 deposited with the ATCC under accession number 207114; (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s); and (b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:3, but excluding the poly(A) tail at the 3' end of SEQ ID NO:3; and

(bb) the nucleotide sequence of the cDN A insert of clone vp 10_1 deposited with the ATCC under accession number 207114; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 3, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:3 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO: 3 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:3. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 3 from nucleotide 6 to nucleotide 1325, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:3 from nucleotide 6 to nucleotide 1325, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO: 3 from nucleotide 6 to nucleotide 1325. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 3 from nucleotide 99 to nucleotide 1325, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:3 from nucleotide 99 to nucleotide 1325, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:3 from nucleotide 99 to nucleotide 1325.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ID NO:4;

(b) a fragment of the amino acid sequence of SEQ ID NO:4, the fragment comprising eight contiguous amino acids of SEQ ID NO:4; and

(c) the amino acid sequence encoded by the cDNA insert of clone vpl0_l deposited with the ATCC under accession number 207114; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:4. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:4, or a protein comprising a fragment of the amino acid sequence of SEQ

ID NO:4 having biological activity, the fragment comprising the amino acid sequence from amino acid 215 to amino acid 224 of SEQ ID NO:4. In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:5; (b) a polynucleotide comprising the nucleotide sequence of SEQ ID

NO:5 from nucleotide 149 to nucleotide 322;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:5 from nucleotide 200 to nucleotide 322;

(d) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone vpl 1_1 deposited with the ATCC under accession number 207114;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vpl 1_1 deposited with the ATCC under accession number 207114; (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vpl l_l deposited with the ATCC under accession number 207114;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vpl 1_1 deposited with the ATCC under accession number 207114; (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:6;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:6; (j) a polynucleotide which is an allelic variant of a polynucleotide of

(a)-(g) above;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;

(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:5.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:5 from nucleotide 149 to nucleotide 322; the nucleotide sequence of SEQ ID NO:5 from nucleotide 200 to nucleotide 322; the nucleotide sequence ofthe full-length protein coding sequence of clone vpl l_l deposited with the ATCC under accession number

207114; or the nucleotide sequence of a mature protein coding sequence of clone vpl 1_1 deposited with the ATCC under accession number 207114. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vpl l_l deposited with the ATCC under accession number

207114. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of

SEQ ID NO:6 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:6, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of

SEQ ID NO:6 having biological activity, the fragment comprising the amino acid sequence from amino acid 24 to amino acid 33 of SEQ ID NO:6.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:5.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of:

(aa) SEQ ID NO:5, but excluding the poly(A) tail at the 3' end of SEQ ID NO:5; and

(ab) the nucleotide sequence of the cDN A insert of clone vpl 1_1 deposited with the ATCC under accession number 207114;

(ba) SEQ ID NO:5, but excluding the poly(A) tail at the 3' end of SEQ ID NO:5; and (bb) the nucleotide sequence of the cDN A insert of clone vp 11_1 deposited with the ATCC under accession number 207114; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:5, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:5 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO: 5 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:5. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:5 from nucleotide 149 to nucleotide 322, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:5 from nucleotide 149 to nucleotide 322, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO: 5 from nucleotide 149 to nucleotide 322. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 5 from nucleotide 200 to nucleotide 322, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:5 from nucleotide 200 to nucleotide 322, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:5 from nucleotide 200 to nucleotide 322. In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:6; (b) a fragment of the amino acid sequence of SEQ ID NO:6, the fragment comprising eight contiguous amino acids of SEQ ID NO:6; and

(c) the amino acid sequence encoded by the cDNA insert of clone vpl 1_1 deposited with the ATCC under accession number 207114; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO: 6. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 6, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 6 having biological activity, the fragment comprising the amino acid sequence from amino acid 24 to amino acid 33 of SEQ ID NO:6.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:7;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:7 from nucleotide 288 to nucleotide 629;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:7 from nucleotide 363 to nucleotide 629; (d) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone vpl3_l deposited with the ATCC under accession number 207114;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vpl3_l deposited with the ATCC under accession number 207114; (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vpl3_l deposited with the ATCC under accession number 207114;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vp 13_1 deposited with the ATCC under accession number 207114;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:8;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 8 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO: 8;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:7. Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID

NO:7 from nucleotide 288 to nucleotide 629; the nucleotide sequence of SEQ ID NO:7 from nucleotide 363 to nucleotide 629; the nucleotide sequence ofthe full-length protein coding sequence of clone vpl3_l deposited with the ATCC under accession number 207114; or the nucleotide sequence of a mature protein coding sequence of clone vpl3_l deposited with the ATCC under accession number 207114. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vpl3_l deposited with the ATCC under accession number 207114. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 8 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:8, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 8 having biological activity, the fragment comprising the amino acid sequence from amino acid 52 to amino acid 61 of SEQ ID NO:8.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:7. Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of:

(aa) SEQ ID NO:7, but excluding the poly(A) tail at the 3' end of SEQ ID NO:7; and

(ab) the nucleotide sequence of the cDN A insert of clone vpl3_J deposited with the ATCC under accession number 207114; (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(ba) SEQ ID NO:7, but excluding the poly(A) tail at the 3' end of SEQ ID NO:7; and

(bb) the nucleotide sequence of the cDN A insert of clone vp 13_1 deposited with the ATCC under accession number 207114; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:7, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:7 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:7 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:7. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:7 from nucleotide 288 to nucleotide 629, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:7 from nucleotide 288 to nucleotide 629, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:7 from nucleotide 288 to nucleotide 629. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:7 from nucleotide 363 to nucleotide 629, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:7 from nucleotide 363 to nucleotide 629, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:7 from nucleotide 363 to nucleotide 629.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ID NO: 8;

(b) a fragment of the amino acid sequence of SEQ ID NO: 8, the fragment comprising eight contiguous amino acids of SEQ ID NO: 8; and

(c) the amino acid sequence encoded by the cDNA insert of clone vpl3_l deposited with the ATCC under accession number 207114; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO: 8. In further preferred embodiments, the present invention provides a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO: 8 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:8, or a protein comprising a fragment of the amino acid sequence of SEQ

ID NO: 8 having biological activity, the fragment comprising the amino acid sequence from amino acid 52 to amino acid 61 of SEQ ID NO:8. In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:9; (b) a polynucleotide comprising the nucleotide sequence of SEQ ID

NO:9 from nucleotide 11 to nucleotide 298;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:9 from nucleotide 149 to nucleotide 298;

(d) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone vpl6_l deposited with the ATCC under accession number 207114;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vpl6_l deposited with the ATCC under accession number 207114; (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vpl6_l deposited with the ATCC under accession number 207114;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vpl6_l deposited with the ATCC under accession number 207114; (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO: 10;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 10 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO: 10; (j) a polynucleotide which is an allelic variant of a polynucleotide of

(a)-(g) above;

(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:9.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO: 9 from nucleotide 11 to nucleotide 298; the nucleotide sequence ofSEQ ID NO:9 from nucleotide 149 to nucleotide 298; the nucleotide sequence ofthe full-length protein coding sequence of clone vp 16_ 1 deposited with the ATCC under accession number 207114 ; or the nucleotide sequence of a mature protein coding sequence of clone vpl6_l deposited with the ATCC under accession number 207114. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vpl6_l deposited with the ATCC under accession number 207114. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 10 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO : 10, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 10 having biological activity, the fragment comprising the amino acid sequence from amino acid 43 to amino acid 52 of SEQ ID NO: 10.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:9.

(aa) SEQ ID NO:9, but excluding the ρoly(A) tail at the 3' end of SEQ ID NO:9; and

(ab) the nucleotide sequence ofthe cDNA insert of clone vp 16_ 1 deposited with the ATCC under accession number 207114;

(ba) SEQ ID NO:9, but excluding the poly(A) tail at the 3' end of SEQ ID NO:9; and (bb) the nucleotide sequence of the cDN A insert of clone vp 16_ 1 deposited with the ATCC under accession number 207114; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:9, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:9 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO: 9 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:9. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:9 from nucleotide 11 to nucleotide 298, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:9 from nucleotide 11 to nucleotide 298, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO: 9 from nucleotide 11 to nucleotide 298. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:9 from nucleotide 149 to nucleotide 298, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO: 9 from nucleotide 149 to nucleotide 298, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:9 from nucleotide 149 to nucleotide 298. In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO: 10; (b) a fragment of the amino acid sequence of SEQ ID NO: 10, the fragment comprising eight contiguous amino acids of SEQ ID NO: 10; and

(c) the amino acid sequence encoded by the cDNA insert of clone vpl6_l deposited with the ATCC under accession number 207114; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO: 10. In further preferred embodiments, the present invention provides a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO: 10 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO : 10, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 10 having biological activity, the fragment comprising the amino acid sequence from amino acid 43 to amino acid 52 of SEQ ID NO: 10.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NOJ 1;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 11 from nucleotide 257 to nucleotide 607;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 11 from nucleotide 479 to nucleotide 607; (d) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone vp21_l deposited with the ATCC under accession number 207114;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vp21_l deposited with the ATCC under accession number 207114; (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vp21_l deposited with the ATCC under accession number 207114;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vp21 _ 1 deposited with the ATCC under accession number 207114;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO: 12;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 12 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO: 12;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO: 11. Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID

NO: 11 from nucleotide 257 to nucleotide 607; the nucleotide sequence of SEQ ID NO: 11 from nucleotide 479 to nucleotide 607; the nucleotide sequence ofthe full-length protein coding sequence of clone vp21_l deposited with the ATCC under accession number 207114; or the nucleotide sequence of a mature protein coding sequence of clone vp21_l deposited with the ATCC under accession number 207114. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vp21_l deposited with the ATCC under accession number 207114. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 12 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 12, or a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO: 12 having biological activity, the fragment comprising the amino acid sequence from amino acid 53 to amino acid 62 of SEQ ID NO: 12.

Other embodiments provide the gene conesponding to the cDNA sequence of SEQ ID NOJ 1. Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of:

(aa) SEQ ID NO: 11 , but excluding the poly( A) tail at the 3' end of SEQ ID NOJ 1; and

(ab) the nucleotide sequence ofthe cDNA insert of clone vp21 _ 1 deposited with the ATCC under accession number 207114; (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(ba) SEQ ID NO: 11 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:l l; and

(bb) the nucleotide sequence of the cDN A insert of clone vp21_1 deposited with the ATCC under accession number 207114; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NOJ 1, and extending contiguously from a nucleotide sequence conesponding to the 5' end of SEQ ID NO: 11 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO: 11 , but excluding the poly (A) tail at the 3' end of SEQ ID NOJ 1. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO: 11 from nucleotide 257 to nucleotide 607, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO: 11 from nucleotide 257 to nucleotide 607, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO: 11 from nucleotide 257 to nucleotide 607. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO: 11 from nucleotide 479 to nucleotide 607, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO: 11 from nucleotide 479 to nucleotide 607, to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ ID NO: 11 from nucleotide 479 to nucleotide 607.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ID NO: 12;

(b) a fragment of the amino acid sequence of SEQ ID NO: 12, the fragment comprising eight contiguous amino acids of SEQ ID NO: 12; and

(c) the amino acid sequence encoded by the cDNA insert of clone vp21_l deposited with the ATCC under accession number 207114; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO: 12. In further prefened embodiments, the present invention provides a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO: 12 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 12, or a protein comprising a fragment of the amino acid sequence of SEQ

ID NO: 12 having biological activity, the fragment comprising the amino acid sequence from amino acid 53 to amino acid 62 of SEQ ID NO: 12. In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 13; (b) a polynucleotide comprising the nucleotide sequence of SEQ ID

NOJ 3 from nucleotide 163 to nucleotide 477;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 13 from nucleotide 238 to nucleotide 477;

(d) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone vp22_l deposited with the ATCC under accession number 207114;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vp22_l deposited with the ATCC under accession number 207114; (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vp22_l deposited with the ATCC under accession number 207114;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vp22_l deposited with the ATCC under accession number 207114; (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO: 14;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 14 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO: 14; (j) a polynucleotide which is an allelic variant of a polynucleotide of

(a)-(g) above;

(k) a polynucleotide which encodes a species homologue ofthe protein of (h) or (i) above ;

(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO: 13.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO: 13 from nucleotide 163 to nucleotide 477; the nucleotide sequence of SEQ ID NO: 13 from nucleotide 238 to nucleotide 477; the nucleotide sequence ofthe full-length protein coding sequence of clone vp22_l deposited with the ATCC under accession number

207114; or the nucleotide sequence of a mature protein coding sequence of clone vp22_l deposited with the ATCC under accession number 207114. In other prefened embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vp22_l deposited with the ATCC under accession number

SEQ ID NO: 14 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 14, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of

SEQ ID NO: 14 having biological activity, the fragment comprising the amino acid sequence from amino acid 47 to amino acid 56 of SEQ ID NO: 14.

Other embodiments provide the gene conesponding to the cDNA sequence of SEQ ID NOJ3.

(aa) SEQ ID NO: 13, but excluding the poly(A) tail atthe 3' end of SEQ ID NO: 13; and

(ab) the nucleotide sequence of the cDN A insert of clone vp22_l deposited with the ATCC under accession number 207114;

(ba) SEQ ID NO: 13, but excluding the poly (A) tail at the 3' end of SEQ ID NO: 13; and (bb) the nucleotide sequence of the cDN A insert of clone vp22_l deposited with the ATCC under accession number 207114; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 13, and extending contiguously from a nucleotide sequence conesponding to the 5' end of SEQ ID NO: 13 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO: 13 , but excluding the poly(A) tail at the 3' end of SEQ ID NO: 13. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 13 from nucleotide 163 to nucleotide 477, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO: 13 from nucleotide 163 to nucleotide 477 , to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO: 13 from nucleotide

163 to nucleotide 477. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 13 from nucleotide 238 to nucleotide 477, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO: 13 from nucleotide 238 to nucleotide 477, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO: 13 from nucleotide 238 to nucleotide 477. In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO: 14; (b) a fragment of the amino acid sequence of SEQ ID NO: 14, the fragment comprising eight contiguous amino acids of SEQ ID NO: 14; and

(c) the amino acid sequence encoded by the cDNA insert of clone vp22_l deposited with the ATCC under accession number 207114; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO: 14. In further prefened embodiments, the present invention provides a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO: 14 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 14, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 14 having biological activity, the fragment comprising the amino acid sequence from amino acid 47 to amino acid 56 of SEQ ID NO: 14.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 15;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 15 from nucleotide 58 to nucleotide 624;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 15 from nucleotide 106 to nucleotide 624; (d) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone vq2_l deposited with the ATCC under accession number 207114;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vq2_l deposited with the ATCC under accession number 207114; (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vq2_l deposited with the ATCC under accession number 207114;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vq2_ 1 deposited with the ATCC under accession number 207114;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO: 16;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 16 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO: 16;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO: 15. Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID

NO: 15 from nucleotide 58 to nucleotide 624; the nucleotide sequence of SEQ ID NO: 15 from nucleotide 106 to nucleotide 624; the nucleotide sequence ofthe full-length protein coding sequence of clone vq2_l deposited with the ATCC under accession number 207114; or the nucleotide sequence of a mature protein coding sequence of clone vq2_l deposited with the ATCC under accession number 207114. In other prefened embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vq2_l deposited with the ATCC under accession number 207114. In further prefened embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 16 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 16, or a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO: 16 having biological activity, the fragment comprising the amino acid sequence from amino acid 89 to amino acid 98 of SEQ ID NOJ 6.

Other embodiments provide the gene conesponding to the cDN A sequence of SEQ ID NO: 15. Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of:

(aa) SEQ ID NO: 15, but excluding the ρoly(A) tail at the 3' end of SEQ ID NO: 15; and

(ab) the nucleotide sequence of the cDN A insert of clone vq2_l deposited with the ATCC under accession number 207114; (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(ba) SEQ ID NO: 15, but excluding the poly (A) tail at the 3' end of SEQ ID NO: 15; and

(bb) the nucleotide sequence of the cDN A insert of clone vq2_l deposited with the ATCC under accession number 207114; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO: 15, and extending contiguously from a nucleotide sequence conesponding to the 5' end of SEQ ID NOJ5 to a nucleotide sequence conesponding to the 3' end of SEQ ID NO: 15 , but excluding the poly(A) tail at the 3' end of SEQ ID NO: 15. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDN A sequence of SEQ ID NO: 15 from nucleotide 58 to nucleotide 624, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO: 15 from nucleotide 58 to nucleotide 624, to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ ID NO: 15 from nucleotide 58 to nucleotide 624. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO: 15 from nucleotide 106 to nucleotide 624, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO: 15 from nucleotide 106 to nucleotide 624, to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ ID NO: 15 from nucleotide 106 to nucleotide 624.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ID NOJ 6;

(b) a fragment of the amino acid sequence of SEQ ID NO: 16, the fragment comprising eight contiguous amino acids of SEQ ID NO: 16; and

(c) the amino acid sequence encoded by the cDNA insert of clone vq2_l deposited with the ATCC under accession number 207114; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO: 16. In further preferred embodiments, the present invention provides a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO: 16 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 16, or a protein comprising a fragment of the amino acid sequence of SEQ

ID NOJ 6 having biological activity, the fragment comprising the amino acid sequence from amino acid 89 to amino acid 98 of SEQ ID NOJ6. In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 17; (b) a polynucleotide comprising the nucleotide sequence of SEQ ID

NO: 17 from nucleotide 773 to nucleotide 1090;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 17 from nucleotide 842 to nucleotide 1090;

(d) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone vq3_l deposited with the ATCC under accession number 207114;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vq3_l deposited with the ATCC under accession number 207114; (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vq3_l deposited with the ATCC under accession number 207114;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vq3_l deposited with the ATCC under accession number 207114; (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO: 18;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 18 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO: 18; (j) a polynucleotide which is an allelic variant of a polynucleotide of

(a)-(g) above;

(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO: 17.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO: 17 from nucleotide 773 to nucleotide 1090; the nucleotide sequence of SEQ ID NO: 17 from nucleotide 842 to nucleotide 1090; the nucleotide sequence ofthe full-length protein coding sequence of clone vq3_l deposited with the ATCC under accession number

207114; or the nucleotide sequence of a mature protein coding sequence of clone vq3_l deposited with the ATCC under accession number 207114. In other prefened embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vq3_l deposited with the ATCC under accession number

207114. In further prefened embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of

SEQ ID NO: 18 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 18, or a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of

SEQ ID NO: 18 having biological activity, the fragment comprising the amino acid sequence from amino acid 48 to amino acid 57 of SEQ ID NO: 18.

Other embodiments provide the gene conesponding to the cDNA sequence of SEQ ID NO: 17.

(aa) SEQ ID NO: 17, but excluding the poly(A) tail at the 3' end of SEQ ID NO: 17; and

(ab) the nucleotide sequence of the cDNA insert of clone vq3_l deposited with the ATCC under accession number 207114;

(ba) SEQ ID NO: 17, but excluding the poly(A) tail at the 3' end of SEQ ID NO: 17; and (bb) the nucleotide sequence of the cDN A insert of clone vq3_l deposited with the ATCC under accession number 207114; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO: 17, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO: 17 to a nucleotide sequence conesponding to the 3' end of SEQ ID NO: 17 , but excluding the poly(A) tail at the 3' end of SEQ ID NO: 17. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NOJ 7 from nucleotide 773 to nucleotide 1090, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO: 17 from nucleotide 773 to nucleotide 1090, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO: 17 from nucleotide

773 to nucleotide 1090. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO: 17 from nucleotide 842 to nucleotide 1090, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO: 17 from nucleotide 842 to nucleotide 1090, to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ ID NO: 17 from nucleotide 842 to nucleotide 1090. In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO: 18; (b) a fragment of the amino acid sequence of SEQ ID NO: 18, the fragment comprising eight contiguous amino acids of SEQ ID NO: 18; and

(c) the amino acid sequence encoded by the cDNA insert of clone vq3_J deposited with the ATCC under accession number 207114; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO: 18. In further prefened embodiments , the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 18 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 18, or a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO: 18 having biological activity, the fragment comprising the amino acid sequence from amino acid 48 to amino acid 57 of SEQ ID NO: 18.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NOJ9;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 19 from nucleotide 96 to nucleotide 275;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 19 from nucleotide 159 to nucleotide 275; (d) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone vq5_l deposited with the ATCC under accession number 207114;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vq5_l deposited with the ATCC under accession number 207114; (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vq5_J deposited with the ATCC under accession number 207114;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vq5_l deposited with the ATCC under accession number 207114;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:20;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:20 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:20;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO: 19. Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID

NO: 19 from nucleotide 96 to nucleotide 275; the nucleotide sequence of SEQ ID NO: 19 from nucleotide 159 to nucleotide 275; the nucleotide sequence ofthe full-length protein coding sequence of clone vq5_l deposited with the ATCC under accession number 207114; or the nucleotide sequence of a mature protein coding sequence of clone vq5_l deposited with the ATCC under accession number 207114. In other prefened embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vq5_J deposited with the ATCC under accession number 207114. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:20 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:20, or a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:20 having biological activity, the fragment comprising the amino acid sequence from amino acid 25 to amino acid 34 of SEQ ID NO:20.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO: 19. Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of:

(aa) SEQ ID NO: 19, but excluding the poly( A) tail at the 3' end of SEQ ID NOJ9; and

(ab) the nucleotide sequence of the cDN A insert of clone vq5_l deposited with the ATCC under accession number 207114; (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(ba) SEQ ID NO: 19, but excluding the poly( A) tail at the 3' end of SEQ ID NO: 19; and

(bb) the nucleotide sequence of the cDN A insert of clone vq5_J deposited with the ATCC under accession number 207114; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NOJ 9, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO: 19 to a nucleotide sequence conesponding to the 3' end of SEQ ID NO: 19 , but excluding the poly (A) tail at the 3' end of SEQ ID NO: 19. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NOJ 9 from nucleotide 96 to nucleotide 275, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO: 19 from nucleotide 96 to nucleotide 275, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO: 19 from nucleotide 96 to nucleotide 275. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO: 19 from nucleotide 159 to nucleotide 275, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO: 19 from nucleotide 159 to nucleotide 275, to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ ID NO: 19 from nucleotide 159 to nucleotide 275.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ID NO:20;

(b) a fragment of the amino acid sequence of SEQ ID NO:20, the fragment comprising eight contiguous amino acids of SEQ ID NO:20; and

(c) the amino acid sequence encoded by the cDNA insert of clone vq5_l deposited with the ATCC under accession number 207114; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:20. In further preferred embodiments, the present invention provides a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:20 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:20, or a protein comprising a fragment of the amino acid sequence of SEQ

ID NO:20 having biological activity, the fragment comprising the amino acid sequence from amino acid 25 to amino acid 34 of SEQ ID NO:20. In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO-21; (b) a polynucleotide comprising the nucleotide sequence of SEQ ID

NO:21 from nucleotide 176 to nucleotide 340;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:21 from nucleotide 230 to nucleotide 340;

(d) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone vq6_l deposited with the ATCC under accession number 207114;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vq6_l deposited with the ATCC under accession number 207114; (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vq6_l deposited with the ATCC under accession number 207114;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vq6_l deposited with the ATCC under accession number 207114; (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:22;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:22 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:22; (j) a polynucleotide which is an allelic variant of a polynucleotide of

(a)-(g) above;

(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:21.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:21 from nucleotide 176 to nucleotide 340; the nucleotide sequence of SEQ ID NO:21 from nucleotide 230 to nucleotide 340; the nucleotide sequence ofthe full-length protein coding sequence of clone vq6_l deposited with the ATCC under accession number

207114; or the nucleotide sequence of a mature protein coding sequence of clone vq6_J deposited with the ATCC under accession number 207114. In other prefened embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vq6_l deposited with the ATCC under accession number

SEQ ID NO:22 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:22, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of

SEQ ID NO:22 having biological activity, the fragment comprising the amino acid sequence from amino acid 22 to amino acid 31 of SEQ ID NO:22.

Other embodiments provide the gene conesponding to the cDNA sequence of SEQ ID NO-21.

(aa) SEQ ID NO:21 , but excluding the poly (A) tail at the 3' end of SEQ ID NO:21; and

(ab) the nucleotide sequence of the cDN A insert of clone vq6_l deposited with the ATCC under accession number 207114;

(ba) SEQ ID NO:21 , but excluding the poly (A) tail at the 3' end of SEQ ID NO:21; and (bb) the nucleotide sequence of the cDN A insert of clone vq6_J deposited with the ATCC under accession number 207114; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:21, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:21 to a nucleotide sequence conesponding to the 3' end of SEQ ID NO:21 , but excluding the poly (A) tail at the 3' end of SEQ ID NO:21. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:21 from nucleotide 176 to nucleotide 340, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO:21 from nucleotide 176 to nucleotide 340, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:21 from nucleotide

176 to nucleotide 340. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:21 from nucleotide 230 to nucleotide 340, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO:21 from nucleotide 230 to nucleotide 340, to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ ID NO:21 from nucleotide 230 to nucleotide 340. In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:22; (b) a fragment of the amino acid sequence of SEQ ID NO:22, the fragment comprising eight contiguous amino acids of SEQ ID NO:22; and

(c) the amino acid sequence encoded by the cDNA insert of clone vq6_l deposited with the ATCC under accession number 207114; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:22. In further preferred embodiments , the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:22 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 22, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:22 having biological activity, the fragment comprising the amino acid sequence from amino acid 22 to amino acid 31 of SEQ ID NO:22.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:23;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:23 from nucleotide 29 to nucleotide 1111;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 23 from nucleotide 167 to nucleotide 1111; (d) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone vrl_l deposited with the ATCC under accession number 207114;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vrl_l deposited with the ATCC under accession number 207114; (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vrl_l deposited with the ATCC under accession number 207114;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vr 1_1 deposited with the ATCC under accession number 207114;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:24;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:24 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:24;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:23. Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID

NO:23 from nucleotide 29 to nucleotide 1111 ; the nucleotide sequence of SEQ ID NO:23 from nucleotide 167 to nucleotide 1111; the nucleotide sequence ofthe full-length protein coding sequence of clone vrl_l deposited with the ATCC under accession number 207114; or the nucleotide sequence of a mature protein coding sequence of clone vrl_l deposited with the ATCC under accession number 207114. In other prefened embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vr 1_1 deposited with the ATCC under accession number 207114. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 24 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:24, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:24 having biological activity, the fragment comprising the amino acid sequence from amino acid 175 to amino acid 184 of SEQ ID NO:24.

Other embodiments provide the gene conesponding to the cDNA sequence of SEQ ID NO:23. Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of:

(aa) SEQ ID NO:23 , but excluding the poly (A) tail at the 3' end of SEQ ID NO:23; and

(ab) the nucleotide sequence of the cDN A insert of clone vrl_l deposited with the ATCC under accession number 207114; (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(ba) SEQ ID NO:23, but excluding the ρoly(A) tail at the 3' end of SEQ ID NO:23; and

(bb) the nucleotide sequence of the cDN A insert of clone vrl_l deposited with the ATCC under accession number 207114; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:23, and extending contiguously from a nucleotide sequence conesponding to the 5' end of SEQ ID NO:23 to a nucleotide sequence conesponding to the 3' end of SEQ ID NO:23 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:23. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:23 from nucleotide 29 to nucleotide 1111, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:23 from nucleotide 29 to nucleotide 1111 , to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:23 from nucleotide 29 to nucleotide 1111. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO: 23 from nucleotide 167 to nucleotide 1111, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO:23 from nucleotide 167 to nucleotide 1111, to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ ID NO:23 from nucleotide 167 to nucleotide 1111.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ID NO: 24;

(b) a fragment of the amino acid sequence of SEQ ID NO:24, the fragment comprising eight contiguous amino acids of SEQ ID NO:24; and

(c) the amino acid sequence encoded by the cDNA insert of clone vrl_l deposited with the ATCC under accession number 207114; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:24. In further prefened embodiments, the present invention provides a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:24 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:24, or a protein comprising a fragment of the amino acid sequence of SEQ

ID NO:24 having biological activity, the fragment comprising the amino acid sequence from amino acid 175 to amino acid 184 of SEQ ID NO:24. In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:25; (b) a polynucleotide comprising the nucleotide sequence of SEQ ID

NO: 25 from nucleotide 13 to nucleotide 513;

(c) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone vc63_l deposited with the ATCC under accession number 207115; (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vc63_l deposited with the ATCC under accession number 207115;

(e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vc63_l deposited with the ATCC under accession number 207115;

(f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vc63_l deposited with the ATCC under accession number 207115;

(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:26; (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:26 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:26;

(i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above; (j ) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ;

(k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and

(1) a polynucleotide that hybridizes under stringent conditions to any one ofthe polynucleotides specified in (a)-(h) and that has a length that is at least

25% of the length of SEQ ID NO:25. Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:25 from nucleotide 13 to nucleotide 513; the nucleotide sequence of the full-length protein coding sequence of clone vc63_l deposited with the ATCC under accession number 207115; or the nucleotide sequence of a mature protein coding sequence of clone vc63_l deposited with the ATCC under accession number 207115. In other prefened embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vc63_l deposited with the ATCC under accession number 207115. In further prefened embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:26 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:26, or a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:26 having biological activity, the fragment comprising the amino acid sequence from amino acid 78 to amino acid 87 of SEQ ID NO:26. Other embodiments provide the gene corresponding to the cDN A sequence of SEQ

ID NO:25.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of: (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:25, but excluding the poly (A) tail at the 3' end of SEQ ID NO:25; and (ab) the nucleotide sequence of the cDN A insert of clone vc63_ 1 deposited with the ATCC under accession number 207115; (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(ba) SEQ ID NO:25, but excluding the ρoly(A) tail at the 3' end of SEQ ID NO:25; and

(bb) the nucleotide sequence of the cDN A insert of clone vc63_l deposited with the ATCC under accession number 207115; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 25, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:25 to a nucleotide sequence conesponding to the 3' end of SEQ ID NO:25 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:25. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO: 25 from nucleotide 13 to nucleotide 513, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:25 from nucleotide 13 to nucleotide 513, to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ ID NO:25 from nucleotide 13 to nucleotide 513.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:26;

(b) a fragment of the amino acid sequence of SEQ ID NO:26, the fragment comprising eight contiguous amino acids of SEQ ID NO:26; and

(c) the amino acid sequence encoded by the cDNA insert of clone vc63_l deposited with the ATCC under accession number 207115; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:26. In further prefened embodiments , the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:26 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:26, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:26 having biological activity, the fragment comprising the amino acid sequence from amino acid 78 to amino acid 87 of SEQ ID NO:26.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:27;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:27 from nucleotide 79 to nucleotide 345;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:27 from nucleotide 130 to nucleotide 345; (d) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone vb25_l deposited with the ATCC under accession number PTA-362;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vb25_l deposited with the ATCC under accession number PTA-362;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vb25_J deposited with the ATCC under accession number PTA-362;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vb25_l deposited with the ATCC under accession number PTA-

362;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:28;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:28 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:28; (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

(k) a polynucleotide which encodes a species homologue ofthe protein of (h) or (i) above ; (1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:27. Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID

NO:27 from nucleotide 79 to nucleotide 345; the nucleotide sequence of SEQ ID NO:27 from nucleotide 130 to nucleotide 345; the nucleotide sequence ofthe full-length protein coding sequence of clone vb25_l deposited with the ATCC under accession number PTA- 362; or the nucleotide sequence of a mature protein coding sequence of clone vb25_l deposited with the ATCC under accession number PTA-362. In other prefened embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vb25_l deposited with the ATCC under accession number PTA- 362. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:28 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:28, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:28 having biological activity, the fragment comprising the amino acid sequence from amino acid 39 to amino acid 48 of SEQ ID NO:28. Other embodiments provide the gene corresponding to the cDN A sequence of SEQ

ID NO:27.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of: (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of: (aa) SEQ ID NO:27, but excluding the poly(A) tail at the 3' end of SEQ ID NO:27; and

(ab) the nucleotide sequence of the cDN A insert of clone vb25_l deposited with the ATCC under accession number PTA- 362;

(ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of: (ba) SEQ ID NO:27, but excluding the poly (A) tail at the

3' end of SEQ ID NO:27; and

(bb) the nucleotide sequence of the cDN A insert of clone vb25_l deposited with the ATCC under accession number PTA- 362; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:27, and extending contiguously from a nucleotide sequence conesponding to the 5' end of SEQ ID NO:27 to a nucleotide sequence conesponding to the 3' end of SEQ ID NO:27 , but excluding the ρoly(A) tail at the 3' end of SEQ ID NO:27. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:27 from nucleotide 79 to nucleotide 345, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO:27 from nucleotide 79 to nucleotide 345, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:27 from nucleotide 79 to nucleotide 345. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:27 from nucleotide 130 to nucleotide 345, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO:27 from nucleotide 130 to nucleotide 345, to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ ID NO:27 from nucleotide 130 to nucleotide 345.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of :

(a) the amino acid sequence of SEQ ID NO: 28;

(b) a fragment of the amino acid sequence of SEQ ID NO: 28, the fragment comprising eight contiguous amino acids of SEQ ID NO:28; and

(c) the amino acid sequence encoded by the cDNA insert of clone vb25_l deposited with the ATCC under accession number PTA-362; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:28. In further preferred embodiments, the present invention provides a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:28 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:28, or a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:28 having biological activity, the fragment comprising the amino acid sequence from amino acid 39 to amino acid 48 of SEQ ID NO:28.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:29;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:29 from nucleotide 72 to nucleotide 236; (c) a polynucleotide comprising the nucleotide sequence of SEQ ID

NO:29 from nucleotide 150 to nucleotide 236; (d) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone vb27_l deposited with the ATCC under accession number PTA-362;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vb27_l deposited with the ATCC under accession number

PTA-362;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vb27_J deposited with the ATCC under accession number PTA-362; (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vb27_l deposited with the ATCC under accession number PTA- 362;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:30; (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:30 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO: 30;

(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above; (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;

(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least

25% of the length of SEQ ID NO:29.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:29 from nucleotide 72 to nucleotide 236; the nucleotide sequence of SEQ ID NO:29 from nucleotide 150 to nucleotide 236; the nucleotide sequence ofthe full-length protein coding sequence of clone vb27_ 1 deposited with the ATCC under accession number PTA-

362; or the nucleotide sequence of a mature protein coding sequence of clone vb27_l deposited with the ATCC under accession number PTA-362. In other prefened embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vb27_l deposited with the ATCC under accession number PTA- 362. In further prefened embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:30 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:30, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:30 having biological activity, the fragment comprising the amino acid sequence from amino acid 22 to amino acid 31 of SEQ ID NO:30. Other embodiments provide the gene corresponding to the cDN A sequence of SEQ

ID NO:29.

Further embodiments ofthe invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(aa) SEQ ID NO:29, but excluding the poly(A) tail at the 3' end of SEQ ID NO:29; and (ab) the nucleotide sequence of the cDN A insert of clone vb27_l deposited with the ATCC under accession number PTA- 362;

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of: (ba) SEQ ID NO:29, but excluding the poly(A) tail at the 3' end of SEQ ID NO:29; and

(bb) the nucleotide sequence ofthe cDNA insert of clone vb27_l deposited with the ATCC under accession number PTA- 362;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:29, and extending contiguously from a nucleotide sequence conesponding to the 5' end of SEQ ID

NO:29 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:29 , but excluding the ρoly(A) tail at the 3' end of SEQ ID NO:29. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO: 29 from nucleotide 72 to nucleotide

236, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:29 from nucleotide 72 to nucleotide 236, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:29 from nucleotide 72 to nucleotide 236. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID

NO:29 from nucleotide 150 to nucleotide 236, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO:29 from nucleotide 150 to nucleotide 236, to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ ID NO:29 from nucleotide 150 to nucleotide 236.

(a) the amino acid sequence of SEQ ID NO: 30; (b) a fragment of the amino acid sequence of SEQ ID NO:30, the fragment comprising eight contiguous amino acids of SEQ ID NO:30; and (c) the amino acid sequence encoded by the cDNA insert of clone vb27_l deposited with the ATCC under accession number PTA-362; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:30. In further prefened embodiments, the present invention provides a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO: 30 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:30, or a protein comprising a fragment of the amino acid sequence of SEQ

ID NO:30 having biological activity, the fragment comprising the amino acid sequence from amino acid 22 to amino acid 31 of SEQ ID NO: 30.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:31; (b) a polynucleotide comprising the nucleotide sequence of SEQ ID

NO:31 from nucleotide 135 to nucleotide 884;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:31 from nucleotide 183 to nucleotide 884;

(d) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone vb28_l deposited with the ATCC under accession number PTA-362;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vb28_l deposited with the ATCC under accession number PTA-362; (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vb28_l deposited with the ATCC under accession number PTA-362;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vb28_l deposited with the ATCC under accession number PTA- 362;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:32; (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:32 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:32;

(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:31.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO: 31 from nucleotide 135 to nucleotide 884; the nucleotide sequence of SEQ ID NO: 31 from nucleotide 183 to nucleotide 884; the nucleotide sequence of the full-length protein coding sequence of clone vb28_l deposited with the ATCC under accession number PTA- 362; or the nucleotide sequence of a mature protein coding sequence of clone vb28_l deposited with the ATCC under accession number PTA-362. In other prefened embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDN A insert of clone vb28_ 1 deposited with the ATCC under accession number PTA- 362. In further prefened embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:32 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:32, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of

SEQ ID NO:32 having biological activity, the fragment comprising the amino acid sequence from amino acid 120 to amino acid 129 of SEQ ID NO:32.

Other embodiments provide the gene conesponding to the cDN A sequence of SEQ ID NO.31. Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of: (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:31 , but excluding the ρoly(A) tail at the 3' end of SEQ ID NO:31; and

(ab) the nucleotide sequence of the cDN A insert of clone vb28_l deposited with the ATCC under accession number PTA- 362;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(ba) SEQ ID NO:31 , but excluding the ρoly(A) tail at the 3' end of SEQ ID NO:31; and (bb) the nucleotide sequence of the cDN A insert of clone vb28_l deposited with the ATCC under accession number PTA- 362;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:31, and extending contiguously from a nucleotide sequence conesponding to the 5' end of SEQ ID NO:31 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:31 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:31. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:31 from nucleotide 135 to nucleotide 884, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO:31 from nucleotide 135 to nucleotide 884, to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ ID NO:31 from nucleotide 135 to nucleotide 884. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:31 from nucleotide 183 to nucleotide 884, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO:31 from nucleotide 183 to nucleotide 884, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:31 from nucleotide 183 to nucleotide 884.

(a) the amino acid sequence of SEQ ID NO:32; (b) a fragment of the amino acid sequence of SEQ ID NO:32, the fragment comprising eight contiguous amino acids of SEQ ID NO:32; and

(c) the amino acid sequence encoded by the cDNA insert of clone vb28_l deposited with the ATCC under accession number PTA-362; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:32. In further prefened embodiments, the present invention provides a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:32 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:32, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:32 having biological activity, the fragment comprising the amino acid sequence from amino acid 120 to amino acid 129 of SEQ ID NO:32.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:33;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:33 from nucleotide 42 to nucleotide 206; (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:33 from nucleotide 111 to nucleotide 206;

(d) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone vb29_l deposited with the ATCC under accession number PTA-362;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vb29_l deposited with the ATCC under accession number PTA-362;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vb29_l deposited with the ATCC under accession number PTA-362;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vb29_l deposited with the ATCC under accession number PTA- 362; (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:34;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 34 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO: 34; (j) a polynucleotide which is an allelic variant of a polynucleotide of

(a)-(g) above;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:33. Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:33 from nucleotide 42 to nucleotide 206; the nucleotide sequence of SEQ ID NO:33 from nucleotide 111 to nucleotide 206; the nucleotide sequence ofthe full-length protein coding sequence of clone vb29_l deposited with the ATCC under accession number PTA- 362; or the nucleotide sequence of a mature protein coding sequence of clone vb29_l deposited with the ATCC under accession number PTA-362. In other prefened embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vb29_l deposited with the ATCC under accession number PTA- 362. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:34 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:34, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:34 having biological activity, the fragment comprising the amino acid sequence from amino acid 22 to amino acid 31 of SEQ ID NO:34.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:33.

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of: (aa) SEQ ID NO:33, but excluding the poly(A) tail at the

3' end of SEQ ID NO:33; and

(ab) the nucleotide sequence of the cDNA insert of clone vb29_l deposited with the ATCC under accession number PTA- 362; (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s); and (b) a process comprising the steps of: (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:33, but excluding the poly(A) tail at the 3' end of SEQ ID NO:33; and

(bb) the nucleotide sequence of the cDNA insert of clone vb29_l deposited with the ATCC under accession number PTA- 362;

(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:33, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO: 33 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO: 33 , but excluding the poly (A) tail at the 3' end of SEQ ID NO:33. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO: 33 from nucleotide 42 to nucleotide 206, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO:33 from nucleotide 42 to nucleotide 206, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO: 33 from nucleotide 42 to nucleotide 206. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:33 from nucleotide 111 to nucleotide 206, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:33 from nucleotide 111 to nucleotide 206, to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ ID NO:33 from nucleotide 111 to nucleotide 206.

(a) the amino acid sequence of SEQ ID NO: 34; (b) a fragment of the amino acid sequence of SEQ ID NO:34, the fragment comprising eight contiguous amino acids of SEQ ID NO:34; and

(c) the amino acid sequence encoded by the cDNA insert of clone vb29_l deposited with the ATCC under accession number PTA-362; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:34. In further prefened embodiments, the present invention provides a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO: 34 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 34, or a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO: 34 having biological activity, the fragment comprising the amino acid sequence from amino acid 22 to amino acid 31 of SEQ ID NO:34.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID

NO:35;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:35 from nucleotide 17 to nucleotide 253;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:35 from nucleotide 98 to nucleotide 253;

(d) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone vb30_l deposited with the ATCC under accession number PTA-362;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vb30_l deposited with the ATCC under accession number

PTA-362;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vb30_l deposited with the ATCC under accession number PTA-362; (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vb30_l deposited with the ATCC under accession number PTA- 362; (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:36;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:36 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:36;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:35. Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID

NO:35 from nucleotide 17 to nucleotide 253; the nucleotide sequence of SEQ ID NO:35 from nucleotide 98 to nucleotide 253; the nucleotide sequence of the full-length protein coding sequence of clone vb30_l deposited with the ATCC under accession number PTA- 362; or the nucleotide sequence of a mature protein coding sequence of clone vb30_l deposited with the ATCC under accession number PTA-362. In other prefened embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vb30_l deposited with the ATCC under accession number PTA- 362. In further prefened embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 36 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:36, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:36 having biological activity, the fragment comprising the amino acid sequence from amino acid 34 to amino acid 43 of SEQ ID NO:36. Other embodiments provide the gene conesponding to the cDN A sequence of SEQ

ID NO:35. Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

(aa) SEQ ID NO:35, but excluding the poly(A) tail at the 3' end of SEQ ID NO:35; and

(ab) the nucleotide sequence of the cDN A insert of clone vb30_l deposited with the ATCC under accession number PTA- 362;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:35, but excluding the ρoly(A) tail at the 3' end of SEQ ID NO:35; and

(bb) the nucleotide sequence of the cDN A insert of clone vb30_l deposited with the ATCC under accession number PTA- 362;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:35, and extending contiguously from a nucleotide sequence conesponding to the 5' end of SEQ ID NO:35 to a nucleotide sequence conesponding to the 3' end of SEQ ID NO:35 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:35. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:35 from nucleotide 17 to nucleotide 253, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO:35 from nucleotide 17 to nucleotide 253, to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ ID NO:35 from nucleotide 17 to nucleotide 253. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:35 from nucleotide 98 to nucleotide 253, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:35 from nucleotide 98 to nucleotide 253, to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ ID NO:35 from nucleotide 98 to nucleotide 253.

(a) the amino acid sequence of SEQ ID NO:36;

(b) a fragment of the amino acid sequence of SEQ ID NO:36, the fragment comprising eight contiguous amino acids of SEQ ID NO: 36; and (c) the amino acid sequence encoded by the cDNA insert of clone vb30_l deposited with the ATCC under accession number PTA-362; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:36. In further preferred embodiments, the present invention provides a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:36 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:36, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:36 having biological activity, the fragment comprising the amino acid sequence from amino acid 34 to amino acid 43 of SEQ ID NO:36. In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:37;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:37 from nucleotide 68 to nucleotide 424; (c) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone vc67_l deposited with the ATCC under accession number PTA-362;

(d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vc67_l deposited with the ATCC under accession number PTA-362;

(e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vc67_l deposited with the ATCC under accession number PTA-362;

(f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vc67_l deposited with the ATCC under accession number PTA- 362;

(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:38;

(h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:38 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO: 38;

(i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;

(j ) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ;

(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:37.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID from nucleotide 68 to nucleotide 424; the nucleotide sequence of the full-length protein coding sequence of clone vc67_l deposited with the ATCC under accession number PTA-362; or the nucleotide sequence of a mature protein coding sequence of clone vc67_J deposited with the ATCC under accession number PTA-362. In other prefened embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDN A insert of clone vc67_ 1 deposited with the ATCC under accession number PTA- 362. In further prefened embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:38 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:38, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:38 having biological activity, the fragment comprising the amino acid sequence from amino acid 54 to amino acid 63 of SEQ ID NO:38.

Other embodiments provide the gene conesponding to the cDN A sequence of SEQ ID NO:37. Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

(aa) SEQ ID NO:37, but excluding the poly(A) tail at the 3' end of SEQ ID NO:37; and

(ab) the nucleotide sequence of the cDN A insert of clone vc67_l deposited with the ATCC under accession number PTA- 362;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(ba) SEQ ID NO:37, but excluding the poly(A) tail at the 3' end of SEQ ID NO:37; and

(bb) the nucleotide sequence ofthe cDNA insert of clone vc67_J deposited with the ATCC under accession number PTA- 362;

(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:37, and extending contiguously from a nucleotide sequence conesponding to the 5 ' end of SEQ ID NO:37 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:37 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:37. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:37 from nucleotide 68 to nucleotide 424, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO:37 from nucleotide 68 to nucleotide 424, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:37 from nucleotide 68 to nucleotide 424.

(a) the amino acid sequence of SEQ ID NO:38;

(b) a fragment of the amino acid sequence of SEQ ID NO:38, the fragment comprising eight contiguous amino acids of SEQ ID NO:38; and (c) the amino acid sequence encoded by the cDNA insert of clone vc67_J deposited with the ATCC under accession number PTA-362; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:38. In further prefened embodiments, the present invention provides a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:38 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:38, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 38 having biological activity, the fragment comprising the amino acid sequence from amino acid 54 to amino acid 63 of SEQ ID NO:38.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:39;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:39 from nucleotide 103 to nucleotide 261; (c) a polynucleotide comprising the nucleotide sequence of SEQ ID

NO: 39 from nucleotide 154 to nucleotide 261;

(d) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone vf4_l deposited with the ATCC under accession number PTA-362; (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vf4_l deposited with the ATCC under accession number PTA-362;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vf4_l deposited with the ATCC under accession number PTA-362;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vf4_l deposited with the ATCC under accession number PTA-362;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:40; (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:40 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:40; (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:39. Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID

NO:39 from nucleotide 103 to nucleotide 261 ; the nucleotide sequence of SEQ ID NO:39 from nucleotide 154 to nucleotide 261 ; the nucleotide sequence of the full-length protein coding sequence of clone vf4_l deposited with the ATCC under accession number PTA- 362; or the nucleotide sequence of a mature protein coding sequence of clone vf4_l deposited with the ATCC under accession number PTA-362. In other prefened embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vf4_l deposited with the ATCC under accession number PTA- 362. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:40 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:40, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:40 having biological activity, the fragment comprising the amino acid sequence from amino acid 21 to amino acid 30 of SEQ ID NO:40. Other embodiments provide the gene conesponding to the cDN A sequence of SEQ

ID NO:39.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of: (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of: (aa) SEQ ID NO:39, but excluding the poly(A) tail at the 3' end of SEQ ID NO: 39; and

(ab) the nucleotide sequence of the cDN A insert of clone vf4_l deposited with the ATCC under accession number PTA-362; (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(ba) SEQ ID NO:39, but excluding the poly(A) tail at the 3' end of SEQ ID NO:39; and

(bb) the nucleotide sequence of the cDN A insert of clone vf4_l deposited with the ATCC under accession number PTA-362; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:39, and extending contiguously from a nucleotide sequence conesponding to the 5' end of SEQ ID NO:39 to a nucleotide sequence conesponding to the 3' end of SEQ ID NO:39 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:39. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:39 from nucleotide 103 to nucleotide 261, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO:39 from nucleotide 103 to nucleotide 261, to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ ID NO:39 from nucleotide 103 to nucleotide 261. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:39 from nucleotide 154 to nucleotide 261, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO:39 from nucleotide 154 to nucleotide 261, to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ ID NO: 39 from nucleotide 154 to nucleotide 261.

(a) the amino acid sequence of SEQ ID NO:40; (b) a fragment of the amino acid sequence of SEQ ID NO:40, the fragment comprising eight contiguous amino acids of SEQ ID NO:40; and

(c) the amino acid sequence encoded by the cDNA insert of clone vf4_l deposited with the ATCC under accession number PTA-362; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:40. In further prefened embodiments, the present invention provides a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:40 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:40, or a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:40 having biological activity, the fragment comprising the amino acid sequence from amino acid 21 to amino acid 30 of SEQ ID NO:40.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:41;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:41 from nucleotide 1575 to nucleotide 3038;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:41 from nucleotide 1650 to nucleotide 3038; (d) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone vg3_l deposited with the ATCC under accession number PTA-362; (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vg3_l deposited with the ATCC under accession number PTA-362;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vg3_l deposited with the ATCC under accession number PTA-362;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vg3_l deposited with the ATCC under accession number PTA-362;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:42;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:42 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:42;

(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least

25% of the length of SEQ ID NO:41.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:41 from nucleotide 1575 to nucleotide 3038; the nucleotide sequence of SEQ ID NO:41 from nucleotide 1650 to nucleotide 3038; the nucleotide sequence of the full- length protein coding sequence of clone vg3_l deposited with the ATCC under accession number PTA-362; or the nucleotide sequence of a mature protein coding sequence of clone vg3_l deposited with the ATCC under accession number PTA-362. In other prefened embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vg3_l deposited with the ATCC under accession number PTA-

362. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:42 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:42, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:42 having biological activity, the fragment comprising the amino acid sequence from amino acid 239 to amino acid 248 of SEQ ID NO:42.

Other embodiments provide the gene conesponding to the cDN A sequence of SEQ ID NO-41.

(aa) SEQ ID NO:41 , but excluding the poly( A) tail at the 3' end of SEQ ID NO:41; and

(ab) the nucleotide sequence of the cDN A insert of clone vg3_l deposited with the ATCC under accession number PTA-362; (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:41 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:41; and

(bb) the nucleotide sequence of the cDN A insert of clone vg3_J deposited with the ATCC under accession number PTA-362;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:41, and extending contiguously from a nucleotide sequence conesponding to the 5 ' end of SEQ ID NO:41 to a nucleotide sequence conesponding to the 3' end of SEQ ID NO:41 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:41. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:41 from nucleotide 1575 to nucleotide 3038, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO:41 from nucleotide 1575 to nucleotide 3038, to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ ID NO:41 from nucleotide 1575 to nucleotide 3038. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:41 from nucleotide 1650 to nucleotide 3038, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO:41 from nucleotide 1650 to nucleotide 3038, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:41 from nucleotide 1650 to nucleotide 3038. In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:42;

(b) a fragment of the amino acid sequence of SEQ ID NO:42, the fragment comprising eight contiguous amino acids of SEQ ID NO:42; and

(c) the amino acid sequence encoded by the cDNA insert of clone vg3_l deposited with the ATCC under accession number PTA-362; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:42. In further prefened embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:42 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:42, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:42 having biological activity, the fragment comprising the amino acid sequence from amino acid 239 to amino acid 248 of SEQ ID NO:42.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:43;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:43 from nucleotide 2112 to nucleotide 2363; (c) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone vo2_l deposited with the ATCC under accession number PTA-362;

(d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vo2_l deposited with the ATCC under accession number PTA-362;

(e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vo2_l deposited with the ATCC under accession number PTA-362;

(f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vo2_ 1 deposited with the ATCC under accession number PT A-362 ;

(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:44;

(h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:44 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:44;

(j ) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ; (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and (1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:43.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:43 from nucleotide 2112 to nucleotide 2363; the nucleotide sequence of the full- length protein coding sequence of clone vo2_l deposited with the ATCC under accession number PTA-362; or the nucleotide sequence of a mature protein coding sequence of clone vo2_l deposited with the ATCC under accession number PTA-362. In other prefened embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vo2_l deposited with the ATCC under accession number PTA- 362. In further prefened embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:44 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:44, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:44 having biological activity, the fragment comprising the amino acid sequence from amino acid 37 to amino acid 46 of SEQ ID NO:44.

Other embodiments provide the gene conesponding to the cDNA sequence of SEQ ID NO:43. Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of:

(aa) SEQ ID NO:43, but excluding the poly(A) tail at the 3' end of SEQ ID NO:43; and

(ab) the nucleotide sequence of the cDN A insert of clone vo2_ 1 deposited with the ATCC under accession number PTA-362; (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s); and

(ba) SEQ ID NO:43, but excluding the ρoly(A) tail at the 3' end of SEQ ID NO:43; and (bb) the nucleotide sequence of the cDN A insert of clone vo2_ 1 deposited with the ATCC under accession number PTA-362; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:43, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:43 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:43 , but excluding the poly (A) tail at the 3' end of SEQ ID NO:43. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:43 from nucleotide 2112 to nucleotide 2363, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO:43 from nucleotide 2112 to nucleotide 2363, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:43 from nucleotide 2112 to nucleotide 2363.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ID NO:44;

(b) a fragment of the amino acid sequence of SEQ ID NO:44, the fragment comprising eight contiguous amino acids of SEQ ID NO:44; and (c) the amino acid sequence encoded by the cDNA insert of clone vo2_l deposited with the ATCC under accession number PTA-362; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:44. In further prefened embodiments , the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:44 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:44, or a protein comprising a fragment of the amino acid sequence of SEQ

ID NO:44 having biological activity, the fragment comprising the amino acid sequence from amino acid 37 to amino acid 46 of SEQ ID NO:44.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:45; (b) a polynucleotide comprising the nucleotide sequence of SEQ ID

NO:45 from nucleotide 36 to nucleotide 707;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:45 from nucleotide 393 to nucleotide 707;

(d) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone vo3_l deposited with the ATCC under accession number PTA-362;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vo3_l deposited with the ATCC under accession number PTA-362; (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vo3_l deposited with the ATCC under accession number PTA-362;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vo3_l deposited with the ATCC under accession number PTA-362; (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:46; (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:46 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:46;

(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:45.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:45 from nucleotide 36 to nucleotide 707; the nucleotide sequence of SEQ ID NO:45 from nucleotide 393 to nucleotide 707; the nucleotide sequence of the full-length protein coding sequence of clone vo3_l deposited with the ATCC under accession number PTA- 362; or the nucleotide sequence of a mature protein coding sequence of clone vo3_l deposited with the ATCC under accession number PTA-362. In other prefened embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vo3_l deposited with the ATCC under accession number PTA- 362. In further prefened embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:46 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:46, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of

SEQ ID NO:46 having biological activity, the fragment comprising the amino acid sequence from amino acid 107 to amino acid 116 of SEQ ID NO:46.

Other embodiments provide the gene conesponding to the cDNA sequence of SEQ ID NO-45. Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of: (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:45, but excluding the poly(A) tail at the 3' end of SEQ ID NO:45; and

(ab) the nucleotide sequence of the cDN A insert of clone vo3_ 1 deposited with the ATCC under accession number PTA-362; (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:45, but excluding the poly( A) tail at the 3' end of SEQ ID NO:45; and

(bb) the nucleotide sequence of the cDN A insert of clone vo3_l deposited with the ATCC under accession number PTA-362;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:45, and extending contiguously from a nucleotide sequence conesponding to the 5' end of SEQ ID NO:45 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:45 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:45. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:45 from nucleotide 36 to nucleotide 707, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO:45 from nucleotide 36 to nucleotide 707, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:45 from nucleotide 36 to nucleotide 707. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:45 from nucleotide 393 to nucleotide 707, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO:45 from nucleotide 393 to nucleotide 707, to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ ID NO:45 from nucleotide 393 to nucleotide 707.

(a) the amino acid sequence of SEQ ID NO:46;

(b) a fragment of the amino acid sequence of SEQ ID NO:46, the fragment comprising eight contiguous amino acids of SEQ ID NO:46; and (c) the amino acid sequence encoded by the cDNA insert of clone vo3_l deposited with the ATCC under accession number PTA-362; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:46. In further prefened embodiments, the present invention provides a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:46 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:46, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:46 having biological activity, the fragment comprising the amino acid sequence from amino acid 107 to amino acid 116 of SEQ ID NO:46. In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:47;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:47 from nucleotide 74 to nucleotide 295;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:47 from nucleotide 134 to nucleotide 295; (d) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone vo5_l deposited with the ATCC under accession number PTA-362;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vo5_l deposited with the ATCC under accession number

PTA-362;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vo5_l deposited with the ATCC under accession number PTA-362; (g) a polynucleotide encoding a mature protein encoded by the cDN A insert of clone vo5_l deposited with the ATCC under accession number PTA-362; (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:48;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:48 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:48;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:47.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:47 from nucleotide 74 to nucleotide 295; the nucleotide sequence of SEQ ID NO:47 from nucleotide 134 to nucleotide 295; the nucleotide sequence ofthe full-length protein coding sequence of clone vo5_l deposited with the ATCC under accession number PTA- 362; or the nucleotide sequence of a mature protein coding sequence of clone vo5_l deposited with the ATCC under accession number PTA-362. In other prefened embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vo5_l deposited with the ATCC under accession number PTA- 362. In further prefened embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:48 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:48, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:48 having biological activity, the fragment comprising the amino acid sequence from amino acid 32 to amino acid 41 of SEQ ID NO:48.

Other embodiments provide the gene conesponding to the cDNA sequence of SEQ ID NO:47.

(a) a process comprising the steps of:

(aa) SEQ ID NO:47, but excluding the poly (A) tail at the 3' end of SEQ ID NO:47; and

(ab) the nucleotide sequence of the cDN A insert of clone vo5_ 1 deposited with the ATCC under accession number PT A-362 ;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of: (ba) SEQ ID NO:47, but excluding the poly(A) tail at the

3' end of SEQ ID NO:47; and (bb) the nucleotide sequence of the cDNA insert of clone vo5_l deposited with the ATCC under accession number PTA-362; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:47, and extending contiguously from a nucleotide sequence conesponding to the 5' end of SEQ ID NO:47 to a nucleotide sequence conesponding to the 3' end of SEQ ID NO:47 , but excluding the poly (A) tail at the 3' end of SEQ ID NO:47. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:47 from nucleotide 74 to nucleotide 295, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO:47 from nucleotide 74 to nucleotide 295, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:47 from nucleotide 74 to nucleotide 295. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:47 from nucleotide 134 to nucleotide 295, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO:47 from nucleotide 134 to nucleotide 295, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:47 from nucleotide 134 to nucleotide 295.

(a) the amino acid sequence of SEQ ID NO:48;

(b) a fragment of the amino acid sequence of SEQ ID NO:48, the fragment comprising eight contiguous amino acids of SEQ ID NO:48; and

(c) the amino acid sequence encoded by the cDNA insert of clone vo5_l deposited with the ATCC under accession number PTA-362; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:48. In further prefened embodiments, the present invention provides a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:48 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:48, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:48 having biological activity, the fragment comprising the amino acid sequence from amino acid 32 to amino acid 41 of SEQ ID NO:48.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO-49;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:49 from nucleotide 45 to nucleotide 383;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:49 from nucleotide 312 to nucleotide 383; (d) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone vo6_l deposited with the ATCC under accession number PTA-362;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vo6_l deposited with the ATCC under accession number PTA-362;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vo6_l deposited with the ATCC under accession number PTA-362;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vo6_l deposited with the ATCC under accession number PTA-362;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:50;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:50 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:50;

(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:49.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:49 from nucleotide 45 to nucleotide 383; the nucleotide sequence of SEQ ID NO:49 from nucleotide 312 to nucleotide 383; the nucleotide sequence of the full-length protein coding sequence of clone vo6_l deposited with the ATCC under accession number PTA- 362; or the nucleotide sequence of a mature protein coding sequence of clone vo6_l deposited with the ATCC under accession number PTA-362. In other prefened embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vo6_l deposited with the ATCC under accession number PTA- 362. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:50 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:50, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:50 having biological activity, the fragment comprising the amino acid sequence from amino acid 51 to amino acid 60 of SEQ ID NO:50.

Other embodiments provide the gene conesponding to the cDNA sequence of SEQ ID NO:49. Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of:

(aa) SEQ ID NO:49, but excluding the ρoly(A) tail at the 3' end of SEQ ID NO:49; and (ab) the nucleotide sequence of the cDN A insert of clone vo6_l deposited with the ATCC under accession number PTA-362; (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:49, but excluding the poly(A) tail at the 3' end of SEQ ID NO:49; and

(bb) the nucleotide sequence of the cDN A insert of clone vo6_l deposited with the ATCC under accession number PTA-362;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:49, and extending contiguously from a nucleotide sequence conesponding to the 5' end of SEQ ID NO:49 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:49 , but excluding the ρoly(A) tail at the 3' end of SEQ ID NO:49. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:49 from nucleotide 45 to nucleotide 383, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO:49 from nucleotide 45 to nucleotide 383, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:49 from nucleotide 45 to nucleotide 383. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:49 from nucleotide 312 to nucleotide 383, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO:49 from nucleotide 312 to nucleotide 383, to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ ID NO:49 from nucleotide 312 to nucleotide 383.

(a) the amino acid sequence of SEQ ID NO:50;

(b) a fragment of the amino acid sequence of SEQ ID NO:50, the fragment comprising eight contiguous amino acids of SEQ ID NO:50; and (c) the amino acid sequence encoded by the cDNA insert of clone vo6_l deposited with the ATCC under accession number PTA-362; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:50. In further prefened embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 50 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:50, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:50 having biological activity, the fragment comprising the amino acid sequence from amino acid 51 to amino acid 60 of SEQ ID NO:50. In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:51;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:51 from nucleotide 186 to nucleotide 1739;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:51 from nucleotide 288 to nucleotide 1739;

(d) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone vo9_l deposited with the ATCC under accession number PTA-362; (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vo9_l deposited with the ATCC under accession number PTA-362;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vo9_ 1 deposited with the ATCC under accession number PTA-362;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vo9_l deposited with the ATCC under accession number PTA-362;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:52;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:52 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:52;

(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:51.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:51 from nucleotide 186 to nucleotide 1739; the nucleotide sequence of SEQ ID NO:51 from nucleotide 288 to nucleotide 1739; the nucleotide sequence ofthe full-length protein coding sequence of clone vo9_l deposited with the ATCC under accession number PTA- 362; or the nucleotide sequence of a mature protein coding sequence of clone vo9_l deposited with the ATCC under accession number PTA-362. In other prefened embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vo9_l deposited with the ATCC under accession number PTA-

362. In further prefened embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 52 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:52, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 52 having biological activity, the fragment comprising the amino acid sequence from amino acid 254 to amino acid 263 of SEQ ID NO:52.

Other embodiments provide the gene conesponding to the cDNA sequence of SEQ ID NO-51.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from, the group consisting of: (a) a process comprising the steps of:

(aa) SEQ ID NO:51 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:51; and

(ab) the nucleotide sequence of the cDN A insert of clone vo9_l deposited with the ATCC under accession number PTA-362; (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:51 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:51; and

(bb) the nucleotide sequence of the cDN A insert of clone vo9_ 1 deposited with the ATCC under accession number PT A-362 ;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:51, and extending contiguously from a nucleotide sequence conesponding to the 5 ' end of SEQ ID NO:51 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:51 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:51. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO: 51 from nucleotide 186 to nucleotide 1739, and extending contiguously from a nucleotide sequence conesponding to the 5 ' end of said sequence of SEQ ID NO:51 from nucleotide 186 to nucleotide 1739, to anucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO: 51 from nucleotide 186 to nucleotide 1739. Also preferably the polynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:51 from nucleotide 288 to nucleotide 1739, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO:51 from nucleotide 288 to nucleotide 1739, to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ ID NO:51 from nucleotide 288 to nucleotide 1739.

(a) the amino acid sequence of SEQ ID NO:52;

(b) a fragment of the amino acid sequence of SEQ ID NO:52, the fragment comprising eight contiguous amino acids of SEQ ID NO:52; and (c) the amino acid sequence encoded by the cDNA insert of clone vo9_l deposited with the ATCC under accession number PTA-362; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:52. In further prefened embodiments, the present invention provides a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:52 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 52, or a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:52 having biological activity, the fragment comprising the amino acid sequence from amino acid 254 to amino acid 263 of SEQ ID NO:52.

NO:53;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:53 from nucleotide 440 to nucleotide 835;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:53 from nucleotide 632 to nucleotide 835;

(d) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone vol 1_1 deposited with the ATCC under accession number PTA-366;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vo 11_ 1 deposited with the ATCC under accession number

PTA-366;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vol l_l deposited with the ATCC under accession number PTA-366; (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vol 1_1 deposited with the ATCC under accession number PTA- 366;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:54; (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:54 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO: 54;

(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above; (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; (1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:53.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:53 from nucleotide 440 to nucleotide 835; the nucleotide sequence of SEQ ID NO:53 from nucleotide 632 to nucleotide 835; the nucleotide sequence ofthe full-length protein coding sequence of clone vo 11_1 deposited with the ATCC under accession number PTA- 366; or the nucleotide sequence of a mature protein coding sequence of clone vol 1_1 deposited with the ATCC under accession number PTA-366. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vol 1_1 deposited with the ATCC under accession number PTA- 366. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:54 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:54, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 54 having biological activity, the fragment comprising the amino acid sequence from amino acid 61 to amino acid 70 of SEQ ID NO:54.

Other embodiments provide the gene conesponding to the cDNA sequence of SEQ ID NO:53.

(aa) SEQ ID NO:53, but excluding the poly(A) tail at the 3' end of SEQ ID NO:53; and (ab) the nucleotide sequence of the cDN A insert of clone vol 1_1 deposited with the ATCC under accession number PTA-366; (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:53, but excluding the poly(A) tail at the 3' end of SEQ ID NO:53; and

(bb) the nucleotide sequence of the cDN A insert of clone vol 1_1 deposited with the ATCC under accession number PTA- 366;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:53, and extending contiguously from a nucleotide sequence conesponding to the 5' end of SEQ ID NO:53 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:53 , but excluding the poly (A) tail at the 3' end of SEQ ID NO:53. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO: 53 from nucleotide 440 to nucleotide 835, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO:53 from nucleotide 440 to nucleotide 835, to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ ID NO:53 from nucleotide

440 to nucleotide 835. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:53 from nucleotide 632 to nucleotide 835, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:53 from nucleotide 632 to nucleotide 835, to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ ID NO:53 from nucleotide 632 to nucleotide 835. In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:54;

(b) a fragment of the amino acid sequence of SEQ ID NO: 54, the fragment comprising eight contiguous amino acids of SEQ ID NO:54; and

(c) the amino acid sequence encoded by the cDNA insert of clone vol 1_1 deposited with the ATCC under accession number PTA-366; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:54. In further prefened embodiments, the present invention provides a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:54 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:54, or a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO: 54 having biological activity, the fragment comprising the amino acid sequence from amino acid 61 to amino acid 70 of SEQ ID NO:54.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:55; (b) a polynucleotide comprising the nucleotide sequence of SEQ ID

NO:55 from nucleotide 72 to nucleotide 329;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:55 from nucleotide 120 to nucleotide 329;

(d) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone vol2_l deposited with the ATCC under accession number PTA-366; (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vol2_l deposited with the ATCC under accession number PTA-366;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vol2_l deposited with the ATCC under accession number PTA-366;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vol2_l deposited with the ATCC under accession number PTA- 366; (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:56;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:56 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:56; (j) a polynucleotide which is an allelic variant of a polynucleotide of

(a)-(g) above;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:55. Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:55 from nucleotide 72 to nucleotide 329; the nucleotide sequence of SEQ ID NO:55 from nucleotide 120 to nucleotide 329; the nucleotide sequence ofthe full-length protein coding sequence of clone vo 12_ 1 deposited with the ATCC under accession number PTA- 366; or the nucleotide sequence of a mature protein coding sequence of clone vol2_l deposited with the ATCC under accession number PTA-366. In other prefened embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vol2_l deposited with the ATCC under accession number PTA- 366. In further prefened embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:56 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 56, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:56 having biological activity, the fragment comprising the amino acid sequence from amino acid 38 to amino acid 47 of SEQ ID NO:56.

Other embodiments provide the gene conesponding to the cDNA sequence of SEQ ID NO:55.

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of: (aa) SEQ ID NO:55, but excluding the poly(A) tail at the

3' end of SEQ ID NO:55; and

(ab) the nucleotide sequence of the cDN A insert of clone vol2_l deposited with the ATCC under accession number PTA- 366; (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(ba) SEQ ID NO:55, but excluding the poly(A) tail at the 3' end of SEQ ID NO:55; and (bb) the nucleotide sequence of the cDN A insert of clone vo 12_J deposited with the ATCC under accession number PTA-366; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:55, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:55 to a nucleotide sequence conesponding to the 3' end of SEQ ID NO:55 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:55. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:55 from nucleotide 72 to nucleotide 329, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:55 from nucleotide 72 to nucleotide 329, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:55 from nucleotide 72 to nucleotide 329. Also preferably the polynucleotide isolated according to the above process comprises anucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:55 from nucleotide 120 to nucleotide 329, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO:55 from nucleotide 120 to nucleotide 329, to anucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:55 from nucleotide 120 to nucleotide 329.

(a) the amino acid sequence of SEQ ID NO:56;

(b) a fragment of the amino acid sequence of SEQ ID NO:56, the fragment comprising eight contiguous amino acids of SEQ ID NO:56; and

(c) the amino acid sequence encoded by the cDNA insert of clone vol2_l deposited with the ATCC under accession number PTA-366; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:56. In further prefened embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:56 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:56, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:56 having biological activity, the fragment comprising the amino acid sequence from amino acid 38 to amino acid 47 of SEQ ID NO:56.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:57;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:57 from nucleotide 227 to nucleotide 439;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:57 from nucleotide 287 to nucleotide 439; (d) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone vol3_l deposited with the ATCC under accession number PTA-366;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vol3_J deposited with the ATCC under accession number PTA-366;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vol3_l deposited with the ATCC under accession number PTA-366;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vol3_l deposited with the ATCC under accession number PTA-

366;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:58;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:58 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:58; (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:57. Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID

NO:57 from nucleotide 227 to nucleotide 439; the nucleotide sequence of SEQ ID NO:57 from nucleotide 287 to nucleotide 439; the nucleotide sequence ofthe full-length protein coding sequence of clone vo 13_1 deposited with the ATCC under accession number PTA- 366; or the nucleotide sequence of a mature protein coding sequence of clone vol3_l deposited with the ATCC under accession number PTA-366. In other prefened embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vol3_l deposited with the ATCC under accession number PTA- 366. In further prefened embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:58 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 58, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:58 having biological activity, the fragment comprising the amino acid sequence from amino acid 30 to amino acid 39 of SEQ ID NO:58. Other embodiments provide the gene conesponding to the cDNA sequence of SEQ

ID NO:57.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of: (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of: (aa) SEQ ID NO:57, but excluding the poly( A) tail at the 3' end of SEQ ID NO:57; and

(ab) the nucleotide sequence of the cDN A insert of clone vol3_J deposited with the ATCC under accession number PTA- 366;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of: (ba) SEQ ID NO:57, but excluding the poly( A) tail at the

3' end of SEQ ID NO:57; and

(bb) the nucleotide sequence of the cDN A insert of clone vol3_l deposited with the ATCC under accession number PTA- 366; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:57, and extending contiguously from anucleotide sequence conesponding to the 5' end of SEQ ID NO:57 to a nucleotide sequence conesponding to the 3' end of SEQ ID NO:57 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:57. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:57 from nucleotide 227 to nucleotide

439, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO:57 from nucleotide 227 to nucleotide 439, to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ ID NO:57 from nucleotide 227 to nucleotide 439. Also preferably the polynucleotide isolated according to the above process comprises anucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:57 from nucleotide 287 to nucleotide 439, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO:57 from nucleotide 287 to nucleotide 439, to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ ID NO:57 from nucleotide 287 to nucleotide 439.

(a) the amino acid sequence of SEQ ID NO:58;

(b) a fragment of the amino acid sequence of SEQ ID NO: 58, the fragment comprising eight contiguous amino acids of SEQ ID NO:58; and

(c) the amino acid sequence encoded by the cDNA insert of clone vol3_l deposited with the ATCC under accession number PTA-366; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:58. In further preferred embodiments, the present invention provides a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:58 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:58, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:58 having biological activity, the fragment comprising the amino acid sequence from amino acid 30 to amino acid 39 of SEQ ID NO:58.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:59;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:59 from nucleotide 96 to nucleotide 341; (c) a polynucleotide comprising the nucleotide sequence of SEQ ID

NO:59 from nucleotide 174 to nucleotide 341; (d) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone vol4_l deposited with the ATCC under accession number PTA-366;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vol4_l deposited with the ATCC under accession number

PTA-366;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vol4_l deposited with the ATCC under accession number PTA-366; (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vol4_l deposited with the ATCC under accession number PTA- 366;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:60; (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:60 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:60;

25% of the length of SEQ ID NO:59.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:59 from nucleotide 96 to nucleotide 341; the nucleotide sequence of SEQ ID NO:59 from nucleotide 174 to nucleotide 341; the nucleotide sequence ofthe full-length protein coding sequence of clone vol4_l deposited with the ATCC under accession number PTA-

366; or the nucleotide sequence of a mature protein coding sequence of clone vol4_l deposited with the ATCC under accession number PTA-366. In other prefened embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vol4_l deposited with the ATCC under accession number PTA- 366. In further prefened embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 60 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:60, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:60 having biological activity, the fragment comprising the amino acid sequence from amino acid 36 to amino acid 45 of SEQ ID NO:60. Other embodiments provide the gene conesponding to the cDN A sequence of SEQ

ID NO:59.

(aa) SEQ ID NO:59, but excluding the poly(A) tail at the 3' end of SEQ ID NO:59; and (ab) the nucleotide sequence of the cDN A insert of clone vol4_l deposited with the ATCC under accession number PTA- 366;

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of: (ba) SEQ ID NO:59, but excluding the poly(A) tail at the 3' end of SEQ ID NO:59; and

(bb) the nucleotide sequence of the cDN A insert of clone vol4_l deposited with the ATCC under accession number PTA- 366;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:59, and extending contiguously from anucleotide sequence corresponding to the 5' end of SEQ ID

NO:59 to a nucleotide sequence conesponding to the 3' end of SEQ ID NO:59 , but excluding the ρoly(A) tail at the 3' end of SEQ ID NO:59. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:59 from nucleotide 96 to nucleotide

341, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO: 59 from nucleotide 96 to nucleotide 341, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:59 from nucleotide 96 to nucleotide 341. Also preferably the polynucleotide isolated according to the above process comprises anucleotide sequence conesponding to the cDNA sequence of SEQ ID

NO: 59 from nucleotide 174 to nucleotide 341, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO:59 from nucleotide 174 to nucleotide 341, to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ ID NO:59 from nucleotide 174 to nucleotide 341.

(a) the amino acid sequence of SEQ ID NO:60; (b) a fragment of the amino acid sequence of SEQ ID NO: 60, the fragment comprising eight contiguous amino acids of SEQ ID NO: 60; and (c) the amino acid sequence encoded by the cDNA insert of clone vol4_l deposited with the ATCC under accession number PTA-366; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:60. In further prefened embodiments, the present invention provides a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:60 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 60, or a protein comprising a fragment of the amino acid sequence of SEQ

ID NO:60 having biological activity, the fragment comprising the amino acid sequence from amino acid 36 to amino acid 45 of SEQ ID NO:60.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:61; (b) a polynucleotide comprising the nucleotide sequence of SEQ ID

NO:61 from nucleotide 90 to nucleotide 599;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 61 from nucleotide 165 to nucleotide 599;

(d) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone vol5_l deposited with the ATCC under accession number PTA-366;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vol5_l deposited with the ATCC under accession number PTA-366; (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vol5_l deposited with the ATCC under accession number PTA-366;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vol5_l deposited with the ATCC under accession number PTA- 366;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:62; (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:62 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:62;

(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:61.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:61 from nucleotide 90 to nucleotide 599; the nucleotide sequence of SEQ ID NO:61 from nucleotide 165 to nucleotide 599; the nucleotide sequence of the full-length protein coding sequence of clone vo 15_ 1 deposited with the ATCC under accession number PTA- 366; or the nucleotide sequence of a mature protein coding sequence of clone vol5_l deposited with the ATCC under accession number PTA-366. In other prefened embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vo 15_1 deposited with the ATCC under accession number PTA- 366. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 62 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:62, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of

SEQ ID NO:62 having biological activity, the fragment comprising the amino acid sequence from amino acid 80 to amino acid 89 of SEQ ID NO:62.

Other embodiments provide the gene conesponding to the cDN A sequence of SEQ ID NO.61. Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of: (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:61 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:61; and

(ab) the nucleotide sequence of the cDN A insert of clone vol5_l deposited with the ATCC under accession number PTA- 366;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(ba) SEQ ID NO:61 , but excluding the poly( A) tail at the 3' end of SEQ ID NO:61; and (bb) the nucleotide sequence of the cDN A insert of clone vol5_l deposited with the ATCC under accession number PTA- 366;

(iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:61, and extending contiguously from anucleotide sequence conesponding to the 5' end of SEQ ID NO:61 to a nucleotide sequence conesponding to the 3' end of SEQ ID NO:61 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:61. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:61 from nucleotide 90 to nucleotide 599, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO: 61 from nucleotide 90 to nucleotide 599, to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ ID NO:61 from nucleotide 90 to nucleotide 599. Also preferably the polynucleotide isolated according to the above process comprises anucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:61 from nucleotide 165 to nucleotide 599, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO:61 from nucleotide 165 to nucleotide 599, to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ ID NO:61 from nucleotide 165 to nucleotide 599.

(a) the amino acid sequence of SEQ ID NO: 62; (b) a fragment of the amino acid sequence of SEQ ID NO: 62, the fragment comprising eight contiguous amino acids of SEQ ID NO:62; and

(c) the amino acid sequence encoded by the cDNA insert of clone vol5_l deposited with the ATCC under accession number PTA-366; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO: 62. In further prefened embodiments, the present invention provides a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:62 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:62, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 62 having biological activity, the fragment comprising the amino acid sequence from amino acid 80 to amino acid 89 of SEQ ID NO:62.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:63;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:63 from nucleotide 209 to nucleotide 451; (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:63 from nucleotide 398 to nucleotide 451;

(d) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone vol6_l deposited with the ATCC under accession number PTA-366;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vol6_l deposited with the ATCC under accession number PTA-366;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vol6_l deposited with the ATCC under accession number PTA-366;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vol6_l deposited with the ATCC under accession number PTA- 366; (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:64;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:64 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO: 64; (j) a polynucleotide which is an allelic variant of a polynucleotide of

(a)-(g) above;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:63. Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO: 63 from nucleotide 209 to nucleotide 451 ; the nucleotide sequence of SEQ ID NO: 63 from nucleotide 398 to nucleotide 451 ; the nucleotide sequence of the full-length protein coding sequence of clone vo 16_ 1 deposited with the ATCC under accession number PTA- 366; or the nucleotide sequence of a mature protein coding sequence of clone vol6_l deposited with the ATCC under accession number PTA-366. In other prefened embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vol6_l deposited with the ATCC under accession number PTA- 366. In further prefened embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 64 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:64, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 64 having biological activity, the fragment comprising the amino acid sequence from amino acid 35 to amino acid 44 of SEQ ID NO:64.

Other embodiments provide the gene conesponding to the cDNA sequence of SEQ ID NO:63.

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of: (aa) SEQ ID NO:63, but excluding the ρoly(A) tail at the

3' end of SEQ ID NO:63; and

(ab) the nucleotide sequence of the cDN A insert of clone vol6_l deposited with the ATCC under accession number PTA- 366; (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(ba) SEQ ID NO:63, but excluding the poly(A) tail at the 3' end of SEQ ID NO:63; and

(bb) the nucleotide sequence of the cDN A insert of clone vol6_l deposited with the ATCC under accession number PTA- 366;

(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:63, and extending contiguously from a nucleotide sequence conesponding to the 5 ' end of SEQ ID NO:63 to a nucleotide sequence conesponding to the 3' end of SEQ ID NO:63 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:63. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:63 from nucleotide 209 to nucleotide 451 , and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:63 from nucleotide 209 to nucleotide 451 , to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ ID NO:63 from nucleotide 209 to nucleotide 451. Also preferably the polynucleotide isolated according to the above process comprises anucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:63 from nucleotide 398 to nucleotide 451, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:63 from nucleotide 398 to nucleotide 451, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:63 from nucleotide 398 to nucleotide 451.

(a) the amino acid sequence of SEQ ID NO:64; (b) a fragment of the amino acid sequence of SEQ ID NO:64, the fragment comprising eight contiguous amino acids of SEQ ID NO:64; and

(c) the amino acid sequence encoded by the cDNA insert of clone vol6_l deposited with the ATCC under accession number PTA-366; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:64. In further prefened embodiments, the present invention provides a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:64 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:64, or aprotein comprising a fragment ofthe amino acid sequence of SEQ ID NO:64 having biological activity, the fragment comprising the amino acid sequence from amino acid 35 to amino acid 44 of SEQ ID NO:64.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:65;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:65 from nucleotide 31 to nucleotide 231; (c) a polynucleotide comprising the nucleotide sequence of SEQ ID

NO:65 from nucleotide 97 to nucleotide 231;

(d) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone vol8_l deposited with the ATCC under accession number PTA-366; (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vol8_l deposited with the ATCC under accession number PTA-366;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vol8_l deposited with the ATCC under accession number PTA-366; (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vol 8_1 deposited with the ATCC under accession number PTA-366; (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:66; (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 66 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:66;

25% ofthe length of SEQ ID NO:65.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO: 65 from nucleotide 31 to nucleotide 231; the nucleotide sequence of SEQ ID NO: 65 from nucleotide 97 to nucleotide 231 ; the nucleotide sequence of the full-length protein coding sequence of clone vo 18_1 deposited with the ATCC under accession number PTA- 366; or the nucleotide sequence of a mature protein coding sequence of clone vol8_l deposited with the ATCC under accession number PTA-366. In other prefened embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDN A insert of clone vo 18_ 1 deposited with the ATCC under accession number PTA- 366. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 66 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:66, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:66 having biological activity, the fragment comprising the amino acid sequence from amino acid 28 to amino acid 37 of SEQ ID NO:66. Other embodiments provide the gene conesponding to the cDNA sequence of SEQ ID NO:65.

(aa) SEQ ID NO:65, but excluding the poly(A) tail at the 3' end of SEQ ID NO:65; and

(ab) the nucleotide sequence of the cDN A insert of clone vol8_l deposited with the ATCC under accession number PTA- 366;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(ba) SEQ ID NO: 65 , but excluding the poly (A) tail at the 3' end of SEQ ID NO:65; and (bb) the nucleotide sequence of the cDN A insert of clone vol8_l deposited with the ATCC under accession number PTA- 366;

(iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:65, and extending contiguously from a nucleotide sequence conesponding to the 5' end of SEQ ID NO:65 to a nucleotide sequence conesponding to the 3' end of SEQ ID NO:65 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:65. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO: 65 from nucleotide 31 to nucleotide 231, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO: 65 from nucleotide 31 to nucleotide 231 , to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO: 65 from nucleotide 31 to nucleotide 231. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO: 65 from nucleotide 97 to nucleotide 231, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO: 65 from nucleotide 97 to nucleotide 231 Jo a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO: 65 from nucleotide 97 to nucleotide 231.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ID NO:66;

(b) a fragment of the amino acid sequence of SEQ ID NO:66, the fragment comprising eight contiguous amino acids of SEQ ID NO:66; and

(c) the amino acid sequence encoded by the cDNA insert of clone vol8_l deposited with the ATCC under accession number PTA-366; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:66. In further prefened embodiments, the present invention provides a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:66 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:66, or a protein comprising a fragment of the amino acid sequence of SEQ

ID NO:66 having biological activity, the fragment comprising the amino acid sequence from amino acid 28 to amino acid 37 of SEQ ID NO: 66. In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:67; (b) a polynucleotide comprising the nucleotide sequence of SEQ ID

NO: 67 from nucleotide 23 to nucleotide 736;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:67 from nucleotide 83 to nucleotide 736;

(d) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone vol9_l deposited with the ATCC under accession number PTA-366;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vol9_l deposited with the ATCC under accession number PTA-366; (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vol9_l deposited with the ATCC under accession number PTA-366;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vol9_l deposited with the ATCC under accession number PTA- 366;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO: 68;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:68 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO: 68;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; (1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:67.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:67 from nucleotide 23 to nucleotide 736; the nucleotide sequence of SEQ ID NO:67 from nucleotide 83 to nucleotide 736; the nucleotide sequence of the full-length protein coding sequence of clone vo 19_ 1 deposited with the ATCC under accession number PT A- 366; or the nucleotide sequence of a mature protein coding sequence of clone vol9_l deposited with the ATCC under accession number PTA-366. In other prefened embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vol9_l deposited with the ATCC under accession number PTA- 366. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:68 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:68, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 68 having biological activity, the fragment comprising the amino acid sequence from amino acid 114 to amino acid 123 of SEQ ID NO:68.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:67.

(aa) SEQ ID NO : 67 , but excluding the poly (A) tail at the 3' end of SEQ ID NO:67; and

(ab) the nucleotide sequence of the cDN A insert of clone vol9_J deposited with the ATCC under accession number PTA- 366; (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of: (ba) SEQ ID NO:67, but excluding the poly(A) tail at the

3' end of SEQ ID NO:67; and

(bb) the nucleotide sequence of the cDN A insert of clone vol9_l deposited with the ATCC under accession number PTA- 366; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO: 67, and extending contiguously from anucleotide sequence corresponding to the 5' end of SEQ ID NO:67 to a nucleotide sequence conesponding to the 3' end of SEQ ID NO:67 , but excluding the poly (A) tail at the 3' end of SEQ ID NO: 67. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO: 67 from nucleotide 23 to nucleotide

736, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO:67 from nucleotide 23 to nucleotide 736, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO: 67 from nucleotide 23 to nucleotide 736. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDN A sequence of SEQ ID

NO:67 from nucleotide 83 to nucleotide 736, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO:67 from nucleotide 83 to nucleotide 736, to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ ID NO:67 from nucleotide 83 to nucleotide 736.

(a) the amino acid sequence of SEQ ID NO:68;

(b) a fragment of the amino acid sequence of SEQ ID NO:68, the fragment comprising eight contiguous amino acids of SEQ ID NO: 68; and

(c) the amino acid sequence encoded by the cDNA insert of clone vol9_l deposited with the ATCC under accession number PTA-366; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:68. In further prefened embodiments, the present invention provides a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:68 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 68, or a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:68 having biological activity, the fragment comprising the amino acid sequence from amino acid 114 to amino acid 123 of SEQ ID NO:68.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:69;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:69 from nucleotide 104 to nucleotide 1399; (c) a polynucleotide comprising the nucleotide sequence of SEQ ID

NO:69 from nucleotide 158 to nucleotide 1399;

(d) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone vo22_l deposited with the ATCC under accession number PTA-366; (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vo22_l deposited with the ATCC under accession number PTA-366; (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vo22_l deposited with the ATCC under accession number PTA-366;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vo22_l deposited with the ATCC under accession number PTA- 366;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:70;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:70 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:70;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:69.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO: 69 from nucleotide 104 to nucleotide 1399; the nucleotide sequence of SEQ ID NO: 69 from nucleotide 158 to nucleotide 1399; the nucleotide sequence ofthe full-length protein coding sequence of clone vo22_l deposited with the ATCC under accession number PTA- 366; or the nucleotide sequence of a mature protein coding sequence of clone vo22_l deposited with the ATCC under accession number PTA-366. In other prefened embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vo22_l deposited with the ATCC under accession number PTA- 366. In further prefened embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 70 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:70, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:70 having biological activity, the fragment comprising the amino acid sequence from amino acid 211 to amino acid 220 of SEQ ID NO:70.

Other embodiments provide the gene conesponding to the cDNA sequence of SEQ ID NO:69.

(a) a process comprising the steps of:

(aa) SEQ ID NO:69, but excluding the poly(A) tail at the 3' end of SEQ ID NO:69; and

(ab) the nucleotide sequence ofthe cDNA insert of clone vo22_l deposited with the ATCC under accession number PTA- 366;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO: 69, but excluding the poly (A) tail at the 3' end of SEQ ID NO:69; and

(bb) the nucleotide sequence of the cDN A insert of clone vo22_l deposited with the ATCC under accession number PTA- 366;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO: 69, and extending contiguously from a nucleotide sequence conesponding to the 5 ' end of SEQ ID NO: 69 to a nucleotide sequence conesponding to the 3' end of SEQ ID NO: 69 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:69. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO: 69 from nucleotide 104 to nucleotide 1399, and extending contiguously from a nucleotide sequence conesponding to the 5 ' end of said sequence of SEQ ID NO:69 from nucleotide 104 to nucleotide 1399, to anucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:69 from nucleotide 104 to nucleotide 1399. Also preferably the polynucleotide isolated according to the above process comprises anucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:69 from nucleotide 158 to nucleotide 1399, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:69 from nucleotide 158 to nucleotide 1399, to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ ID NO:69 from nucleotide 158 to nucleotide 1399.

(a) the amino acid sequence of SEQ ID NO: 70;

(b) a fragment of the amino acid sequence of SEQ ID NO:70, the fragment comprising eight contiguous amino acids of SEQ ID NO: 70; and (c) the amino acid sequence encoded by the cDNA insert of clone vo22_l deposited with the ATCC under accession number PTA-366; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:70. In further prefened embodiments, the present invention provides a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:70 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:70, or a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:70 having biological activity, the fragment comprising the amino acid sequence from amino acid 211 to amino acid 220 of SEQ ID NO:70.

NO-71;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:71 from nucleotide 174 to nucleotide 1595;

(c) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone vo23_l deposited with the ATCC under accession number PTA-366;

(d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vo23_l deposited with the ATCC under accession number PTA-366; (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vo23_l deposited with the ATCC under accession number PTA-366;

(f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vo23_l deposited with the ATCC under accession number PTA- 366;

(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:72;

(h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:72 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:72;

(j ) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ; (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and (1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:71.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:71 from nucleotide 174 to nucleotide 1595; the nucleotide sequence of the full-length protein coding sequence of clone vo23_l deposited with the ATCC under accession number PTA-366; or the nucleotide sequence of a mature protein coding sequence of clone vo23_l deposited with the ATCC under accession number PTA-366. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDN A insert of clone vo23_ 1 deposited with the ATCC under accession number PTA- 366. In further prefened embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:72 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:72, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:72 having biological activity, the fragment comprising the amino acid sequence from amino acid 232 to amino acid 241 of SEQ ID NO:72.

Other embodiments provide the gene conesponding to the cDNA sequence of SEQ ID NO:71. Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of:

(aa) SEQ ID NO:71 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:71 ; and

(ab) the nucleotide sequence of the cDN A insert of clone vo23_l deposited with the ATCC under accession number PTA- 366;

(ba) SEQ ID NO:71 , but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:71 ; and (bb) the nucleotide sequence of the cDN A insert of clone vo23_l deposited with the ATCC under accession number PTA- 366;

(iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:71, and extending contiguously from anucleotide sequence conesponding to the 5' end of SEQ ID NO:71 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:71 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:71. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:71 from nucleotide 174 to nucleotide 1595, and extending contiguously from a nucleotide sequence conesponding to the 5' end ofsaid sequence of SEQ ID NO:71 from nucleotide 174 to nucleotide 1595 Jo anucleotide sequence conesponding to the 3' end ofsaid sequence of SEQ ID NO:71 from nucleotide 174 to nucleotide 1595.

(a) the amino acid sequence of SEQ ID NO:72; (b) a fragment of the amino acid sequence of SEQ ID NO:72, the fragment comprising eight contiguous amino acids of SEQ ID NO:72; and

(c) the amino acid sequence encoded by the cDNA insert of clone vo23_l deposited with the ATCC under accession number PTA-366; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:72. In further prefened embodiments, the present invention provides a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:72 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 72, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:72 having biological activity, the fragment comprising the amino acid sequence from amino acid 232 to amino acid 241 of SEQ ID NO:72.

NO:73;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:73 from nucleotide 129 to nucleotide 311;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:73 from nucleotide 195 to nucleotide 311;

(d) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone vo24_l deposited with the ATCC under accession number PTA-366;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vo24_l deposited with the ATCC under accession number

PTA-366;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vo24_l deposited with the ATCC under accession number PTA-366; (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vo24_l deposited with the ATCC under accession number PTA- 366; (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:74;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:74 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:74;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:73. Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID

NO:73 from nucleotide 129 to nucleotide 311 ; the nucleotide sequence of SEQ ID NO:73 from nucleotide 195 to nucleotide 311; the nucleotide sequence of the full-length protein coding sequence of clone vo24_l deposited with the ATCC under accession number PTA- 366; or the nucleotide sequence of a mature protein coding sequence of clone vo24_l deposited with the ATCC under accession number PTA-366. In other prefened embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vo24_l deposited with the ATCC under accession number PTA- 366. In further prefened embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:74 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:74, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:74 having biological activity, the fragment comprising the amino acid sequence from amino acid 25 to amino acid 34 of SEQ ID NO:74. Other embodiments provide the gene conesponding to the cDN A sequence of SEQ

ID NO:73. Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

(aa) SEQ ID NO:73, but excluding the poly(A) tail at the 3' end of SEQ ID NO:73; and

(ab) the nucleotide sequence ofthe cDNA insert of clone vo24_l deposited with the ATCC under accession number PTA- 366;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:73, but excluding the poly(A) tail at the 3' end of SEQ ID NO:73; and

(bb) the nucleotide sequence of the cDN A insert of clone vo24_l deposited with the ATCC under accession number PTA- 366;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:73, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:73 to a nucleotide sequence conesponding to the 3' end of SEQ ID NO:73 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:73. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:73 from nucleotide 129 to nucleotide 311, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO:73 from nucleotide 129 to nucleotide 311 , to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:73 from nucleotide 129 to nucleotide 311. Also preferably the polynucleotide isolated according to the above process comprises anucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:73 from nucleotide 195 to nucleotide 311, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO:73 from nucleotide 195 to nucleotide 311, to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ ID NO:73 from nucleotide 195 to nucleotide 311.

(a) the amino acid sequence of SEQ ID NO:74;

(b) a fragment of the amino acid sequence of SEQ ID NO:74, the fragment comprising eight contiguous amino acids of SEQ ID NO:74; and (c) the amino acid sequence encoded by the cDNA insert of clone vo24_l deposited with the ATCC under accession number PTA-366; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:74. In further prefened embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:74 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:74, or a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:74 having biological activity, the fragment comprising the amino acid sequence from amino acid 25 to amino acid 34 of SEQ ID NO:74. In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:75;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:75 from nucleotide 73 to nucleotide 798; (c) a polynucleotide comprising the nucleotide sequence of SEQ ID

NO:75 from nucleotide 142 to nucleotide 798;

(d) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone vo25_l deposited with the ATCC under accession number PTA-366; (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vo25_l deposited with the ATCC under accession number PTA-366;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vo25_l deposited with the ATCC under accession number PTA-366;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vo25_l deposited with the ATCC under accession number PTA- 366;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:76;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:76 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:76;

(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:75. Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:75 from nucleotide 73 to nucleotide 798; the nucleotide sequence of SEQ ID NO:75 from nucleotide 142 to nucleotide 798; the nucleotide sequence of the full-length protein coding sequence of clone vo25_l deposited with the ATCC under accession number PTA- 366; or the nucleotide sequence of a mature protein coding sequence of clone vo25_l deposited with the ATCC under accession number PTA-366. In other prefened embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vo25_l deposited with the ATCC under accession number PTA- 366. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:76 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:76, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:76 having biological activity, the fragment comprising the amino acid sequence from amino acid 116 to amino acid 125 of SEQ ID NO:76.

Other embodiments provide the gene conesponding to the cDN A sequence of SEQ ID NO:75.

(aa) SEQ ID NO:75, but excluding the poly(A) tail at the 3' end of SEQ ID NO:75; and

(ab) the nucleotide sequence ofthe cDNA insert of clone vo25_l deposited with the ATCC under accession number PTA- 366;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:75, but excluding the poly(A) tail at the 3' end of SEQ ID NO:75; and

(bb) the nucleotide sequence of the cDN A insert of clone vo25_l deposited with the ATCC under accession number PTA- 366;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:75, and extending contiguously from anucleotide sequence corresponding to the 5' end of SEQ ID NO:75 to a nucleotide sequence conesponding to the 3' end of SEQ ID NO:75 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:75. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:75 from nucleotide 73 to nucleotide 798, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO:75 from nucleotide 73 to nucleotide 798, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:75 from nucleotide 73 to nucleotide 798. Also preferably the polynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:75 from nucleotide 142 to nucleotide 798, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:75 from nucleotide 142 to nucleotide 798, to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ ID NO:75 from nucleotide 142 to nucleotide 798. In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:76; (b) a fragment of the amino acid sequence of SEQ ID NO:76, the fragment comprising eight contiguous amino acids of SEQ ID NO:76; and

(c) the amino acid sequence encoded by the cDNA insert of clone vo25_l deposited with the ATCC under accession number PTA-366; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:76. In further prefened embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:76 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:76, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:76 having biological activity, the fragment comprising the amino acid sequence from amino acid 116 to amino acid 125 of SEQ ID NO:76.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:77;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:77 from nucleotide 26 to nucleotide 307;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:77 from nucleotide 101 to nucleotide 307; (d) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone vo26_l deposited with the ATCC under accession number PTA-366;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vo26_l deposited with the ATCC under accession number PTA-366; (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vo26_l deposited with the ATCC under accession number PTA-366;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vo26_l deposited with the ATCC under accession number PTA- 366;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:78;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:78 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:78;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:77.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:77 from nucleotide 26 to nucleotide 307; the nucleotide sequence of SEQ ID NO:77 from nucleotide 101 to nucleotide 307; the nucleotide sequence ofthe full-length protein coding sequence of clone vo26_l deposited with the ATCC under accession number PTA- 366; or the nucleotide sequence of a mature protein coding sequence of clone vo26_l deposited with the ATCC under accession number PTA-366. In other prefened embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vo26_l deposited with the ATCC under accession number PTA- 366. In further prefened embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:78 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:78, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:78 having biological activity, the fragment comprising the amino acid sequence from amino acid 42 to amino acid 51 of SEQ ID NO:78.

Other embodiments provide the gene conesponding to the cDNA sequence of SEQ ID NO:77.

(a) a process comprising the steps of:

(aa) SEQ ID NO:77, but excluding the poly(A) tail at the 3' end of SEQ ID NO:77; and

(ab) the nucleotide sequence of the cDN A insert of clone vo26_l deposited with the ATCC under accession number PTA- 366;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:77, but excluding the ρoly(A) tail at the 3' end of SEQ ID NO:77; and

(bb) the nucleotide sequence of the cDN A insert of clone vo26_l deposited with the ATCC under accession number PTA- 366;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:77, and extending contiguously from a nucleotide sequence conesponding to the 5 ' end of SEQ ID NO:77 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:77 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:77. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 77 from nucleotide 26 to nucleotide 307, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO:77 from nucleotide 26 to nucleotide 307, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:77 from nucleotide 26 to nucleotide 307. Also preferably the polynucleotide isolated according to the above process comprises anucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:77 from nucleotide 101 to nucleotide 307, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:77 from nucleotide 101 to nucleotide 307, to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ ID NO:77 from nucleotide 101 to nucleotide 307.

(a) the amino acid sequence of SEQ ID NO:78;

(b) a fragment of the amino acid sequence of SEQ ID NO:78, the fragment comprising eight contiguous amino acids of SEQ ID NO:78; and (c) the amino acid sequence encoded by the cDNA insert of clone vo26_l deposited with the ATCC under accession number PTA-366; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:78. In further preferred embodiments, the present invention provides a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:78 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:78, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:78 having biological activity, the fragment comprising the amino acid sequence from amino acid 42 to amino acid 51 of SEQ ID NO:78.

NO:79;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:79 from nucleotide 43 to nucleotide 228;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:79 from nucleotide 94 to nucleotide 228;

(d) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone vp23_l deposited with the ATCC under accession number PTA-368;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vp23_l deposited with the ATCC under accession number

PTA-368;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vp23_J deposited with the ATCC under accession number PTA-368; (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vp23_l deposited with the ATCC under accession number PTA- 368;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:80; (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:80 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO: 80;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:79.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:79 from nucleotide 43 to nucleotide 228; the nucleotide sequence of SEQ ID NO:79 from nucleotide 94 to nucleotide 228; the nucleotide sequence of the full-length protein coding sequence of clone vp23_l deposited with the ATCC under accession number PTA- 368; or the nucleotide sequence of a mature protein coding sequence of clone vp23_l deposited with the ATCC under accession number PTA-368. In other prefened embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vp23_J deposited with the ATCC under accession number PTA- 368. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 80 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:80, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 80 having biological activity, the fragment comprising the amino acid sequence from amino acid 26 to amino acid 35 of SEQ ID NO:80.

Other embodiments provide the gene conesponding to the cDNA sequence of SEQ ID NO:79.

(aa) SEQ ID NO:79, but excluding the poly(A) tail at the 3' end of SEQ ID NO:79; and (ab) the nucleotide sequence of the cDNA insert of clone vp23_l deposited with the ATCC under accession number PTA-368; (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:79, but excluding the poly(A) tail at the 3' end of SEQ ID NO:79; and

(bb) the nucleotide sequence of the cDN A insert of clone vp23_l deposited with the ATCC under accession number PTA- 368;

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:79, and extending contiguously from anucleotide sequence corresponding to the 5' end of SEQ ID NO:79 to a nucleotide sequence conesponding to the 3' end of SEQ ID NO:79 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:79. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:79 from nucleotide 43 to nucleotide 228, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO:79 from nucleotide 43 to nucleotide 228, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:79 from nucleotide

43 to nucleotide 228. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:79 from nucleotide 94 to nucleotide 228, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO:79 from nucleotide 94 to nucleotide 228, to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ ID NO:79 from nucleotide 94 to nucleotide 228. In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:80;

(b) a fragment of the amino acid sequence of SEQ ID NO: 80, the fragment comprising eight contiguous amino acids of SEQ ID NO: 80; and

(c) the amino acid sequence encoded by the cDNA insert of clone vp23_l deposited with the ATCC under accession number PTA-368; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:80. In further prefened embodiments , the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 80 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:80, or a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:80 having biological activity, the fragment comprising the amino acid sequence from amino acid 26 to amino acid 35 of SEQ ID NO:80.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:81; (b) a polynucleotide comprising the nucleotide sequence of SEQ ID

NO:81 from nucleotide 245 to nucleotide 427;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:81 from nucleotide 308 to nucleotide 427;

(d) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone vq7_l deposited with the ATCC under accession number PTA-368; (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vq7_l deposited with the ATCC under accession number PTA-368;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vq7_ 1 deposited with the ATCC under accession number PTA-368;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vq7_l deposited with the ATCC under accession number PTA-368;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:82;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 82 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO: 82;

(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:81.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:81 from nucleotide 245 to nucleotide 427; the nucleotide sequence of SEQ ID NO:81 from nucleotide 308 to nucleotide 427; the nucleotide sequence of the full-length protein coding sequence of clone vq7_l deposited with the ATCC under accession number PTA- 368; or the nucleotide sequence of a mature protein coding sequence of clone vq7_l deposited with the ATCC under accession number PTA-368. In other prefened embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vq7_l deposited with the ATCC under accession number PTA-

368. In further prefened embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 82 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:82, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:82 having biological activity, the fragment comprising the amino acid sequence from amino acid 25 to amino acid 34 of SEQ ID NO: 82.

Other embodiments provide the gene conesponding to the cDNA sequence of SEQ ID NO:81.

(aa) SEQ ID NO:81 , but excluding the ρoly(A) tail at the 3' end of SEQ ID NO:81; and

(ab) the nucleotide sequence of the cDN A insert of clone vq7_l deposited with the ATCC under accession number PTA-368; (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO: 81 , but excluding the poly (A) tail at the 3' end of SEQ ID NO:81; and

(bb) the nucleotide sequence of the cDN A insert of clone vq7_l deposited with the ATCC under accession number PTA-368;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:81, and extending contiguously from a nucleotide sequence conesponding to the 5' end of SEQ ID NO:81 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:81 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:81. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:81 from nucleotide 245 to nucleotide 427, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO:81 from nucleotide 245 to nucleotide 427, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:81 from nucleotide 245 to nucleotide 427. Also preferably the polynucleotide isolated according to the above process comprises anucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:81 from nucleotide 308 to nucleotide 427, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:81 from nucleotide 308 to nucleotide 427, to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ ID NO:81 from nucleotide 308 to nucleotide 427.

(a) the amino acid sequence of SEQ ID NO:82;

(b) a fragment of the amino acid sequence of SEQ ID NO: 82, the fragment comprising eight contiguous amino acids of SEQ ID NO:82; and (c) the amino acid sequence encoded by the cDNA insert of clone vq7_l deposited with the ATCC under accession number PTA-368; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO: 82. In further prefened embodiments , the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 82 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:82, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 82 having biological activity, the fragment comprising the amino acid sequence from amino acid 25 to amino acid 34 of SEQ ID NO:82.

NO:83;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:83 from nucleotide 119 to nucleotide 475;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:83 from nucleotide 185 to nucleotide 475;

(d) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone vq8_l deposited with the ATCC under accession number PTA-368;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vq8_l deposited with the ATCC under accession number

PTA-368;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vq8_l deposited with the ATCC under accession number PTA-368; (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vq8_l deposited with the ATCC under accession number PTA-368;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO: 84;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 84 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:84;

(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:83.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:83 from nucleotide 119 to nucleotide 475; the nucleotide sequence of SEQ ID NO:83 from nucleotide 185 to nucleotide 475; the nucleotide sequence ofthe full-length protein coding sequence of clone vq8_l deposited with the ATCC under accession number PTA- 368; or the nucleotide sequence of a mature protein coding sequence of clone vq8_l deposited with the ATCC under accession number PTA-368. In other prefened embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vq8_l deposited with the ATCC under accession number PTA- 368. In further prefened embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 84 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:84, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:84 having biological activity, the fragment comprising the amino acid sequence from amino acid 54 to amino acid 63 of SEQ ID NO: 84.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:83.

(aa) SEQ ID NO:83, but excluding the ρoly(A) tail at the 3' end of SEQ ID NO:83; and

(ab) the nucleotide sequence of the cDN A insert of clone vq8_l deposited with the ATCC under accession number PTA-368;

(ba) SEQ ID NO:83, but excluding the ρoly(A) tail at the 3' end of SEQ ID NO:83; and (bb) the nucleotide sequence of the cDN A insert of clone vq8_ 1 deposited with the ATCC under accession number PTA-368 ; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:83, and extending contiguously from anucleotide sequence conesponding to the 5' end of SEQ ID NO:83 to a nucleotide sequence conesponding to the 3' end of SEQ ID NO:83 , but excluding the poly (A) tail at the 3' end of SEQ ID NO: 83. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO: 83 from nucleotide 119 to nucleotide 475, and extending contiguously from a nucleotide sequence corresponding to the 5' end ofsaid sequence of SEQ ID NO: 83 from nucleotide 119 to nucleotide 475, to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ ID NO:83 from nucleotide

119 to nucleotide 475. Also preferably the polynucleotide isolated according to the above process comprises anucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:83 from nucleotide 185 to nucleotide 475, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO:83 from nucleotide 185 to nucleotide 475, to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ ID NO:83 from nucleotide 185 to nucleotide 475. In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO: 84; (b) a fragment of the amino acid sequence of SEQ ID NO: 84, the fragment comprising eight contiguous amino acids of SEQ ID NO: 84; and

(c) the amino acid sequence encoded by the cDNA insert of clone vq8_l deposited with the ATCC under accession number PTA-368; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO: 84. In further prefened embodiments, the present invention provides aprotein comprising a fragment ofthe amino acid sequence of SEQ ID NO: 84 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:84, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 84 having biological activity, the fragment comprising the amino acid sequence from amino acid 54 to amino acid 63 of SEQ ID NO:84.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:85;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:85 from nucleotide 90 to nucleotide 323;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:85 from nucleotide 141 to nucleotide 323; (d) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone vq9_l deposited with the ATCC under accession number PTA-368;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vq9_l deposited with the ATCC under accession number PTA-368; (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vq9_l deposited with the ATCC under accession number PTA-368;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vq9_l deposited with the ATCC under accession number PTA-368;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:86;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 86 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:86;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:85. Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID

NO:85 from nucleotide 90 to nucleotide 323; the nucleotide sequence of SEQ ID NO:85 from nucleotide 141 to nucleotide 323; the nucleotide sequence ofthe full-length protein coding sequence of clone vq9_l deposited with the ATCC under accession number PTA- 368; or the nucleotide sequence of a mature protein coding sequence of clone vq9_l deposited with the ATCC under accession number PTA-368. In other prefened embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vq9_l deposited with the ATCC under accession number PTA- 368. In further prefened embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:86 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:86, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:86 having biological activity, the fragment comprising the amino acid sequence from amino acid 34 to amino acid 43 of SEQ ID NO: 86.

Other embodiments provide the gene conesponding to the cDNA sequence of SEQ ID NO:85. Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of:

(aa) SEQ ID NO: 85, but excluding the poly( A) tail at the 3' end of SEQ ID NO:85; and

(ab) the nucleotide sequence ofthe cDNA insert of clone vq9_ 1 deposited with the ATCC under accession number PT A-368 ; (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(ba) SEQ ID NO:85, but excluding the poly(A) tail at the 3' end of SEQ ID NO: 85; and

(bb) the nucleotide sequence of the cDN A insert of clone vq9_l deposited with the ATCC under accession number PTA-368; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:85, and extending contiguously from anucleotide sequence conesponding to the 5' end of SEQ ID NO:85 to a nucleotide sequence conesponding to the 3' end of SEQ ID NO:85 , but excluding the poly(A) tail at the 3' end of SEQ ID NO: 85. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO: 85 from nucleotide 90 to nucleotide 323, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO: 85 from nucleotide 90 to nucleotide 323, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:85 from nucleotide 90 to nucleotide 323. Also preferably the polynucleotide isolated according to the above process comprises anucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:85 from nucleotide 141 to nucleotide 323, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO:85 from nucleotide 141 to nucleotide 323, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:85 from nucleotide 141 to nucleotide 323.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ID NO: 86;

(b) a fragment of the amino acid sequence of SEQ ID NO:86, the fragment comprising eight contiguous amino acids of SEQ ID NO:86; and

(c) the amino acid sequence encoded by the cDNA insert of clone vq9_l deposited with the ATCC under accession number PTA-368; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO: 86. In further prefened embodiments, the present invention provides a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:86 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 86, or a protein comprising a fragment of the amino acid sequence of SEQ

ID NO: 86 having biological activity, the fragment comprising the amino acid sequence from amino acid 34 to amino acid 43 of SEQ ID NO:86. In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:87; (b) a polynucleotide comprising the nucleotide sequence of SEQ ID

NO: 87 from nucleotide 18 to nucleotide 452;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 87 from nucleotide 72 to nucleotide 452;

(d) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone vqlO_l deposited with the ATCC under accession number PTA-368;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vql0_l deposited with the ATCC under accession number PTA-368; (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vql0_l deposited with the ATCC under accession number PTA-368;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vql0_l deposited with the ATCC under accession number PTA- 368;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:88;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:88 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO: 88;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; (1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:87.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:87 from nucleotide 18 to nucleotide 452; the nucleotide sequence of SEQ ID NO:87 from nucleotide 72 to nucleotide 452; the nucleotide sequence of the full-length protein coding sequence of clone vq 10_ 1 deposited with the ATCC under accession number PTA- 368; or the nucleotide sequence of a mature protein coding sequence of clone vql0_l deposited with the ATCC under accession number PTA-368. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vql0_l deposited with the ATCC under accession number PTA- 368. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 88 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:88, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:88 having biological activity, the fragment comprising the amino acid sequence from amino acid 67 to amino acid 76 of SEQ ID NO:88.

Other embodiments provide the gene conesponding to the cDNA sequence of SEQ ID NO:87.

(aa) SEQ ID NO: 87, but excluding the poly (A) tail at the 3' end of SEQ ID NO:87; and

(ab) the nucleotide sequence ofthe cDNA insert of clone vql0_l deposited with the ATCC under accession number PTA-

368; (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of: (ba) SEQ ID NO:87, but excluding the ρoly(A) tail at the

3' end of SEQ ID NO:87; and

(bb) the nucleotide sequence ofthe cDNA insert of clone vql0_l deposited with the ATCC under accession number PTA- 368; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:87, and extending contiguously from anucleotide sequence conesponding to the 5' end of SEQ ID NO:87 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:87 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:87. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO: 87 from nucleotide 18 to nucleotide

452, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO: 87 from nucleotide 18 to nucleotide 452, to a nucleotide sequence corresponding to the 3' end ofsaid sequence of SEQ ID NO: 87 from nucleotide 18 to nucleotide 452. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDN A sequence of SEQ ID

NO: 87 from nucleotide 72 to nucleotide 452, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO:87 from nucleotide 72 to nucleotide 452, to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ ID NO:87 from nucleotide 72 to nucleotide 452.

(a) the amino acid sequence of SEQ ID NO:88;

(b) a fragment of the amino acid sequence of SEQ ID NO: 88, the fragment comprising eight contiguous amino acids of SEQ ID NO:88; and

(c) the amino acid sequence encoded by the cDNA insert of clone vql0_l deposited with the ATCC under accession number PTA-368; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:88. In further prefened embodiments, the present invention provides a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO: 88 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 88, or a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:88 having biological activity, the fragment comprising the amino acid sequence from amino acid 67 to amino acid 76 of SEQ ID NO:88.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:89;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 89 from nucleotide 196 to nucleotide 378; (c) a polynucleotide comprising the nucleotide sequence of SEQ ID

NO: 89 from nucleotide 262 to nucleotide 378;

(d) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone vql3_l deposited with the ATCC under accession number PTA-368; (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vql3_l deposited with the ATCC under accession number PTA-368; (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vql3_l deposited with the ATCC under accession number PTA-368;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vql3_l deposited with the ATCC under accession number PTA- 368;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:90;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:90 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:90;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO: 89.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:89 from nucleotide 196 to nucleotide 378; the nucleotide sequence of SEQ ID NO:89 from nucleotide 262 to nucleotide 378; the nucleotide sequence ofthe full-length protein coding sequence of clone vq 13_ 1 deposited with the ATCC under accession number PTA- 368; or the nucleotide sequence of a mature protein coding sequence of clone vql3_l deposited with the ATCC under accession number PTA-368. In other prefened embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vql3_l deposited with the ATCC under accession number PTA- 368. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:90 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:90, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:90 having biological activity, the fragment comprising the amino acid sequence from amino acid 25 to amino acid 34 of SEQ ID NO:90.

Other embodiments provide the gene conesponding to the cDNA sequence of SEQ ID NO:89.

(a) a process comprising the steps of:

(aa) SEQ ID NO:89, but excluding the poly(A) tail at the 3' end of SEQ ID NO:89; and

(ab) the nucleotide sequence of the cDN A insert of clone vql3_l deposited with the ATCC under accession number PTA- 368;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:89, but excluding the poly(A) tail at the 3' end of SEQ ID NO: 89; and

(bb) the nucleotide sequence of the cDN A insert of clone vql3_l deposited with the ATCC under accession number PTA- 368;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:89, and extending contiguously from a nucleotide sequence conesponding to the 5 ' end of SEQ ID NO:89 to a nucleotide sequence conesponding to the 3' end of SEQ ID NO:89 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:89. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO: 89 from nucleotide 196 to nucleotide 378, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO:89 from nucleotide 196 to nucleotide 378, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:89 from nucleotide 196 to nucleotide 378. Also preferably the polynucleotide isolated according to the above process comprises anucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:89 from nucleotide 262 to nucleotide 378, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO: 89 from nucleotide 262 to nucleotide 378, to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ ID NO: 89 from nucleotide 262 to nucleotide 378.

(a) the amino acid sequence of SEQ ID NO: 90;

(b) a fragment of the amino acid sequence of SEQ ID NO:90, the fragment comprising eight contiguous amino acids of SEQ ID NO:90; and (c) the amino acid sequence encoded by the cDNA insert of clone vql3_l deposited with the ATCC under accession number PTA-368; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:90. In further prefened embodiments, the present invention provides a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:90 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:90, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:90 having biological activity, the fragment comprising the amino acid sequence from amino acid 25 to amino acid 34 of SEQ ID NO:90.

NO-91;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:91 from nucleotide 35 to nucleotide 718;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:91 from nucleotide 173 to nucleotide 718;

(d) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone vql6_l deposited with the ATCC under accession number PTA-368;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vq 16_1 deposited with the ATCC under accession number

PTA-368;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vql6_l deposited with the ATCC under accession number PTA-368; (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vql6_l deposited with the ATCC under accession number PTA- 368;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:92; (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:92 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:92;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:91.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:91 from nucleotide 35 to nucleotide 718; the nucleotide sequence of SEQ ID NO:91 from nucleotide 173 to nucleotide 718; the nucleotide sequence ofthe full-length protein coding sequence of clone vq 16_ 1 deposited with the ATCC under accession number PT A- 368; or the nucleotide sequence of a mature protein coding sequence of clone vql6_l deposited with the ATCC under accession number PTA-368. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vql6_l deposited with the ATCC under accession number PTA- 368. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:92 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:92, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 92 having biological activity, the fragment comprising the amino acid sequence from amino acid 109 to amino acid 118 of SEQ ID NO: 92.

Other embodiments provide the gene conesponding to the cDNA sequence of SEQ ID NO-91.

(aa) SEQ ID NO:91 , but excluding the poly (A) tail at the 3' end of SEQ ID NO:91; and (ab) the nucleotide sequence of the cDN A insert of clone vq 16_ 1 deposited with the ATCC under accession number PT A-368 ; (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:91 , but excluding the poly( A) tail at the 3' end of SEQ ID NO:91; and

(bb) the nucleotide sequence of the cDN A insert of clone vql6_l deposited with the ATCC under accession number PTA- 368;

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:91, and extending contiguously from a nucleotide sequence conesponding to the 5' end of SEQ ID NO:91 to a nucleotide sequence conesponding to the 3' end of SEQ ID NO:91 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:91. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:91 from nucleotide 35 to nucleotide 718, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO:91 from nucleotide 35 to nucleotide 718, to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ ID NO: 91 from nucleotide

35 to nucleotide 718. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:91 from nucleotide 173 to nucleotide 718, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO:91 from nucleotide 173 to nucleotide 718, to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ ID NO:91 from nucleotide 173 to nucleotide 718. In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:92;

(b) a fragment of the amino acid sequence of SEQ ID NO:92, the fragment comprising eight contiguous amino acids of SEQ ID NO:92; and

(c) the amino acid sequence encoded by the cDNA insert of clone vql6_l deposited with the ATCC under accession number PTA-368; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:92. In further prefened embodiments , the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:92 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:92, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:92 having biological activity, the fragment comprising the amino acid sequence from amino acid 109 to amino acid 118 of SEQ ID NO:92.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:93; (b) a polynucleotide comprising the nucleotide sequence of SEQ ID

NO:93 from nucleotide 1 to nucleotide 762;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 93 from nucleotide 70 to nucleotide 762;

(d) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone vq 19_1 deposited with the ATCC under accession number PTA-368; (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vql9_l deposited with the ATCC under accession number PTA-368;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vql9_l deposited with the ATCC under accession number PTA-368;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vql9_l deposited with the ATCC under accession number PTA- 368; (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:94;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:94 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:94; (j) a polynucleotide which is an allelic variant of a polynucleotide of

(a)-(g) above;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:93.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:93 from nucleotide 1 to nucleotide 762; the nucleotide sequence of SEQ ID NO:93 from nucleotide 70 to nucleotide 762; the nucleotide sequence of the full-length protein coding sequence of clone vq 19_1 deposited with the ATCC under accession number PTA- 368; or the nucleotide sequence of a mature protein coding sequence of clone vql9_l deposited with the ATCC under accession number PTA-368. In other prefened embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDN A insert of clone vq 19_ 1 deposited with the ATCC under accession number PTA- 368. In further prefened embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:94 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:94, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:94 having biological activity, the fragment comprising the amino acid sequence from amino acid 122 to amino acid 131 of SEQ ID NO:94.

Other embodiments provide the gene conesponding to the cDNA sequence of SEQ ID NO:93.

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of: (aa) SEQ ID NO:93, but excluding the poly(A) tail at the

3' end of SEQ ID NO:93; and

(ab) the nucleotide sequence of the cDN A insert of clone vql9_l deposited with the ATCC under accession number PTA- 368; (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(ba) SEQ ID NO:93, but excluding the poly(A) tail at the 3' end of SEQ ID NO:93; and (bb) the nucleotide sequence of the cDN A insert of clone vq 19_J deposited with the ATCC under accession number PT A-368 ; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:93, and extending contiguously from a nucleotide sequence conesponding to the 5' end of SEQ ID NO:93 to a nucleotide sequence conesponding to the 3' end of SEQ ID NO:93 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:93. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:93 from nucleotide 1 to nucleotide 762, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO:93 from nucleotide 1 to nucleotide 762, to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ ID NO:93 from nucleotide 1 to nucleotide 762. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:93 from nucleotide 70 to nucleotide 762, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO: 93 from nucleotide 70 to nucleotide 762, to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ ID NO:93 from nucleotide 70 to nucleotide 762.

(a) the amino acid sequence of SEQ ID NO:94;

(b) a fragment of the amino acid sequence of SEQ ID NO:94, the fragment comprising eight contiguous amino acids of SEQ ID NO:94; and

(c) the amino acid sequence encoded by the cDNA insert of clone vql9_l deposited with the ATCC under accession number PTA-368; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:94. In further prefened embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:94 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:94, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:94 having biological activity, the fragment comprising the amino acid sequence from amino acid 122 to amino acid 131 of SEQ ID NO:94.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:95;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:95 from nucleotide 106 to nucleotide 792;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:95 from nucleotide 172 to nucleotide 792; (d) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone vq20_l deposited with the ATCC under accession number PTA-368;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vq20_l deposited with the ATCC under accession number PTA-368;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vq20_l deposited with the ATCC under accession number PTA-368;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vq20_l deposited with the ATCC under accession number PTA-

368;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:96;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:96 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:96; (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; (1) a polynucleotide that hybridizes under stringent conditions to any one ofthe polynucleotides specified in (a)-(i); and

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:95. Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID

NO:95 from nucleotide 106 to nucleotide 792; the nucleotide sequence of SEQ ID NO:95 from nucleotide 172 to nucleotide 792; the nucleotide sequence ofthe full-length protein coding sequence of clone vq20_ 1 deposited with the ATCC under accession number PTA- 368; or the nucleotide sequence of a mature protein coding sequence of clone vq20_l deposited with the ATCC under accession number PTA-368. In other prefened embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vq20_l deposited with the ATCC under accession number PTA- 368. In further prefened embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 96 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:96, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:96 having biological activity, the fragment comprising the amino acid sequence from amino acid 109 to amino acid 118 of SEQ ID NO:96. Other embodiments provide the gene conesponding to the cDN A sequence of SEQ

ID NO:95.

Further embodiments ofthe invention provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of: (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of: (aa) SEQ ID NO:95, but excluding the poly(A) tail at the 3' end of SEQ ID NO:95; and

(ab) the nucleotide sequence of the cDN A insert of clone vq20_l deposited with the ATCC under accession number PTA- 368;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of: (ba) SEQ ID NO:95, but excluding the poly (A) tail at the

3' end of SEQ ID NO:95; and

(bb) the nucleotide sequence of the cDN A insert of clone vq20_l deposited with the ATCC under accession number PTA- 368; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:95, and extending contiguously from a nucleotide sequence conesponding to the 5' end of SEQ ID NO:95 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:95 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:95. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:95 from nucleotide 106 to nucleotide 792, and extending contiguously from a nucleotide sequence conesponding to the 5' end ofsaid sequence of SEQ ID NO:95 from nucleotide 106 to nucleotide 792, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:95 from nucleotide 106 to nucleotide 792. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:95 from nucleotide 172 to nucleotide 792, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO:95 from nucleotide 172 to nucleotide 792, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:95 from nucleotide 172 to nucleotide 792.

(a) the amino acid sequence of SEQ ID NO:96;

(b) a fragment of the amino acid sequence of SEQ ID NO:96, the fragment comprising eight contiguous amino acids of SEQ ID NO:96; and

(c) the amino acid sequence encoded by the cDNA insert of clone vq20_l deposited with the ATCC under accession number PTA-368; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:96. In further prefened embodiments, the present invention provides a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:96 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:96, or a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:96 having biological activity, the fragment comprising the amino acid sequence from amino acid 109 to amino acid 118 of SEQ ID NO:96.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:97;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 97 from nucleotide 40 to nucleotide 315; (c) a polynucleotide comprising the nucleotide sequence of SEQ ID

NO:97 from nucleotide 124 to nucleotide 315; (d) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone vq21_l deposited with the ATCC under accession number PTA-368;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vq21_l deposited with the ATCC under accession number

PTA-368;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vq21_l deposited with the ATCC under accession number PTA-368; (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vq21_l deposited with the ATCC under accession number PTA- 368;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:98; (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:98 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:98;

(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above; (k) a polynucleotide which encodes a species homologue ofthe protein of (h) or (i) above ;

25% of the length of SEQ ID NO:97.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:97 from nucleotide 40 to nucleotide 315; the nucleotide sequence of SEQ ID NO:97 from nucleotide 124 to nucleotide 315; the nucleotide sequence ofthe full-length protein coding sequence of clone vq21_1 deposited with the ATCC under accession number PTA-

368; or the nucleotide sequence of a mature protein coding sequence of clone vq21_l deposited with the ATCC under accession number PTA-368. In other prefened embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vq21_1 deposited with the ATCC under accession number PTA- 368. In further prefened embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:98 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:98, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:98 having biological activity, the fragment comprising the amino acid sequence from amino acid 41 to amino acid 50 of SEQ ID NO:98. Other embodiments provide the gene conesponding to the cDN A sequence of SEQ

ID NO:97.

(aa) SEQ ID NO:97, but excluding the poly(A) tail at the 3' end of SEQ ID NO:97; and (ab) the nucleotide sequence of the cDN A insert of clone vq21_l deposited with the ATCC under accession number PTA- 368;

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of: (ba) SEQ ID NO:97, but excluding the poly(A) tail at the 3' end of SEQ ID NO:97; and

(bb) the nucleotide sequence of the cDN A insert of clone vq21_l deposited with the ATCC under accession number PTA- 368;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:97, and extending contiguously from anucleotide sequence conesponding to the 5' end of SEQ ID

NO:97 to a nucleotide sequence conesponding to the 3' end of SEQ ID NO:97 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:97. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 97 from nucleotide 40 to nucleotide

315, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO: 97 from nucleotide 40 to nucleotide 315, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:97 from nucleotide 40 to nucleotide 315. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID

NO:97 from nucleotide 124 to nucleotide 315, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO:97 from nucleotide 124 to nucleotide 315, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO: 97 from nucleotide 124 to nucleotide 315.

(a) the amino acid sequence of SEQ ID NO:98; (b) a fragment of the amino acid sequence of SEQ ID NO:98, the fragment comprising eight contiguous amino acids of SEQ ID NO:98; and (c) the amino acid sequence encoded by the cDNA insert of clone vq21_l deposited with the ATCC under accession number PTA-368; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:98. In further prefened embodiments, the present invention provides a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:98 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:98, or a protein comprising a fragment of the amino acid sequence of SEQ

ID NO: 98 having biological activity, the fragment comprising the amino acid sequence from amino acid 41 to amino acid 50 of SEQ ID NO:98.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:99; (b) a polynucleotide comprising the nucleotide sequence of SEQ ID

NO:99 from nucleotide 70 to nucleotide 699;

(c) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone vr2_l deposited with the ATCC under accession number PTA-368; (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vr2_J deposited with the ATCC under accession number PTA-368;

(e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vr2_l deposited with the ATCC under accession number PTA-368;

(f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vr2_l deposited with the ATCC under accession number PTA-368;

(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO: 100; (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 100 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO: 100; (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;

(j ) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ; (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and

(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:99. Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID

NO:99 from nucleotide 70 to nucleotide 699; the nucleotide sequence of the full-length protein coding sequence of clone vr2_l deposited with the ATCC under accession number PTA-368; or the nucleotide sequence of a mature protein coding sequence of clone vr2_l deposited with the ATCC under accession number PTA-368. In other prefened embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vr2_l deposited with the ATCC under accession number PTA- 368. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 100 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 100, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NOJ 00 having biological activity, the fragment comprising the amino acid sequence from amino acid 100 to amino acid 109 of SEQ ID NO: 100.

Other embodiments provide the gene conesponding to the cDNA sequence of SEQ ID NO.99.

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of: (aa) SEQ ID NO:99, but excluding the poly(A) tail at the 3' end of SEQ ID NO:99; and

(ab) the nucleotide sequence of the cDN A insert of clone vr2_l deposited with the ATCC under accession number PTA-368 ; (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(ba) SEQ ID NO:99, but excluding the poly(A) tail at the 3' end of SEQ ID NO:99; and

(bb) the nucleotide sequence of the cDN A insert of clone vr2_ 1 deposited with the ATCC under accession number PTA-368 ; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:99, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:99 to a nucleotide sequence conesponding to the 3' end of SEQ ID NO:99 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:99. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO: 99 from nucleotide 70 to nucleotide 699, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO:99 from nucleotide 70 to nucleotide 699, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:99 from nucleotide 70 to nucleotide 699. In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO: 100; (b) a fragment of the amino acid sequence of SEQ ID NO: 100, the fragment comprising eight contiguous amino acids of SEQ ID NO: 100; and

(c) the amino acid sequence encoded by the cDNA insert of clone vr2_l deposited with the ATCC under accession number PTA-368; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO: 100. In further prefened embodiments, the present invention provides a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO: 100 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 100, or a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO: 100 having biological activity, the fragment comprising the amino acid sequence from amino acid 100 to amino acid 109 of SEQ ID NO: 100.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NOJ01;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 101 from nucleotide 170 to nucleotide 394;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 101 from nucleotide 227 to nucleotide 394; (d) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone vc69_l deposited with the ATCC under accession number PTA-1075;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vc69_l deposited with the ATCC under accession number PTA-1075; (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vc69_l deposited with the ATCC under accession number PTA-1075;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vc69_l deposited with the ATCC under accession number PTA- 1075;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO: 102;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NOJ 02 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO: 102;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO: 101.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO: 101 from nucleotide 170 to nucleotide 394; the nucleotide sequence of SEQ ID NO: 101 from nucleotide 227 to nucleotide 394; the nucleotide sequence ofthe full-length protein coding sequence of clone vc69_l deposited with the ATCC under accession number PTA-1075; or the nucleotide sequence of a mature protein coding sequence of clone vc69_l deposited with the ATCC under accession number PTA-1075. In other prefened embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vc69_l deposited with the ATCC under accession number PTA-1075. In further prefened embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of

SEQ ID NOJ 02 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 102, or a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO: 102 having biological activity, the fragment comprising the amino acid sequence from amino acid 32 to amino acid 41 of SEQ ID NO: 102.

Other embodiments provide the gene conesponding to the cDNA sequence of SEQ ID NOJ01.

(a) a process comprising the steps of:

(aa) SEQ ID NO: 101, but excluding the poly(A) tail at the 3' end of SEQ ID NO: 101; and

(ab) the nucleotide sequence of the cDN A insert of clone vc69_l deposited with the ATCC under accession number PTA- 1075;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO: 101, but excluding the poly(A) tail at the 3' end of SEQ ID NO: 101 ; and

(bb) the nucleotide sequence ofthe cDNA insert of clone vc69_l deposited with the ATCC under accession number PTA- 1075;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO: 101, and extending contiguously from a nucleotide sequence conesponding to the 5' end of SEQ ID NOJ01 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO: 101 , but excluding the poly(A) tail at the 3' end of SEQ ID NO: 101. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NOJ 01 from nucleotide 170 to nucleotide 394, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO: 101 from nucleotide 170 to nucleotide 394, to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ ID NO: 101 from nucleotide 170 to nucleotide 394. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 101 from nucleotide 227 to nucleotide 394, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO: 101 from nucleotide 227 to nucleotide 394, to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ ID NO: 101 from nucleotide 227 to nucleotide 394. In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO: 102;

(b) a fragment of the amino acid sequence of SEQ ID NO: 102, the fragment comprising eight contiguous amino acids of SEQ ID NO: 102; and

(c) the amino acid sequence encoded by the cDNA insert of clone vc69_l deposited with the ATCC under accession number PTA-1075; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO: 102. In further prefened embodiments, the present invention provides a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO: 102 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 102, or a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO: 102 having biological activity, the fragment comprising the amino acid sequence from amino acid 32 to amino acid 41 of SEQ ID NOJ 02.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 103;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 103 from nucleotide 43 to nucleotide 198; (c) a polynucleotide comprising the nucleotide sequence of SEQ ID

NOJ03 from nucleotide 85 to nucleotide 198;

(d) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone vc71_l deposited with the ATCC under accession number PTA-1075; (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vc71_l deposited with the ATCC under accession number PTA-1075;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vc71_l deposited with the ATCC under accession number PT A- 1075 ;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vc71_l deposited with the ATCC under accession number PTA- 1075;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO: 104;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 104 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO: 104;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO: 103.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO: 103 from nucleotide 43 to nucleotide 198; the nucleotide sequence of SEQ ID NO: 103 from nucleotide 85 to nucleotide 198; the nucleotide sequence of the full-length protein coding sequence of clone vc71_ 1 deposited with the ATCC under accession number PTA- 1075; or the nucleotide sequence of a mature protein coding sequence of clone vc71_l deposited with the ATCC under accession number PTA-1075. In other prefened embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vc71_1 deposited with the ATCC under accession number PTA- 1075. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO: 104 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 104, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NOJ04 having biological activity, the fragment comprising the amino acid sequence from amino acid 21 to amino acid 30 of SEQ ID NO: 104.

Other embodiments provide the gene conesponding to the cDNA sequence of SEQ ID NO: 103.

(aa) SEQ ID NO: 103, but excluding the poly(A) tail at the 3' end of SEQ ID NO: 103; and (ab) the nucleotide sequence ofthe cDNA insert of clone vc71_1 deposited with the ATCC under accession number PTA-1075; (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO: 103, but excluding the poly(A) tail at the 3' end of SEQ ID NO: 103; and

(bb) the nucleotide sequence of the cDN A insert of clone vc71_l deposited with the ATCC under accession number PTA- 1075;

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO: 103, and extending contiguously from a nucleotide sequence conesponding to the 5' end of SEQ ID NO: 103 to a nucleotide sequence conesponding to the 3' end of SEQ ID NO: 103 , but excluding the poly (A) tail at the 3' end of SEQ ID NOJ 03. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 103 from nucleotide 43 to nucleotide 198, and extending contiguously from a nucleotide sequence conesponding to the 5' end ofsaid sequence of SEQ ID NO: 103 from nucleotide 43 to nucleotide 198, to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ ID NO: 103 from nucleotide

43 to nucleotide 198. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NOJ03 from nucleotide 85 to nucleotide 198, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NOJ 03 from nucleotide 85 to nucleotide 198 Jo a nucleotide sequence conesponding to the 3' end of said sequence of SEQ ID NO: 103 from nucleotide 85 to nucleotide 198. In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO: 104;

(b) a fragment of the amino acid sequence of SEQ ID NOJ04, the fragment comprising eight contiguous amino acids of SEQ ID NO: 104; and

(c) the amino acid sequence encoded by the cDNA insert of clone vc71_l deposited with the ATCC under accession number PTA-1075; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO: 104. In further prefened embodiments , the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 104 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 104, or a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO: 104 having biological activity, the fragment comprising the amino acid sequence from amino acid 21 to amino acid 30 of SEQ ID NO: 104.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 105; (b) a polynucleotide comprising the nucleotide sequence of SEQ ID

NO.J05 from nucleotide 260 to nucleotide 1552;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 105 from nucleotide 335 to nucleotide 1552;

(d) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone vo27_l deposited with the ATCC under accession number PTA-1075; (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vo27_l deposited with the ATCC under accession number PTA-1075;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vo27_l deposited with the ATCC under accession number PTA-1075;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vo27_l deposited with the ATCC under accession number PTA- 1075; (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO: 106;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 106 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO: 106; (j) a polynucleotide which is an allelic variant of a polynucleotide of

(a)-(g) above;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO: 105.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO: 105 from nucleotide 260 to nucleotide 1552; the nucleotide sequence of SEQ ID NO: 105 from nucleotide 335 to nucleotide 1552; the nucleotide sequence of the full- length protein coding sequence of clone vo27_l deposited with the ATCC under accession number PTA-1075; or the nucleotide sequence of a mature protein coding sequence of clone vo27_l deposited with the ATCC under accession number PTA-1075. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vo27_l deposited with the ATCC under accession number PTA-1075. In further prefened embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 106 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 106, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 106 having biological activity, the fragment comprising the amino acid sequence from amino acid 210 to amino acid 219 of SEQ ID NO: 106.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO: 105.

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of: (aa) SEQ ID NO: 105, but excluding the poly(A) tail at the 3' end of SEQ ID NO: 105; and

(ab) the nucleotide sequence of the cDN A insert of clone vo27_l deposited with the ATCC under accession number PTA- 1075; (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(ba) SEQ ID NO: 105, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO: 105; and (bb) the nucleotide sequence ofthe cDNA insert of clone vo27_ 1 deposited with the ATCC under accession number PT A- 1075 ; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO: 105, and extending contiguously from a nucleotide sequence conesponding to the 5' end of SEQ ID NO: 105 to a nucleotide sequence conesponding to the 3' end of SEQ ID NO: 105 , but excluding the ρoly(A) tail at the 3' end of SEQ ID NO: 105. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 105 from nucleotide 260 to nucleotide 1552, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO: 105 from nucleotide 260 to nucleotide 1552, to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ ID NO: 105 from nucleotide 260 to nucleotide 1552. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO: 105 from nucleotide 335 to nucleotide 1552, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO: 105 from nucleotide 335 to nucleotide 1552, to a nucleotide sequence corresponding to the 3 ' end of said sequence of SEQ ID NO : 105 from nucleotide 335 to nucleotide 1552.

(a) the amino acid sequence of SEQ ID NO: 106;

(b) a fragment of the amino acid sequence of SEQ ID NO: 106, the fragment comprising eight contiguous amino acids of SEQ ID NO: 106; and (c) the amino acid sequence encoded by the cDNA insert of clone vo27_l deposited with the ATCC under accession number PTA-1075; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO: 106. In further prefened embodiments, the present invention provides a protein comprising a fragment ofthe amino acid sequence of SEQ ID NOJ06 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 106, or aprotein comprising a fragment ofthe amino acid sequence of SEQ ID NO: 106 having biological activity, the fragment comprising the amino acid sequence from amino acid 210 to amino acid 219 of SEQ ID NO: 106.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 107;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 107 from nucleotide 15 to nucleotide 320; (c) a polynucleotide comprising the nucleotide sequence of SEQ ID

NO: 107 from nucleotide 72 to nucleotide 320;

(d) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone vo31_1 deposited with the ATCC under accession number PTA-1075; (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vo31_l deposited with the ATCC under accession number PTA-1075;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vo31_l deposited with the ATCC under accession number PTA- 1075 ;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vo31_1 deposited with the ATCC under accession number PTA- 1075;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO: 108; (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 108 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO: 108;

(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO: 107.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO: 107 from nucleotide 15 to nucleotide 320; the nucleotide sequence of SEQ ID NO: 107 from nucleotide 72 to nucleotide 320; the nucleotide sequence of the full-length protein coding sequence of clone vo31_1 deposited with the ATCC under accession number PTA- 1075; or the nucleotide sequence of a mature protein coding sequence of clone vo31_l deposited with the ATCC under accession number PTA-1075. In other prefened embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDN A insert of clone vo31 _ 1 deposited with the ATCC under accession number PT A- 1075. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO: 108 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 108, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of

SEQ ID NO: 108 having biological activity, the fragment comprising the amino acid sequence from amino acid 46 to amino acid 55 of SEQ ID NO: 108.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO: 107. Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of: (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO: 107, but excluding the poly(A) tail at the 3' end of SEQ ID NO: 107; and

(ab) the nucleotide sequence ofthe cDNA insert of clone vo31_l deposited with the ATCC under accession number PTA- 1075;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(ba) SEQ ID NO: 107, but excluding the ρoly(A) tail at the 3' end of SEQ ID NO: 107; and (bb) the nucleotide sequence ofthe cDNA insert of clone vo31_l deposited with the ATCC under accession number PTA- 1075;

(iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO: 107, and extending contiguously from a nucleotide sequence conesponding to the 5' end of SEQ ID NO: 107 to a nucleotide sequence conesponding to the 3' end of SEQ ID NO: 107 , but excluding the poly (A) tail at the 3' end of SEQ ID NO: 107. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO: 107 from nucleotide 15 to nucleotide 320, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO: 107 from nucleotide 15 to nucleotide 320, to a nucleotide sequence conesponding to the 3' end ofsaid sequence of SEQ ID NO: 107 from nucleotide 15 to nucleotide 320. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO: 107 from nucleotide 72 to nucleotide 320, and extending contiguously from a nucleotide sequence corresponding to the 5' end ofsaid sequence of SEQ ID NO: 107 from nucleotide 72 to nucleotide 320, to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ ID NO: 107 from nucleotide 72 to nucleotide 320.

(a) the amino acid sequence of SEQ ID NO: 108; (b) a fragment of the amino acid sequence of SEQ ID NO: 108, the fragment comprising eight contiguous amino acids of SEQ ID NO: 108; and

(c) the amino acid sequence encoded by the cDNA insert of clone vo31_l deposited with the ATCC under accession number PTA-1075; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO: 108. In further prefened embodiments, the present invention provides aprotein comprising a fragment ofthe amino acid sequence of SEQ ID NO: 108 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 108, or aprotein comprising a fragment ofthe amino acid sequence of SEQ ID NO: 108 having biological activity, the fragment comprising the amino acid sequence from amino acid 46 to amino acid 55 of SEQ ID NO: 108.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NOJ09;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 109 from nucleotide 38 to nucleotide 1255; (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 109 from nucleotide 86 to nucleotide 1255;

(d) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone vo32_l deposited with the ATCC under accession number PTA- 1075 ;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vo32_l deposited with the ATCC under accession number PTA-1075;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vo32_l deposited with the ATCC under accession number PTA-1075;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vo32_l deposited with the ATCC under accession number PTA- 1075; (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO: 110;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NOJ 10 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO: 110; (j) a polynucleotide which is an allelic variant of a polynucleotide of

(a)-(g) above;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO: 109. Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO: 109 from nucleotide 38 to nucleotide 1255; the nucleotide sequence of SEQ ID

NO: 109 from nucleotide 86 to nucleotide 1255; the nucleotide sequence ofthe full-length protein coding sequence of clone vo32_l deposited with the ATCC under accession number PTA-1075; or the nucleotide sequence of a mature protein coding sequence of clone vo32_l deposited with the ATCC under accession number PTA-1075. In other prefened embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vo32_l deposited with the ATCC under accession number PTA-1075. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 110 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 110, or a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO: 110 having biological activity, the fragment comprising the amino acid sequence from amino acid 198 to amino acid 207 of SEQ ID NO: 110.

Other embodiments provide the gene conesponding to the cDNA sequence of SEQ ID NO: 109.

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of: (aa) SEQ ID NO: 109, but excluding the poly(A) tail at the 3' end of SEQ ID NO: 109; and

(ab) the nucleotide sequence of the cDN A insert of clone vo32_l deposited with the ATCC under accession number PTA- 1075; (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(ba) SEQ ID NO: 109, but excluding the poly(A) tail at the 3' end of SEQ ID NO: 109; and

(bb) the nucleotide sequence of the cDN A insert of clone vo32_l deposited with the ATCC under accession number PTA- 1075;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO: 109, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID

NO: 109 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO: 109 , but excluding the ρoly(A) tail at the 3' end of SEQ ID NO: 109. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO: 109 from nucleotide 38 to nucleotide 1255, and extending contiguously from a nucleotide sequence conesponding to the 5' end ofsaid sequence of SEQ ID NO: 109 from nucleotide 38 to nucleotide 1255, to anucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO: 109 from nucleotide

38 to nucleotide 1255. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO: 109 from nucleotide 86 to nucleotide 1255, and extending contiguously from a nucleotide sequence corresponding to the 5' end ofsaid sequence of SEQ ID NO: 109 from nucleotide 86 to nucleotide 1255, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO: 109 from nucleotide 86 to nucleotide 1255.

(a) the amino acid sequence of SEQ ID NO: 110; (b) a fragment of the amino acid sequence of SEQ ID NO: 110, the fragment comprising eight contiguous amino acids of SEQ ID NO: 110; and

(c) the amino acid sequence encoded by the cDNA insert of clone vo32_l deposited with the ATCC under accession number PTA-1075; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO: 110. In further prefened embodiments, the present invention provides a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO: 110 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 110, or aprotein comprising a fragment ofthe amino acid sequence of SEQ ID NO: 110 having biological activity, the fragment comprising the amino acid sequence from amino acid 198 to amino acid 207 of SEQ ID NO: 110.

NOJ11;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NOJ 11 from nucleotide 80 to nucleotide 1276;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 111 from nucleotide 131 to nucleotide 1276;

(d) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone vo33_l deposited with the ATCC under accession number PTA-1075;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vo33_l deposited with the ATCC under accession number

PTA-1075;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vo33_l deposited with the ATCC under accession number PTA-1075; (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vo33_l deposited with the ATCC under accession number PTA- 1075; (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO: 112;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 112 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO: 112;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO: 111. Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID

NOJ 11 from nucleotide 80 to nucleotide 1276; the nucleotide sequence of SEQ ID NOJ 11 from nucleotide 131 to nucleotide 1276; the nucleotide sequence of the full- length protein coding sequence of clone vo33_l deposited with the ATCC under accession number PTA-1075; or the nucleotide sequence of a mature protein coding sequence of clone vo33_J deposited with the ATCC under accession number PTA-1075. In other prefened embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vo33_l deposited with the ATCC under accession number PTA-1075. In further prefened embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 112 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 112, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 112 having biological activity, the fragment comprising the amino acid sequence from amino acid 194 to amino acid 203 of SEQ ID NO: 112. Other embodiments provide the gene conesponding to the cDN A sequence of SEQ

ID NOJ 11. Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

(aa) SEQ ID NO: 111 , but excluding the poly(A) tail at the 3' end of SEQ ID NO: 111 ; and

(ab) the nucleotide sequence ofthe cDNA insert of clone vo33_l deposited with the ATCC under accession number PTA- 1075;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO: 111 , but excluding the poly(A) tail at the 3' end of SEQ ID NO: 111 ; and

(bb) the nucleotide sequence of the cDN A insert of clone vo33_l deposited with the ATCC under accession number PTA- 1075;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 111, and extending contiguously from a nucleotide sequence conesponding to the 5' end of SEQ ID NOJ 11 to a nucleotide sequence conesponding to the 3' end of SEQ ID NOJ 11 , but excluding the poly(A) tail at the 3' end of SEQ ID NO: 111. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 111 from nucleotide 80 to nucleotide 1276, and extending contiguously from a nucleotide sequence conesponding to the 5' end ofsaid sequence of SEQ ID NO: 111 from nucleotide 80 to nucleotide 1276, to anucleotide sequence corresponding to the 3' end ofsaid sequence of SEQ ID NO: 111 from nucleotide 80 to nucleotide 1276. Also preferably the polynucleotide isolated according to the above process comprises anucleotide sequence conesponding to the cDNA sequence of SEQ ID NOJ 11 from nucleotide 131 to nucleotide 1276, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO: 111 from nucleotide 131 to nucleotide 1276, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO: 111 from nucleotide 131 to nucleotide 1276.

(a) the amino acid sequence of SEQ ID NO: 112;

(b) a fragment of the amino acid sequence of SEQ ID NO: 112, the fragment comprising eight contiguous amino acids of SEQ ID NO: 112; and (c) the amino acid sequence encoded by the cDNA insert of clone vo33_l deposited with the ATCC under accession number PTA-1075; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO: 112. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 112 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 112, or a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO: 112 having biological activity, the fragment comprising the amino acid sequence from amino acid 194 to amino acid 203 of SEQ ID NO: 112. In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NOJ 13;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 113 from nucleotide 202 to nucleotide 429; (c) a polynucleotide comprising the nucleotide sequence of SEQ ID

NO: 113 from nucleotide 292 to nucleotide 429;

(d) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone vq23_l deposited with the ATCC under accession number PTA-1075; (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vq23_l deposited with the ATCC under accession number PTA-1075;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vq23_l deposited with the ATCC under accession number PTA- 1075 ;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vq23_l deposited with the ATCC under accession number PTA- 1075;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO: 114;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 114 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO: 114;

(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO: 113. Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID

NO: 113 from nucleotide 202 to nucleotide 429; the nucleotide sequence of SEQ ID

NO: 113 from nucleotide 292 to nucleotide 429; the nucleotide sequence ofthe full-length protein coding sequence of clone vq23_l deposited with the ATCC under accession number PTA-1075; or the nucleotide sequence of a mature protein coding sequence of clone vq23_l deposited with the ATCC under accession number PTA-1075. In other prefened embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vq23_l deposited with the ATCC under accession number PTA-1075. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of

SEQ ID NO: 114 having biological activity, the fragment preferably comprising eight

(more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID

NO: 114, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NOJ 14 having biological activity, the fragment comprising the amino acid sequence from amino acid 33 to amino acid 42 of SEQ ID NO: 114.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NOJ13.

(aa) SEQ ID NO: 113, but excluding the poly(A) tail at the 3' end of SEQ ID NO: 113; and

(ab) the nucleotide sequence of the cDN A insert of clone vq23_l deposited with the ATCC under accession number PTA- 1075;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO: 113, but excluding the poly(A) tail at the 3' end of SEQ ID NOJ 13; and

(bb) the nucleotide sequence of the cDN A insert of clone vq23_l deposited with the ATCC under accession number PTA- 1075;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 113, and extending contiguously from anucleotide sequence corresponding to the 5' end of SEQ ID NOJ 13 to a nucleotide sequence corresponding to the 3' end of SEQ ID NOJ 13 , but excluding the poly (A) tail at the 3' end of SEQ ID NO: 113. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NOJ 13 from nucleotide 202 to nucleotide 429, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO: 113 from nucleotide 202 to nucleotide 429, to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ ID NOJ 13 from nucleotide 202 to nucleotide 429. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO: 113 from nucleotide 292 to nucleotide 429, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NOJ 13 from nucleotide 292 to nucleotide 429, to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ ID NO: 113 from nucleotide 292 to nucleotide 429. In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO: 114; (b) a fragment of the amino acid sequence of SEQ ID NO: 114, the fragment comprising eight contiguous amino acids of SEQ ID NOJ 14; and

(c) the amino acid sequence encoded by the cDNA insert of clone vq23_l deposited with the ATCC under accession number PTA-1075; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO: 114. In further prefened embodiments, the present invention provides a protein comprising a fragment ofthe amino acid sequence of SEQ ID NOJ 14 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 114, or aprotein comprising a fragment ofthe amino acid sequence of SEQ ID NO: 114 having biological activity, the fragment comprising the amino acid sequence from amino acid 33 to amino acid 42 of SEQ ID NO: 114.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 115;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 115 from nucleotide 37 to nucleotide 1113;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 115 from nucleotide 88 to nucleotide 1113; (d) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone vq24_l deposited with the ATCC under accession number PTA-1075;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vq24_l deposited with the ATCC under accession number PTA-1075; (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vq24_l deposited with the ATCC under accession number PTA-1075;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vq24_l deposited with the ATCC under accession number PTA- 1075;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO: 116;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 116 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO: 116;

(m) a polynucleotide that hybridizes under stringent conditions to any one ofthe polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NOJ 15.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO: 115 from nucleotide 37 to nucleotide 1113; the nucleotide sequence of SEQ ID NO: 115 from nucleotide 88 to nucleotide 1113; the nucleotide sequence ofthe full-length protein coding sequence of clone vq24_l deposited with the ATCC under accession number PTA-1075; or the nucleotide sequence of a mature protein coding sequence of clone vq24_l deposited with the ATCC under accession number PTA-1075. In other prefened embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vq24_l deposited with the ATCC under accession number PTA- 1075. In further prefened embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NOJ 16 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 116, or a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO: 116 having biological activity, the fragment comprising the amino acid sequence from amino acid 174 to amino acid 183 of SEQ ID NO: 116.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NOJ 15.

(a) a process comprising the steps of:

(aa) SEQ ID NO: 115, but excluding the poly(A) tail at the 3' end of SEQ ID NOJ 15; and

(ab) the nucleotide sequence of the cDN A insert of clone vq24_l deposited with the ATCC under accession number PTA- 1075;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO: 115, but excluding the poly (A) tail at the 3' end of SEQ ID NO: 115; and

(bb) the nucleotide sequence of the cDN A insert of clone vq24_l deposited with the ATCC under accession number PTA- 1075;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO: 115, and extending contiguously from a nucleotide sequence conesponding to the 5 ' end of SEQ ID NO: 115 to a nucleotide sequence conesponding to the 3' end of SEQ ID NO: 115 , but excluding the poly(A) tail at the 3' end of SEQ ID NOJ 15. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO: 115 from nucleotide 37 to nucleotide 1113, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO: 115 from nucleotide 37 to nucleotide 1113, to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ ID NO: 115 from nucleotide 37 to nucleotide 1113. Also preferably the polynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 115 from nucleotide 88 to nucleotide 1113, and extending contiguously from a nucleotide sequence corresponding to the 5' end ofsaid sequence of SEQ ID NO: 115 from nucleotide 88 to nucleotide 1113, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO: 115 from nucleotide 88 to nucleotide 1113.

(a) the amino acid sequence of SEQ ID NO: 116;

(b) a fragment of the amino acid sequence of SEQ ID NOJ 16, the fragment comprising eight contiguous amino acids of SEQ ID NO: 116; and (c) the amino acid sequence encoded by the cDNA insert of clone vq24_l deposited with the ATCC under accession number PTA-1075; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO: 116. In further prefened embodiments, the present invention provides a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO: 116 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 116, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 116 having biological activity, the fragment comprising the amino acid sequence from amino acid 174 to amino acid 183 of SEQ ID NO: 116.

NO: 117;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 117 from nucleotide 40 to nucleotide 207;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 117 from nucleotide 103 to nucleotide 207 ;

(d) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone vq26_J deposited with the ATCC under accession number PTA-1075;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vq26_l deposited with the ATCC under accession number

PTA-1075;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vq26_l deposited with the ATCC under accession number PTA-1075; (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vq26_l deposited with the ATCC under accession number PTA- 1075;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO: 118; (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 118 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO: 118;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO: 117.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO: 117 from nucleotide 40 to nucleotide 207; the nucleotide sequence of SEQ ID NO: 117 from nucleotide 103 to nucleotide 207; the nucleotide sequence ofthe full-length protein coding sequence of clone vq26_l deposited with the ATCC under accession number PTA- 1075; or the nucleotide sequence of a mature protein coding sequence of clone vq26_l deposited with the ATCC under accession number PTA-1075. In other prefened embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vq26_l deposited with the ATCC under accession number PTA- 1075. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 118 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NOJ 18, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NOJ 18 having biological activity, the fragment comprising the amino acid sequence from amino acid 23 to amino acid 32 of SEQ ID NO: 118.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO: 117.

(aa) SEQ ID NO: 117, but excluding the poly(A) tail at the 3' end of SEQ ID NO: 117; and (ab) the nucleotide sequence of the cDN A insert of clone vq26_l deposited with the ATCC under accession number PTA- 1075 ; (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO: 117, but excluding the poly(A) tail at the 3' end of SEQ ID NO: 117; and

(bb) the nucleotide sequence of the cDN A insert of clone vq26_l deposited with the ATCC under accession number PTA- 1075;

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO: 117, and extending contiguously from anucleotide sequence conesponding to the 5' end of SEQ ID NO: 117 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO: 117 , but excluding the poly(A) tail at the 3' end of SEQ ID NO: 117. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 117 from nucleotide 40 to nucleotide 207, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO: 117 from nucleotide 40 to nucleotide 207, to a nucleotide sequence conesponding to the 3 ' end of said sequence ofSEQIDNO:117 from nucleotide

40 to nucleotide 207. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NOJ 17 from nucleotide 103 to nucleotide 207, and extending contiguously from a nucleotide sequence conesponding to the 5' end ofsaid sequence of SEQ ID NO: 117 from nucleotide 103 to nucleotide 207, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO: 117 from nucleotide 103 to nucleotide 207. In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO : 118 ;

(b) a fragment of the amino acid sequence of SEQ ID NOJ 18, the fragment comprising eight contiguous amino acids of SEQ ID NO: 118; and

(c) the amino acid sequence encoded by the cDNA insert of clone vq26_l deposited with the ATCC under accession number PTA-1075; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO: 118. In further prefened embodiments, the present invention provides a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO: 118 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 118, or a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO: 118 having biological activity, the fragment comprising the amino acid sequence from amino acid 23 to amino acid 32 of SEQ ID NO: 118.

In certain prefened embodiments, the polynucleotide is operably linked to an expression control sequence. The invention also provides a host cell, including bacterial, yeast, insect and mammalian cells, transformed with such polynucleotide compositions. Also provided by the present invention are organisms that have enhanced, reduced, or modified expression of the gene(s) conesponding to the polynucleotide sequences disclosed herein.

Processes are also provided for producing a protein, which comprise:

(a) growing a culture of the host cell transformed with such polynucleotide compositions in a suitable culture medium; and

(b) purifying the protein from the culture.

The protein produced according to such methods is also provided by the present invention. Protein compositions of the present invention may further comprise a pharmaceutically acceptable carrier . Compositions comprising an antibody which specifically reacts with such protein are also provided by the present invention.

Methods are also provided for preventing, treating or ameliorating a medical condition which comprises administering to a mammalian subject a therapeutically effective amount of a composition comprising a protein of the present invention and a pharmaceutically acceptable earner.

BRIEF DESCRIPTION OF THE DRAWINGS Figures 1 A and 1 B are schematic representations of the pED6 and pNOTs vectors, respectively, used for deposit of clones disclosed herein.

DETAILED DESCRIPTION ISOLATED PROTEINS AND POLYNUCLEOTIDES Nucleotide and amino acid sequences, as presently determined, are reported below for each clone and * irotein disclosed in the present application. The nucleotide sequence of each clone caji readily be determined by sequencing of the deposited clone in accordance with known methods. The predicted amino acid sequence (both full-length and mature forms^'! can then be determined from such nucleotide sequence. The amino acid sequence of the protein encoded by a particular clone can also be determined by expression ofthe clone in a suitable host cell, collecting the protein and determining its sequence. For each disclosed protein applicants have identified what they have determined to be the reading frame best identifiable with sequence information available at the time of filing.

As used herein a "secreted" protein is one which, when expressed in a suitable host cell, is transported across or through a membrane, including transport as a result of signal sequences in its amino acid sequence. "Secreted" proteins include without limitation proteins secreted wholly (e.g., soluble proteins) or partially (e.g. , receptors) from the cell in which they are expressed. "Secreted" proteins also include without limitation proteins which are transported across the membrane of the endoplasmic reticulum. Clone "vc62 1"

A polynucleotide ofthe present invention has been identified as clone "vc62_J". vc62_l was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vc62_l is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vc62_l protein").

The nucleotide sequence of vc62_l as presently determined is reported in SEQ ID NOJ, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vc62_ 1 protein conesponding to the foregoing nucleotide sequence is reported in SEQ ID NO: 2. Amino acids 3 to 15 of SEQ ID NO:2 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 16. Due to the hydrophobic nature ofthe predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vc62_l protein. If the 'G' residue at position 254 of SEQ ID NO: 1 were deleted, another potential vc62_l reading frame and predicted amino acid sequence that would then be encoded by nucleotides 27 to 365 of SEQ ID NO: 1 is reported in SEQ ID NO: 169.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone vc62_l should be approximately 4221 bp.

The nucleotide sequence disclosed herein for vc62_l was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vc62_l demonstrated at least some similarity with sequences identified as AA580489 (nn22al0.sl NCI_CGAP_Col2 Homo sapiens cDNA clone IMAGE 1084602, mRNA sequence), AF047042 (Homo sapiens citrate synthase mRNA, complete eds), and T04200 (Sugar beet citrate synthase cDNA; standard; cDNA to mRNA). The predicted amino acid sequence disclosed herein for vc62_J was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vc62_l protein demonstrated at least some similarity to sequences identified as AF047042 (citrate synthase [Homo sapiens]) and R82839 (Sugar beet citrate synthase). Based upon sequence similarity, vc62_l proteins and each similar protein or peptide may share at least some activity. Clone "vplO 1"

A polynucleotide of the present invention has been identified as clone "vpl0_l". vpl0_l was isolated from a human adult prostate cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vpl0_l is a full-length clone, including the entire coding sequence of a secreted protein (also refened to herein as "vpl0_l protein"). The nucleotide sequence of vpl0_l as presently determined is reported in SEQ ID NO:3, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence ofthe vpl0_l protein conesponding to the foregoing nucleotide sequence is reported in SEQ ID NO:4. Amino acids 19 to 31 of SEQ ID NO:4 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 32. Due to the hydrophobic nature ofthe predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vpl0_l protein. If another 'G' residue were inserted in SEQ ID NO:3 after the 'G' residue at position 868, another potential vpl0_l reading frame and predicted amino acid sequence that would be encoded by what would then be nucleotides 6 to 968 of SEQ ID NO: 3 is reported in SEQ ID NOJ70.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone vpl0_l should be approximately 1401 bp.

The nucleotide sequence disclosed herein for vpl0_l was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vpl0_l demonstrated at least some similarity with sequences identified as AA733074 (zg79d07.sl Soares fetal heart NbHH19W Homo sapiens cDNA clone 399565 3' similar to WP:C15H9.5 CE06834; mRNA sequence). The predicted amino acid sequence disclosed herein for vpl0_l was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vpl0_l protein demonstrated at least some similarity to the sequence identified as U56965 (unknown protein [Caenorhabditis elegans]). Based upon sequence similarity, vpl0_l proteins and each similar protein or peptide may share at least some activity. The TopPredll computer program predicts a potential transmembrane domain within the vpl0_l protein sequence centered around amino acid 270 of SEQ ID NO:4. Clone "vp 11 1"

A polynucleotide of the present invention has been identified as clone "vpl 1_1 ". vpl l_l was isolated from a human adult prostate cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein, vpl 1_1 is a full-length clone, including the entire coding sequence of a secreted protein (also refened to herein as "vpl 1_1 protein").

The nucleotide sequence of vpl 1_1 as presently determined is reported in SEQ ID

NO:5, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vp 11 _ 1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO: 6. Amino acids 5 to 17 of SEQ ID NO:6 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 18. Due to the hydrophobic nature ofthe predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vpl 1_1 protein.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone vpl 1_1 should be approximately 1329 bp.

The nucleotide sequence disclosed herein for vpl l_l was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. No hits were found in the database.

Clone "VP 13 1"

A polynucleotide of the present invention has been identified as clone "vpl3_l". vpl3_l was isolated from a human adult prostate cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vpl3_l is a full-length clone, including the entire coding sequence of a secreted protein (also refened to herein as "vpl3_l protein").

The nucleotide sequence of vpl3_l as presently determined is reported in SEQ ID

NO:7, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vp 13_ 1 protein conesponding to the foregoing nucleotide sequence is reported in SEQ ID NO: 8. Amino acids 13 to 25 of SEQ ID NO:8 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 26. Due to the hydrophobic nature ofthe predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vpl3_l protein.

Other potential vpl3_l reading frames and predicted amino acid sequences are encoded by nucleotides 151 to 267 of SEQ ID NO:7, with the encoded amino acid sequence reported in SEQ ID NO: 171, and by nucleotides 209 to 787 of SEQ ID NO:7, with the encoded amino acid sequence reported in SEQ ID NO: 172. Amino acids 1 to 13 of SEQ ID NO: 172 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 14. Due to the hydrophobic nature of this predicted leader/signal sequence, it is likely to act as a transmembrane domain should it not be separated from the remainder of the protein of SEQ ID NO: 172. The protein of SEQ ID NO: 172 also demonstrates significant homology to the human Notch protein, Delta proteins _^from various species, and other EGF-repeat-containing transmembrane proteins. A deletion or insertion causing a frame-shift in the nucleotide sequence of SEQ ID NO:7 in the region approximately between nucleotides 208 and 267 of SEQ ID NO:7 could join the reading frames of SEQ ID NO: 171 and SEQ ID NO: 172 into a single reading frame encoding an EGF-repeat-containing protein. Further, the region approximately between nucleotides 605 and 850 may be an alternatively spliced exon.

If the 'A' residue at position 423 of SEQ ID NO:7 were deleted, another potential vp 13_ 1 reading frame and predicted amino acid sequence that would be encoded by what would then be nucleotides 288 to 503 of SEQ ID NO:7 is reported in SEQ ID NO: 173.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone vpl3_l should be approximately 1048 bp.

The nucleotide sequence disclosed herein for vpl3_l was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vpl3_l demonstrated at least some similarity with sequences identified as AA190865 (zp85b02.sl Stratagene HeLa cell s3937216 Homo sapiens cDNA clone 6269553' similar to TR G1336628 Gl 336628 EGF REPEAT TRANSMEMBRANE PROTEIN; mRNA sequence), and U57368 (Mus musculus EGF repeat transmembrane protein mRNA, complete eds). The predicted amino acid sequence disclosed herein for vpl3_l was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vpl3_l protein demonstrated at least some similarity to sequences identified as AC004663 (Notch 3 [Homo sapiens]), R28960 (Delta Di l), and U57368 (EGF repeat transmembrane protein [Mus museums]). Based upon sequence similarity, vpl3_l proteins and each similar protein or peptide may share at least some activity. The TopPredll computer program predicts a potential transmembrane domain within the vpl3_l protein sequence centered around amino acid 56 of SEQ ID NO:8.

Clone "vpl 6 1"

A polynucleotide of the present invention has been identified as clone "vpl6_l". vpl6_l was isolated from a human adult prostate cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vpl6_l is a full-length clone, including the entire coding sequence of a secreted protein (also refened to herein as "vpl6_l protein").

The nucleotide sequence of vpl6_l as presently determined is reported in SEQ ID NO:9, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence ofthe vpl6_l protein conesponding to the foregoing nucleotide sequence is reported in SEQ ID NO: 10. Amino acids 34 to 46 of SEQ ID NO: 10 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 47. Due to the hydrophobic nature ofthe predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vpl6_l protein. Another potential vp 16_ 1 reading frame and predicted amino acid sequence is encoded by basepairs 1621 to 1839 of SEQ ID NO:9 and is reported in SEQ ID NO: 174.

The EcoRI Notl restriction fragment obtainable from the deposit containing clone vp 16_ 1 should be approximately 2105 bp .

The nucleotide sequence disclosed herein for vpl6_l was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vpl6_l demonstrated at least some similarity with sequences identified as AA523851 (ng31e01.sl NCI_CGAP_Co3 Homo sapiens cDNA clone IMAGE:936408, mRNA sequence). Based upon sequence similarity, vpl6_l proteins and each similar protein or peptide may share at least some activity. The TopPredll computer program predicts two potential transmembrane domains within the vpl6_l protein sequence, one centered around amino acid 36 and another around amino acid 69 of SEQ ID NO: 10. The nucleotide sequence of vpl6_l indicates that it may contain an Alu repetitive element.

Clone "vp21 1"

A polynucleotide of the present invention has been identified as clone "vp21_l". vp21_l was isolated from a human adult prostate cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vp21_l is a full-length clone, including the entire coding sequence of a secreted protein (also refened to herein as "vp21_l protein").

The nucleotide sequence of vp21_l as presently determined is reported in SEQ ID

NO: 11, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence ofthe vp21_1 protein conesponding to the foregoing nucleotide sequence is reported in SEQ ID NO: 12. Amino acids 62 to 74 of SEQ ID NO: 12 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 75. Due to the hydrophobic nature ofthe predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vp21_l protein. Another potential vp21_l reading frame and predicted amino acid sequence encoded by basepairs 598 to 831 of SEQ ID NO: 11 is reported in SEQ ID NO: 175. Amino acids 1 to

6 of SEQ ID NO: 175 and amino acids 41 to 43 of SEQ ID NO: 175 are predicted leader/signal sequences, with the predicted mature amino acid sequences beginning at amino acid 7 or at amino acid 44, respectively.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone vp21_l should be approximately 1538 bp.

The nucleotide sequence disclosed herein for vp21_l was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vp21_l demonstrated at least some similarity with sequences identified as AC004076 (Homo sapiens chromosome 19, cosmid R30217, complete sequence). The predicted amino acid sequence disclosed herein for vp21_l was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vp21_l protein demonstrated at least some similarity to sequences identified as AC003682 (Zinc finger protein F18547_l [Homo sapiens]) and W19106 (Tat pheromone receptor VN5). Based upon sequence similarity, vp21_l proteins and each similar protein or peptide may share at least some activity. The TopPredll computer program predicts potential transmembrane domains within the predicted vp21 _ 1 protein sequences, one centered around amino acid 70 of SEQ ID NO: 12, and one centered around amino acid 17 of SEQ ID NO: 175.

Clone "vp22 1"

A polynucleotide of the present invention has been identified as clone "vp22_l". vp22_l was isolated from a human adult prostate cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vp22_l is a full-length clone, including the entire coding sequence of a secreted protein (also refened to herein as "vp22_l protein").

The nucleotide sequence of vp22_l as presently determined is reported in SEQ ID NO: 13, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence ofthe vp22_l protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO: 14. Amino acids 13 to 25 of SEQ ID NO: 14 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 26. Due to the hydrophobic nature ofthe predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vp22_l protein. Another potential vp22_l reading frame and predicted amino acid sequence encoded by basepairs 408 to 1154 of SEQ ID NO: 13 is reported in SEQ ID NO: 176. Amino acids 40 to 52 of SEQ ID NO: 176 are apredicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 53. Due to the hydrophobic nature of this predicted leader/signal sequence, it is likely to act as a transmembrane domain should it not be separated from the remainder of the protein of SEQ ID NOJ 76. A frameshift within the nucleotide sequence of SEQ ID NO: 13 approximately between nucleotides 163 and 477 could join the openreading frames of SEQ ID NO: 14 and SEQ ID NO: 176. The EcoRI/Notl restriction fragment obtainable from the deposit containing clone vp22_l should be approximately 1718 bp. The nucleotide sequence disclosed herein for vp22_l was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vp22_l demonstrated at least some similarity with sequences identified as AA526186 (ni94h03.sl NCI_CGAP_Pr21 Homo sapiens cDNA clone IMAGE:984533, mRNA sequence), AA570505 (nk64h01.sl NCI_CGAP_Schl Homo sapiens cDNA clone IMAGE 1018321, mRNA sequence), AB006085 (DanioreriomRNA for MINDIN2, complete eds), and T78360 (Human neuronal attachment factor- 1 DNA; standard; DNA). The predicted amino acid sequence disclosed herein for vp22_l was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vp22_J protein demonstrated at least some similarity to sequences identified as AB006085 (MINDIN2 [Danio rerio]) and W23663 (Human neuronal attachment factor- 1). Based upon sequence similarity, vp22_l proteins and each similar protein or peptide may share at least some activity.

Clone "vq2 1"

A polynucleotide of the present invention has been identified as clone "vq2_l". vq2_l was isolated from a human adult lung cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence ofthe encoded protein. vq2_l is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vq2_l protein").

The nucleotide sequence of vq2_l as presently determined is reported in SEQ ID NO: 15, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence ofthe vq2_l protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO: 16. Amino acids 4 to 16 of SEQ ID NO: 16 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 17. Due to the hydrophobic nature ofthe predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vq2_l protein.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone vq2_l should be approximately 896 bp.

The nucleotide sequence disclosed herein for vq2_l was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vq2_J demonstrated at least some similarity with sequences identified as AI203981 (qe76h05.xl Soares_fetal_lung_NbHL19W Homo sapiens cDNA clone IMAGE: 17449533', mRNA sequence) and T97082 (Human haematopoietic-specific protein (HSP) DNA; standard; DNA). The predicted amino acid sequence disclosed herein for vq2_l was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vq2_l protein demonstrated at least some similarity to the sequence identified as W35904 (Human haematopoietic-specific protein (HSP)). Based upon sequence similarity, vq2_l proteins and each similar protein or peptide may share at least some activity.

Clone "VQ3 1"

A polynucleotide of the present invention has been identified as clone "vq3_l". vq3_l was isolated from a human adult lung cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vq3_l is a full-length clone, including the entire coding sequence of a secreted protein (also refened to herein as "vq3_l protein").

The nucleotide sequence of vq3_l as presently determined is reported in SEQ ID NO: 17, and includes a poly (A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vq3_J protein conesponding to the foregoing nucleotide sequence is reported in SEQ ID NO: 18. Amino acids 11 to 23 of SEQ ID NO: 18 are apredicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 24. Due to the hydrophobic nature ofthe predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vq3_l protein. The EcoRI/Notl restriction fragment obtainable from the deposit containing clone vq3_l should be approximately 1490 bp.

The nucleotide sequence disclosed herein for vq3_J was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. No significant hits were found in the database. The nucleotide sequence of vq3_l indicates that it may contain an Alu repetitive element. Clone "vα5 1"

A polynucleotide of the present invention has been identified as clone "vq5_l". vq5_J was isolated from a human adult lung cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence ofthe encoded protein. vq5_l is a full-length clone, including the entire coding sequence of a secreted protein (also refened to herein as "vq5_l protein").

The nucleotide sequence of vq5_l as presently determined is reported in SEQ ID NO: 19, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vq5_l protein conesponding to the foregoing nucleotide sequence is reported in SEQ ID NO:20. Amino acids 9 to 21 of SEQ ID NO:20 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 22. Due to the hydrophobic nature ofthe predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vq5_J protein. The EcoRI/Notl restriction fragment obtainable from the deposit containing clone vq5_l should be approximately 2207 bp.

The nucleotide sequence disclosed herein for vq5_l was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vq5_l demonstrated at least some similarity with sequences identified as AQ036276 (CIT-HSP-2331M15.TF CIT-HSP Homo sapiens genomic clone 2331M15, genomic survey sequence) and T24918 (Human gene signature HUMGS07027; standard; cDNA to mRNAP). Based upon sequence similarity, vq5_l proteins and each similar protein or peptide may share at least some activity. The TopPredll computer program predicts that the signal sequence at residue 22 of SEQ ID NO:20 is also a potential transmembrane domain.

Clone "vq6 1"

A polynucleotide of the present invention has been identified as clone "vq6_l". vq6_l was isolated from a human adult lung cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence ofthe encoded protein. vq6_l is a full-length clone, including the entire coding sequence of a secreted protein (also refened to herein as "vq6_l protein"). The nucleotide sequence of vq6_l as presently determined is reported in SEQ ID NO:21, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vq6_l protein conesponding to the foregoing nucleotide sequence is reported in SEQ ID NO:22. Amino acids 6 to 18 of SEQ ID NO:22 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 19. Due to the hydrophobic nature ofthe predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vq6_J protein.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone vq6_J should be approximately 1875 bp.

The nucleotide sequence disclosed herein for vq6_l was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vq6_l demonstrated at least some similarity with sequences identified as AA729043 (nw22d09.sl NCI_CGAP_GCB0 Homo sapiens cDNA clone IMAGE: 1241201 similar to contains Alu repetitive element; mRNA sequence). Based upon sequence similarity, vq6_l proteins and each similar protein or peptide may share at least some activity. The TopPredll computer program predicts an additional potential transmembrane domain within the vq6_l protein sequence centered around amino acid 37 of SEQ ID NO:22. The nucleotide sequence of vq6_ 1 indicates that it may contain an Alu repetitive element.

Clone "yrl 1"

A polynucleotide of the present invention has been identified as clone "vrl_l". vrl_J was isolated from a human adult muscle cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vrl_l is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vrl_l protein"). The nucleotide sequence of vrl_l as presently determined is reported in SEQ ID NO:23, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vr 1_1 protein conesponding to the foregoing nucleotide sequence is reported in SEQ ID NO:24. Amino acids 34 to 46 of SEQ ID NO:24 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 47. Due to the hydrophobic nature ofthe predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vrl_l protein. The region of SEQ ID NO:23 approximately between nucleotides 1931 and 1977 of SEQ ID NO:23 may be an alternatively spliced exon.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone vrl_l should be approximately 1512 bp.

The nucleotide sequence disclosed herein for vrl_l was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vrl_l demonstrated at least some similarity with sequences identified as AL031602 (Human DNA sequence *** SEQUENCING IN PROGRESS *** from clone 1174N9; HTGS phase 1), 164695 (Sequence 1 from patent US 5665588), and T35233 (Natural killer lytic associated protein cDNA; standard; cDNA). The predicted amino acid sequence disclosed herein for vrl_l was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vrl_l protein demonstrated at least some similarity to sequences identified as R99256 (Natural killer lytic associated protein), and X71642 (GEG- 154 gene product [Mus museums]). Based upon sequence similarity, vrl_l proteins and each similar protein or peptide may share at least some activity. The TopPredll computer program predicts an additional potential transmembrane domain within the vrl_l protein sequence centered around amino acid 150 of SEQ ID NO:24.

Clone "vc63 1"

A polynucleotide of the present invention has been identified as clone "vc63_l". vc63_l was isolated from a human fetal brain cDNA library and was identified as encoding a novel protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vc63_l is a full-length clone, including the entire coding sequence of a novel protein (also refened to herein as "vc63_l protein").

The nucleotide sequence of vc63_l as presently determined is reported in SEQ ID NO:25, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence ofthe vc63_l protein conesponding to the foregoing nucleotide sequence is reported in SEQ ID NO:26. Another potential vc63_l reading frame and predicted amino acid sequence encoded by basepairs 528 to 1100 of SEQ ID NO:25 is reported in SEQ ID NO: 177. Amino acids 140 to 152 of SEQ ID NO: 177 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 153. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the protein of SEQ ID NO: 177.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone vc63_l should be approximately 2397 bp. The nucleotide sequence disclosed herein for vc63_l was searched against the

GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vc63_l demonstrated at least some similarity with sequences identified as N66555 (yy69b07.sl Homo sapiens cDNA clone 278773 3") and T21367 (Human gene signature HUMGS02731 ; standard; cDNA to mRNA). The predicted amino acid sequence disclosed herein f or vc63_ 1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vc63_l protein demonstrated at least some similarity to the sequence identified as Z36948 (D2089.2 [Caenorhabditis elegans]). Based upon sequence similarity, vc63_l proteins and each similar protein or peptide may share at least some activity. The TopPredll computer program predicts a potential transmembrane domain within the protein sequence of SEQ

ID NO: 177, centered around amino acid 153 of SEQ ID NO: 177.

Clone "vb25 1"

A polynucleotide of the present invention has been identified as clone "vb25_J". vb25_l was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vb25_l is a full-length clone, including the entire coding sequence of a secreted protein (also refened to herein as "vb25_l protein").

The nucleotide sequence of vb25_l as presently determined is reported in SEQ ID NO:27, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence ofthe vb25_l protein conesponding to the foregoing nucleotide sequence is reported in SEQ ID NO:28. Amino acids 5 to 17 of SEQ ID NO:28 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 18. Due to the hydrophobic nature ofthe predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vb25_l protein. The EcoRI/Notl restriction fragment obtainable from the deposit containing clone vb25_l should be approximately 1677 bp.

The nucleotide sequence disclosed herein for vb25_l was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vb25_l demonstrated at least some similarity with sequences identified as Z73429 (Human DNA sequence from cosmid cN32F9 on chromosome 22ql 1.2-qter Contains CpG island). Based upon sequence similarity, vb25_l proteins and each similar protein or peptide may share at least some activity. The nucleotide sequence of vb25_l indicates that it may contain one or more of the following repetitive elements: AC simple repeat, AG simple repeat, ALU, MIR.

Clone "vb27 1"

A polynucleotide of the present invention has been identified as clone "vb27_l". vb27_l was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vb27_l is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vb27_l protein"). The nucleotide sequence of vb27_l as presently determined is reported in SEQ ID NO:29, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence ofthe vb27_l protein conesponding to the foregoing nucleotide sequence is reported in SEQ ID NO:30. Amino acids 14 to 26 of SEQ ID NO:30 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 27. Due to the hydrophobic nature ofthe predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vb27_l protein. The EcoRI/Notl restriction fragment obtainable from the deposit containing clone vb27_l should be approximately 3456 bp. The nucleotide sequence disclosed herein for vb27_l was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vb27_l demonstrated at least some similarity with sequences identified as AC005035 (Homo sapiens BAC clone NH0353P23 from 2, complete sequence) and H73579 (yu29f09.rl Homo sapiens cDNA clone 235241 5'). Based upon sequence similarity, vb27_l proteins and each similar protein or peptide may share at least some activity. The nucleotide sequence of vb27_l indicates that it may contain one or mor of the following repetitive elements: ALU, Mer3.

Clone "vb28 1"

A polynucleotide of the present invention has been identified as clone "vb28_J". vb28_l was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vb28_l is a full-length clone, including the entire coding sequence of a secreted protein (also refened to herein as "vb28_l protein").

The nucleotide sequence of vb28_l as presently determined is reported in SEQ ID

NO:31, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence ofthe vb28_l protein conesponding to the foregoing nucleotide sequence is reported in SEQ ID NO:32. Amino acids 4 to 16 of SEQ ID NO:32 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 17. Due to the hydrophobic nature ofthe predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vb28_l protein.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone vb28_J should be approximately 3008 bp.

The nucleotide sequence disclosed herein for vb28_l was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vb28_l demonstrated at least some similarity with sequences identified as AA046671 (zf 12d09.rl Soares_fetal_heart_NbHH19WHomo sapiens cDNA clone IMAGE:376721 5' similar to PIR:A38745 A38745 cell adhesion molecule CD44 precursor - rat; mRNA sequence) and V22687 (DNA encoding a CD44-like protein). The predicted amino acid sequence disclosed herein for vb28_l was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vb28_l protein demonstrated at least some similarity to sequences identified as W56249 (Amino acid sequence of a CD44-like protein) and X66081 (CD44 [Mus museums]). Based upon sequence similarity, vb28_J proteins and each similar protein or peptide may share at least some activity.

Clone "vb29 1"

A polynucleotide of the present invention has been identified as clone "vb29_l". vb29_l was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vb29_l is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vb29_l protein").

The nucleotide sequence of vb29_l as presently determined is reported in SEQ ID NO:33, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vb29_ 1 protein conesponding to the foregoing nucleotide sequence is reported in SEQ ID NO: 34. Amino acids 11 to 23 of SEQ ID NO: 34 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 24. Due to the hydrophobic nature ofthe predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vb29_l protein.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone vb29_l should be approximately 2970 bp.

The nucleotide sequence disclosed herein for vb29_l was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vb29_l demonstrated at least some similarity with sequences identified as AA084068 (znl6dl2.rl Stratagene neuroepithelium NT2RAMI 937234 Homo sapiens cDNA clone 547607 5', mRNA sequence) and AQ418918 (RPCI- 11-185K12.TV RPCI- 11 Homo sapiens genomic clone RPCI- 11-185K12, genomic survey sequence). Based upon sequence similarity, vb29_l proteins and each similar protein or peptide may share at least some activity. The TopPredll computer program predicts a potential transmembrane domain within the vb29_l protein sequence centered around amino acid 41 of SEQ ID NO:34. The nucleotide sequence of vb29_l indicates that it may contain an Alu repetitive element.

Clone "vb30 1" A polynucleotide of the present invention has been identified as clone "vb30_l ". vb30_l was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence ofthe encoded protein. vb30_l is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vb30_l protein"). The nucleotide sequence of vb30_ 1 as presently determined is reported in SEQ ID

NO:35, and includes a poly (A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence ofthe vb30_l protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:36. Amino acids 15 to 27 of SEQ ID NO:36 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 28. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vb30_l protein.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone vb30_l should be approximately 3325 bp. The nucleotide sequence disclosed herein for vb30_l was searched against the

GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. No significant hits were found in the databases. The nucleotide sequence of vb30_l indicates that it may contain an Alu repetitive element.

Clone "vc67 1"

A polynucleotide of the present invention has been identified as clone "vc67_l". vc67_l was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vc67_l is a full-length clone, including the entire coding sequence of a secreted protein (also refened to herein as "vc67_l protein"). The nucleotide sequence of vc67_l as presently determined is reported in SEQ ID NO:37, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence ofthe vc67_l protein conesponding to the foregoing nucleotide sequence is reported in SEQ ID NO:38. Another potential vc67_l reading frame and predicted amino acid sequence encoded by basepairs 3 to 242 of SEQ ID NO:37 is reported in SEQ ID NO: 178. The EcoRI/Notl restriction fragment obtainable from the deposit containing clone vc67_l should be approximately 2305 bp.

The nucleotide sequence disclosed herein for vc67_l was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vc67_J demonstrated at least some similarity with sequences identified as T23222 (Human gene signature HUMGS05018), W87297 (zh67h03.sl Soares_fetal_liver_spleen_lNFLS_Sl Homo sapiens cDNA clone IMAGE 417173 3', mRNA sequence), and Z97201 (Human DNA sequence *** SEQUENCING IN PROGRESS *** from clone 94M16, WORKING DRAFT SEQUENCE). The predicted amino acid sequence disclosed herein for vc67_l was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vc67_l protein demonstrated at least some similarity to sequences identified as W69427 (Human secreted protein bk291_3) and Z68751 (Similarity to Yeast hypothetical protein YKKO (SW YKK0_YEAST); cDNA EST EMBL C12578 comes from this gene; cDNA EST yk329gl2.5 comes from this gene; cDNA EST yk415). Based upon sequence similarity, vc67_l proteins and each similar protein or peptide may share at least some activity. The TopPredll computer program predicts two potential transmembrane domains within the vc67_l protein sequence of SEQ ID NO:38, one centered around amino acid 58 and another around amino acid 85 of SEQ ID NO:38.

Clone "vf4 1"

A polynucleotide of the present invention has been identified as clone "vf4_l". vf4_l was isolated from a human adult heart cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vf4_l is a full-length clone, including the entire coding sequence of a secreted protein (also refened to herein as "vf4_l protein").

The nucleotide sequence of vf4_l as presently determined is reported in SEQ ID NO:39, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence ofthe vf4_l protein conesponding to the foregoing nucleotide sequence is reported in SEQ ID NO:40. Amino acids 5 to 17 of SEQ ID NO:40 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 18. Due to the hydrophobic nature ofthe predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vf4_l protein.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone vf4_l should be approximately 972 bp.

The nucleotide sequence disclosed herein for vf4_J was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vf4_l demonstrated at least some similarity with sequences identified as AA813690 (ai71a09.sl Soares_testis_NHT Homo sapiens cDNA clone 1376248 3', mRNA sequence) and V86544 (EST clone AZ285). Based upon sequence similarity, vf4_J proteins and each similar protein or peptide may share at least some activity.

Clone "vg3 1"

A polynucleotide of the present invention has been identified as clone "vg3_l". vg3_J was isolated from a human adult brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence ofthe encoded protein. vg3_l is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vg3_l protein").

The nucleotide sequence of vg3_l as presently determined is reported in SEQ ID NO:41, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vg3_l protein conesponding to the foregoing nucleotide sequence is reported in SEQ ID NO:42. Amino acids 13 to 25 of SEQ ID NO:42 are apredicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 26. Due to the hydrophobic nature ofthe predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vg3_l protein.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone vg3_l should be approximately 3667 bp. The nucleotide sequence disclosed herein for vg3_J was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vg3_l demonstrated at least some similarity with sequences identified as AI283122 (qm51hl0.xl Soares_placenta_8to9weeks_2NbHP8to9W Homo sapiens cDNA clone IMAGE 1892323 3', mRNA sequence). The predicted amino acid sequence disclosed herein for vg3_J was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vg3_l protein demonstrated at least some similarity to sequences identified as U53155 (ZC513.5 [Caenorhabditis elegans]). Based upon sequence similarity, vg3_l proteins and each similar protein or peptide may share at least some activity. The TopPredll computer program predicts the following transmembrane domains within the vg3_l protein sequence: four certain transmembrane domains centered around amino acids 78, 133, 156, and 298 of SEQ ID NO:42, respectively; four strongly putative transmembrane domains centered around amino acids 105, 189, 221, and 354 of SEQ ID NO:42, respectively; and six possible transmembrane domains centered around amino acids 262, 272, 322, 367, 432, and 460 of SEQ ID NO:42, respectively. Motifs analysis detected a Crystallins beta and gamma 'Greek key' motif signature around amino acid 52 of SEQ ID NO:42. The nucleotide sequence of vg3_l indicates that it may contain an Alu repetitive element.

Clone "vo2 1"

A polynucleotide of the present invention has been identified as clone "vo2_l". vo2_l was isolated from a human adult pancreas cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vo2_l is a full-length clone, including the entire coding sequence of a secreted protein (also refened to herein as "vo2_l protein").

The nucleotide sequence of vo2_l as presently determined is reported in SEQ ID NO:43, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vo2_l protein conesponding to the foregoing nucleotide sequence is reported in SEQ ID NO:44. Another potential vo2_ 1 reading frame and predicted amino acid sequence encoded by basepairs 95 to 280 of SEQ ID NO:43 is reported in SEQ ID NO: 179. Amino acids 9 to 21 of SEQ ID NO: 179 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 22. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder ofthe protein of SEQ ID NO: 179. Another potential vo2_ 1 reading frame and predicted amino acid sequence encoded by basepairs 76 to 258 of SEQ ID NO:43 is reported in SEQ ID NO: 180. Amino acids 18 to 30 of SEQ ID NO: 180 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 31. Due to the hydrophobic nature of this predicted leader/signal sequence, it is likely to act as a transmembrane domain should it not be separated from the remainder of the protein of SEQ ID NO: 180.

Another potential vo2_ 1 reading frame and predicted amino acid sequence encoded by basepairs 2131 to 2310 of SEQ ID NO:43 is reported in SEQ ID NO: 181. Amino acids 38 to 50 of SEQ ID NO: 181 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 11 ; amino acids 19 to 31 of SEQ ID NO: 181 are also a possible leader/signal sequence, with the predicted mature amino acid sequence in this case beginning at amino acid 32. Due to the hydrophobic nature of these predicted leader/signal sequences, each is likely to act as a transmembrane domain should it not be separated from the remainder of the protein of SEQ ID NO: 181.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone vo2_l should be approximately 2903 bp.

The nucleotide sequence disclosed herein for vo2_l was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vo2_l demonstrated at least some similarity with sequences identified as AI094627 (oy61b07.sl NCI_CGAP_Brn23 Homo sapiens cDNA clone IMAGE 1670293 3', mRNA sequence). Based upon sequence similarity, vo2_l proteins and each similar protein or peptide may share at least some activity.

Clone "vo3 1"

A polynucleotide of the present invention has been identified as clone "vo3_l". vo3_l was isolated from a human adult pancreas cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vo3_J is a full-length clone, including the entire coding sequence of a secreted protein (also refened to herein as "vo3_l protein").

The nucleotide sequence of vo3_l as presently determined is reported in SEQ ID

NO:45, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence ofthe vo3_l protein conesponding to the foregoing nucleotide sequence is reported in SEQ ID NO:46. Amino acids 107 to

119 of SEQ ID NO:46 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 120. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder ofthe vo3_l protein.

If a "C" residue were to be deleted from the nucleotide sequence of SEQ ID NO:45 at either position 917 or position 918, another potential vo3_l reading frame and predicted amino acid sequence encoded by what would then be basepairs 697 to 1377 of SEQ ID

NO:45 is reported in SEQ ID NO: 182. Amino acids 62 to 74 of SEQ ID NO: 182 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 75. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the protein of SEQ ID NO: 182.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone vo3_l should be approximately 1592 bp.

The nucleotide sequence disclosed herein for vo3_l was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vo3_l demonstrated at least some similarity with sequences identified as AA530997 (nj07a06.sl NCI_CGAP_Pr22 Homo sapiens cDNA clone IMAGE:985618 3', mRNA sequence), AA683481 (zl55b03.sl Soares pregnant uterus NbHPU Homo sapiens cDNA clone IMAGE:505805 3', mRNA sequence), D88158 (Pig mRNA for cytochrome b561, complete eds), and V84516 (Human secreted protein gene 106 clone HTOEY16). The predicted amino acid sequence disclosed herein for vo3_l was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vo3_l protein demonstrated at least some similarity to sequences identified as U06715 (HC YTO B561 [Homo sapiens]) and W89024 (Polypeptide fragment encoded by gene 156). Based upon sequence similarity, vo3_l proteins and each similar protein or peptide may share at least some activity. The TopPredll computer program predicts five potential transmembrane domains within the vo3_l protein sequence, centered around amino acids 35, 75, 113, 146, and 191 of SEQ ID NO:46, respectively.

Clone "vo5 1"

A polynucleotide of the present invention has been identified as clone "vo5_l". vo5_l was isolated from a human adult pancreas cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vo5_l is a full-length clone, including the entire coding sequence of a secreted protein (also refened to herein as "vo5_l protein").

The nucleotide sequence of vo5_l as presently determined is reported in SEQ ID NO:47, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vo5_l protein conesponding to the foregoing nucleotide sequence is reported in SEQ ID NO:48. Amino acids 8 to 20 of SEQ ID NO:48 are apredicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 21. Due to the hydrophobic nature ofthe predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vo5_l protein. The EcoRI/Notl restriction fragment obtainable from the deposit containing clone vo5_l should be approximately 2487 bp.

The nucleotide sequence disclosed herein for vo5_l was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vo5_l demonstrated at least some similarity with sequences identified as AA868551 (ak43f09.sl Soares testis NHT Homo sapiens cDNA clone IMAGE: 14087453', mRNA sequence) and AC005500 (complete sequence [Homo sapiens Chromosome 22ql l PAC Clone p52f6 In DGCR Region]). Based upon sequence similarity, vo5_l proteins and each similar protein or peptide may share at least some activity. The nucleotide sequence of vo5_l indicates that it may contain an Alu repetitive element. Clone "vo6 1"

A polynucleotide of the present invention has been identified as clone "vo6_l". vo6_J was isolated from a human adult pancreas cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vo6_l is a full-length clone, including the entire coding sequence of a secreted protein (also refened to herein as "vo6_l protein").

The nucleotide sequence of vo6_l as presently determined is reported in SEQ ID NO:49, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vo6_l protein conesponding to the foregoing nucleotide sequence is reported in SEQ ID NO:50. Amino acids 77 to 89 of SEQ ID NO:50 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 90. Due to the hydrophobic nature ofthe predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vo6_l protein. The EcoRI/Notl restriction fragment obtainable from the deposit containing clone vo6_l should be approximately 1272 bp.

The nucleotide sequence disclosed herein for vo6_l was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vo6_l demonstrated at least some similarity with sequences identified as AL020989 (Human DNA sequence *** SEQUENCING IN PROGRESS *** from clone 192P9; HTGS phase 1), T34592 (NTII-11 nerve protein coding sequence), and U 13617 (Rattus norvegicus Sprague-Dawley plasmolipin mRNA, complete eds). The predicted amino acid sequence disclosed herein for vo6_l was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vo6_l protein demonstrated at least some similarity to sequences identified as R99799 (NTII-11 nerve protein, facilitates regeneration of nerve cells) and U13617 (plasmolipin [Rattus norvegicus]). Plasmolipin is an 18-kDaproteolipid protein found in kidney and brain, where it is restricted to the apical surface of tubular epithelial cells and to mammalian myelinated tracts, respectively; addition of plasmolipin to lipid bilayers induces the formation of ion channels, which are voltage-dependent and K(+)-selective.

(See Fischer and Sapirstein , 1994, J. Biol. Chem. 269(40): 24912-24919, which is incorporated by reference herein). Based upon sequence similarity, vo6_l proteins and each similar protein or peptide may share at least some activity. The TopPredll computer program predicts three potential transmembrane domains within the vo6_l protein sequence, centered around amino acids 14, 42, and 90 of SEQ ID NO:50, respectively.

Clone "vo9 1"

A polynucleotide of the present invention has been identified as clone "vo9_l". vo9_l was isolated from a human adult pancreas cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vo9_l is a full-length clone, including the entire coding sequence of a secreted protein (also refened to herein as "vo9_l protein").

The nucleotide sequence of vo9_l as presently determined is reported in SEQ ID

NO:51, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence ofthe vo9_l protein conesponding to the foregoing nucleotide sequence is reported in SEQ ID NO:52. Amino acids 22 to 34 of SEQ ID NO: are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 35. Due to the hydrophobic nature ofthe predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vo9_l protein.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone vo9_l should be approximately 3331 bp.

The nucleotide sequence disclosed herein for vo9_l was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vo9_l demonstrated at least some similarity with sequences identified as AA936961 (oo65f04.sl NCI_CGAP_GC4 Homo sapiens cDNA clone IMAGE 1571071 3', mRNA sequence), AF010496 9Rhodobacter capsulatus strain SB 1003, partial genome), AL035661 (Human DNA sequence *** SEQUENCING IN PROGRESS *** from clone 568C11, WORKING DRAFT SEQUENCE), and Q24673 (facA gene). The predicted amino acid sequence disclosed herein for vo9_l was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vo9_l protein demonstrated at least some similarity to sequences identified as R23968 (facA gene product) and Y15417 (acetate— CoA ligase [Coprinus cinereus]). Based upon sequence similarity, vo9_l proteins and each similar protein or peptide may share at least some activity.

Clone "vo 11 1" A polynucleotide of the present invention has been identified as clone "vol 1_1 ". vol 1_1 was isolated from a human adult pancreas cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein, vol 1_1 is a full-length clone, including the entire coding sequence of a secreted protein (also refened to herein as "vol 1_1 protein"). The nucleotide sequence of vo 11 _ 1 as presently determined is reported in SEQ ID

NO:53, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence ofthe vol 1_1 protein conesponding to the foregoing nucleotide sequence is reported in SEQ ID NO:54. Amino acids 52 to 64 of SEQ ID NO:54 are apredicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 65.

Another potential vol l_l reading frame and predicted amino acid sequence, encoded by basepairs 18 to 308 of SEQ ID NO:53Js reported in SEQ ID NO: 183. Amino acids 10 to 22 of SEQ ID NO: 183 are a possible leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 23. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the protein of SEQ ID NO: 183.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone vol 1_1 should be approximately 1509 bp. The nucleotide sequence disclosed herein for vol l_l was searched against the

GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols, vol 1_1 demonstrated at least some similarity with sequences identified as D83866 (similar to none, mRNA sequence). Based upon sequence similarity, vol 1_1 proteins and each similar protein or peptide may share at least some activity. Clone "vol2 1"

A polynucleotide of the present invention has been identified as clone "vol2_J". vol2_l was isolated from a human adult pancreas cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vol2_l is a full-length clone, including the entire coding sequence of a secreted protein (also refened to herein as "vol2_l protein").

The nucleotide sequence of vol2_l as presently determined is reported in SEQ ID NO:55, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence ofthe vol2_l protein conesponding to the foregoing nucleotide sequence is reported in SEQ ID NO:56. Amino acids 4 to 16 of SEQ ID NO:56 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 17.

Another potential vol2_l reading frame and predicted amino acid sequence, encoded by basepairs 107 to 310 of SEQ ID NO:55, is reported in SEQ ID NO: 184. Amino acids 14 to 26 and amino acids 18 to 30 of SEQ ID NO: 184 are predicted leader/signal sequences, with the predicted mature amino acid sequence beginning at amino acid 27 or at amino acid 31, respectively. Due to the hydrophobic nature of these predicted leader/signal sequences, each is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder ofthe protein of SEQ ID NO: 184.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone vol2_l should be approximately 986 bp.

The nucleotide sequence disclosed herein for vol2_l was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vol2_l demonstrated at least some similarity with sequences identified as AA444152 (zv51g06.rl Soares testis NHT Homo sapiens cDNA clone 7572105', mRNA sequence). Based upon sequence similarity, vol2_l proteins and each similar protein or peptide may share at least some activity. The TopPredll computer program predicts a potential transmembrane domain within the vol2_l protein sequence centered around amino acid 51 of SEQ ID NO:56. Clone "vol 3 1"

A polynucleotide of the present invention has been identified as clone "vol3_l". vol3_J was isolated from a human adult pancreas cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. The vo 13_ 1 clone includes coding sequence of a secreted protein (also refened to herein as "vol3_l protein").

The nucleotide sequence of vol3_l as presently determined is reported in SEQ ID NO:57, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence ofthe vo 13_1 protein conesponding to the foregoing nucleotide sequence is reported in SEQ ID NO:58. Amino acids 8 to 20 of SEQ ID NO:58 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 21.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone vol3_l should be approximately 1073 bp. The nucleotide sequence disclosed herein for vol3_l was searched against the

GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vol3_l demonstrated at least some similarity with sequences identified as AA988298 (os32a02.sl NCI_CGAP_Br2 Homo sapiens cDNA clone IMAGE: 16070183', mRNA sequence) and V69614 (Human secreted protein gene 4 clone HE8ND56). The predicted amino acid sequence disclosed herein for vol3_l was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vol3_l protein demonstrated at least some similarity to sequences identified as W83934 (Human secreted protein from gene 4 clone HE8ND56). Based upon sequence similarity, vol3_l proteins and each similar protein or peptide may share at least some activity. The TopPredll computer program predicts a potential transmembrane domain within the vol3_l protein sequence centered around amino acid 50 of SEQ ID NO:58.

Clone "vol4 1" A polynucleotide of the present invention has been identified as clone "vol4_l ". vol4_l was isolated from a human adult pancreas cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vol4_J is a full-length clone, including the entire coding sequence of a secreted protein (also refened to herein as "vol4_l protein"). The nucleotide sequence of vol4_l as presently determined is reported in SEQ ID NO:59, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vo 14_ 1 protein conesponding to the foregoing nucleotide sequence is reported in SEQ ID NO:60. Amino acids 14 to 26 of SEQ ID NO: 60 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 27.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone vol4_l should be approximately 1605 bp.

The nucleotide sequence disclosed herein for vol4_l was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. No significant hits were found in the databases. Based upon sequence similarity , vo 14_ 1 proteins and each similar protein or peptide may share at least some activity. The nucleotide sequence of vol4_l indicates that it may contain one or more of the following repetitive elements: Alu, TAAAA repeat.

Clone "vol5 1"

A polynucleotide of the present invention has been identified as clone "vol5_l". vol5_l was isolated from a human adult pancreas cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vol5_l is a full-length clone, including the entire coding sequence of a secreted protein (also refened to herein as "vol5_l protein").

The nucleotide sequence of vol5_ l as presently determined is reported in SEQ ID NO:61, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence ofthe vol5_l protein conesponding to the foregoing nucleotide sequence is reported in SEQ ID NO: 62. Amino acids 13 to 25 of SEQ ID NO: 62 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 26. If a nucleotide were deleted between nucleotide 458 and nucleotide 460 of SEQ ID

NO:61, another potential vol5_J reading frame and predicted amino acid sequence, encoded by what would then be basepairs 90 to 515 of SEQ ID NO:61, is reported in SEQ ID NO: 185. Amino acids 16 to 28 and amino acids 13 to 25 of SEQ ID NO: 185 are predicted leader/signal sequences, with the predicted mature amino acid sequence beginning at amino acid 29 or at amino acid 26, respectively. Due to the hydrophobic nature of these predicted leader/signal sequences, each is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the protein of SEQ ID NO: 185.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone vol5_l should be approximately 2842 bp.

The nucleotide sequence disclosed herein for vol5_l was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vol5_l demonstrated at least some similarity with sequences identified as AI096756 (qb46el0.xl NCI_CGAP_Brn23 Homo sapiens cDNA clone IMAGE 17031783', mRNA sequence). Based upon sequence similarity, vol5_l proteins and each similar protein or peptide may share at least some activity. The TopPredll computer program predicts a potential transmembrane domain within the vo 15_ 1 protein sequence centered around amino acid 126 of SEQ ID NO: 62. The nucleotide sequence of vol5_l indicates that it may contain one ore more repeat sequences.

Clone "vol6 1" A polynucleotide of the present invention has been identified as clone "vol6_l ". vol6_l was isolated from a human adult pancreas cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vol6_l is a full-length clone, including the entire coding sequence of a secreted protein (also refened to herein as "vol6_l protein"). The nucleotide sequence of vo 16_ 1 as presently determined is reported in SEQ ID

NO:63, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence ofthe vol6_l protein conesponding to the foregoing nucleotide sequence is reported in SEQ ID NO: 64. Amino acids 51 to 63 of SEQ ID NO: 64 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 64. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vol6_l protein. If an "A" or "G" nucleotide were inserted between nucleotides 102 and 103of SEQ ID NO:63 and an additional "A" residue inserted between nucleotides 271 and 273 of SEQ ID NO:63, another potential vol6_l reading frame and predicted amino acid sequence, encoded by what would then be basepairs 6 to 338 of SEQ ID NO:63, is reported in SEQ ID NO:. Amino acids 5 to 17 and amino acids 4 to 16 of SEQ ID NO: 186 are predicted leader/signal sequences, with the predicted mature amino acid sequence beginning at amino acid 18 or at amino acid 17, respectively. Due to the hydrophobic nature of these predicted leader/signal sequences, each is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder ofthe protein of SEQ ID NO: 186.

Another potential vol6_l reading frame and predicted amino acid sequence, encoded by basepairs 846 to 1061 of SEQ ID NO:63, is reported in SEQ ID NO: 187. Amino acids 12 to 24 and amino acids 11 to 23 of SEQ ID NO: 187 are predicted leader/signal sequences, with the predicted mature amino acid sequence beginning at amino acid 25 or at amino acid 24, respectively. Due to the hydrophobic nature of these predicted leader/signal sequences, each is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder ofthe protein of SEQ ID NO: 187.

Nucleotides 1 to 133 of SEQ ID NO:63 are nearly identical to nucleotides 862 to 994 of SEQ ID NO:63, resulting in amino acids 1 to 33 of SEQ ID NO: 186 being identical to amino acids 8 to 40 of SEQ ID NOJ 87.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone vol6_l should be approximately 2113 bp.

The nucleotide sequence disclosed herein for vol6_l was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vol6_l demonstrated at least some similarity with sequences identified as R79825 (yi89a06.sl Soares placenta Nb2HP Homo sapiens cDNA clone IMAGE: 146386 3', mRNA sequence). Based upon sequence similarity, vol6_l proteins and each similar protein or peptide may share at least some activity. The TopPredll computer program predicts a potential transmembrane domain within the vo 16_ 1 protein sequence centered around amino acid 64 of SEQ ID NO:64. The nucleotide sequence of vol6_l indicates that it may contain an Alu repeat region. Clone "vol 8 1"

A polynucleotide of the present invention has been identified as clone "vol8_J". vol8_l was isolated from a human adult pancreas cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence ofthe encoded protein. vol8_l is a full-length clone, including the entire coding sequence of a secreted protein (also refened to herein as "vol8_l protein").

The nucleotide sequence of vol8_l as presently determined is reported in SEQ ID

NO:65, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vo 18_ 1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:66. Amino acids 10 to 22 of SEQ ID NO: 66 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 23.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone vo 18_ 1 should be approximately 624 bp.

The nucleotide sequence disclosed herein for vol8_l was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vol8_l demonstrated at least some similarity with sequences identified as All 98956 (qfόόhOl.xl Soares_testis_NHT Homo sapiens cDNA clone IMAGE 1755025 3', mRNA sequence). Based upon sequence similarity, vo 18_1 proteins and each similar protein or peptide may share at least some activity.

Clone "vol9 1"

A polynucleotide of the present invention has been identified as clone "vol9_l ". vol9_l was isolated from a human adult pancreas cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vol9_l is a full-length clone, including the entire coding sequence of a secreted protein (also refened to herein as "vol9_l protein").

The nucleotide sequence of vol9_l as presently determined is reported in SEQ ID NO:67, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence ofthe vol9_l protein conesponding to the foregoing nucleotide sequence is reported in SEQ ID NO:68. Amino acids 8 to 20 of SEQ ID NO:68 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 21.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone vol9_l should be approximately 1957 bp. The nucleotide sequence disclosed herein for vol9_l was searched against the

GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vol9_l demonstrated at least some similarity with sequences identified as AI524085 (th01e09.xl NCI_CGAP_CLL1 Homo sapiens cDNA clone IMAGE:2117032 3', mRNA sequence) and V42646 (DNA encoding a human pathogenesis-related protein designated HPRP). The predicted amino acid sequence disclosed herein for vol9_J was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vol9_l protein demonstrated at least some similarity to sequences identified as U 16307 (glioma pathogenesis-related protein [Homo sapiens] and W63115 (A human pathogenesis-related protein designated HPRP). Based upon sequence similarity, vol9_J proteins and each similar protein or peptide may share at least some activity.

Clone "vo22 1"

A polynucleotide of the present invention has been identified as clone "vo22_J". vo22_l was isolated from a human adult pancreas cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vo22_l is a full-length clone, including the entire coding sequence of a secreted protein (also refened to herein as "vo22_l protein").

The nucleotide sequence of vo22_l as presently determined is reported in SEQ ID NO:69, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence ofthe vo22_l protein conesponding to the foregoing nucleotide sequence is reported in SEQ ID NO:70. Amino acids 6 to 18 of SEQ ID NO:70 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 19. If one of the "G" nucleotides at positions 385 and 386 of SEQ ID NO:69 were deleted, and the "G" residue at position 312 of SEQ ID NO:69 changed to a "T", another potential vo22_l reading frame and predicted amino acid sequence, encoded by what would then be basepairs 104 to 430 of SEQ ID NO:69, is reported in SEQ ID NO: 188. Amino acids 8 to 20, amino acids 7 to 19, amino acids 6 tol8, and amino acids 9 to 21 of SEQ ID NO: 188 are predicted leader/signal sequences, with the predicted mature amino acid sequence beginning at amino acid 21, or at amino acid 20, or at amino acid 19,or at amino acid 22, respectively. Due to the hydrophobic nature of these predicted leader/signal sequences, each is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder ofthe protein of SEQ ID NOJ88.

Another potential vo22_J reading frame and predicted amino acid sequence, encoded by basepairs 1150 to 1357 of SEQ ID NO:69, is reported in SEQ ID NO: 189. Amino acids 3 to 15 of SEQ ID NO: 189 are a possible leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 16. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the protein of SEQ ID NO: 189.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone vo22_l should be approximately 2091 bp.

The nucleotide sequence disclosed herein for vo22_l was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vo22_l demonstrated at least some similarity with sequences identified as AA706247 (ah28cl l.sl Soares parathyroid tumor NbHPA Homo sapiens cDNA clone 1240148 3', mRNA sequence) and V34194 (Human secreted protein gene 41 clone HNTME13). The predicted amino acid sequence disclosed herein for vo22_l was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vo22_l protein demonstrated at least some similarity to sequences identified as AF01644 (No definition line found [Caenorhabditis elegans]) and W75155 (Human secreted protein encoded by gene 41 clone HNTME13). Based upon sequence similarity, vo22_l proteins and each similar protein or peptide may share at least some activity. The TopPredll computer program predicts 9 potential transmembrane domains within the vo22_ 1 protein sequence, centered around amino acids

50, 120, 165, 250, 275, 309, 356, 374, and 392 of SEQ ID NO:70, respectively. Clone "vo23 1"

A polynucleotide of the present invention has been identified as clone "vo23_l". vo23_l was isolated from a human adult pancreas cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vo23_l is a full-length clone, including the entire coding sequence of a secreted protein (also refened to herein as "vo23_l protein").

The nucleotide sequence of vo23_l as presently determined is reported in SEQ ID

NO:71, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence ofthe vo23_l protein conesponding to the foregoing nucleotide sequence is reported in SEQ ID NO:72.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone vo23_l should be approximately 2598 bp.

The nucleotide sequence disclosed herein for vo23_l was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vo23_l demonstrated at least some similarity with sequences identified as T23658 (Human gene signature HUMGS05523), W81246 (zd85b01.rl Soares fetal heart NbHH19W Homo sapiens cDNA clone 347401 5', mRNA sequence), and Z84488 (Human DNA sequence from PAC 93H18 on chromosome 6 contains ESTs heterochromatin protein HPlHs-gamma pseudogene, STS and CpG island). Based upon sequence similarity, vo23_l proteins and each similar protein or peptide may share at least some activity. The TopPredll computer program predicts two potential transmembrane domains within the vo23_l protein sequence, one centered around amino acid 428 and another around amino acid 472 of SEQ ID NO:72.

Clone "vo24 1"

A polynucleotide of the present invention has been identified as clone "vo24_l". vo24_l was isolated from a human adult pancreas cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vo24_l is a full-length clone, including the entire coding sequence of a secreted protein (also refened to herein as "vo24_l protein").

The nucleotide sequence of vo24_l as presently determined is reported in SEQ ID NO:73, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence ofthe vo24_l protein conesponding to the foregoing nucleotide sequence is reported in SEQ ID NO:74. Amino acids 10 to 22 of SEQ ID NO:74 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 23. The EcoRI/Notl restriction fragment obtainable from the deposit containing clone vo24_l should be approximately 3484 bp.

The nucleotide sequence disclosed herein for vo24_l was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vo24_l demonstrated at least some similarity with sequences identified as AC003117 (*** SEQUENCING IN PROGRESS *** Human chromosome 1 BAC 308G1 genomic sequence; HTGS phase 1, 3 unordered pieces), V10696 (Human 3.5 kB DNA fragment predicted to contain CHl-9al 1-2 gene), and Z94054 (Human DNA sequence from PAC 125H23 on chromosome Iq24-lq25). The predicted amino acid sequence disclosed herein for vo24_l was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vo24_ 1 protein demonstrated at least some similarity to sequences identified as W58774 (Human breast cancer gene CHl-9al 1-2 protein fragment #1). Based upon sequence similarity, vo24_l proteins and each similar protein or peptide may share at least some activity. The nucleotide sequence of vo24_l indicates that it may contain one or more ofthe following repetitive elements: Alu, Mer33.

Clone "vo25 1"

A polynucleotide of the present invention has been identified as clone "vo25_l". vo25_l was isolated from a human adult pancreas cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence ofthe encoded protein. vo25_l is a full-length clone, including the entire coding sequence of a secreted protein (also refened to herein as "vo25_l protein").

The nucleotide sequence of vo25_l as presently determined is reported in SEQ ID

NO:75, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vo25_ 1 protein conesponding to the foregoing nucleotide sequence is reported in SEQ ID NO:76. Amino acids 11 to 23 of SEQ ID NO:76 are apredicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 24.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone vo25_l should be approximately 1200 bp. The nucleotide sequence disclosed herein for vo25_l was searched against the

GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vo25_l demonstrated at least some similarity with sequences identified as AI300566 (qn56a09.xl NCI_CGAP_Kid5 Homo sapiens cDNA clone IMAGE 1902232 3' similar to WP C35D10J CE01190 ;, mRNA sequence), V34218 (Human secreted protein gene 65 clone HSREG44), and Z55702 (H.sapiens CpG island DNA genomic Msel fragment, clone 58el0, forward read cpg58el0.ftla). The predicted amino acid sequence disclosed herein for vo25_l was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vo25_l protein demonstrated at least some similarity to sequences identified as U21324 (similar to S. cerevisiae hypothetical protein YKL166 [Caenorhabditis elegans]) and W57893 (Protein of clone AT340_1). Based upon sequence similarity, vo25_l proteins and each similar protein or peptide may share at least some activity. Motifs analysis detected an ATP/GTP-binding site motif A (P-loop) centered around residue 229 of SEQ ID NO:76. The TopPredll computer program predicts a potential transmembrane domain within the vo25_l protein sequence centered around amino acid 170 of SEQ ID

NO:76.

Clone "vo26 1"

A polynucleotide of the present invention has been identified as clone "vo26_l". vo26_l was isolated from a human adult pancreas cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vo26_l is a full-length clone, including the entire coding sequence of a secreted protein (also refened to herein as "vo26_l protein").

The nucleotide sequence of vo26_l as presently determined is reported in SEQ ID NO:77, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence ofthe vo26_l protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:78. Amino acids 13 to 25 of SEQ ID NO:78 are apredicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 26.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone vo26_l should be approximately 2503 bp. The nucleotide sequence disclosed herein for vo26_l was searched against the

GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vo26_l demonstrated at least some similarity with sequences identified as AC004707 (Homo sapiens chromosome 17, clone hRPC.117_B_12, complete sequence), AI160442 (qc08g02.xl Soares_fetal_heart_NbHH19W Homo sapiens cDNA clone IMAGE 17090423' similarto SWRM02_YEAST P12687 MITOCHONDRIAL 60S RIBOSOMAL PROTEIN L2 PRECURSOR; mRNA sequence), and T23473 (Human gene signature HUMGS05312). The predicted amino acid sequence disclosed herein for vo26_l was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vo26_l protein demonstrated at least some similarity to sequences identified as L37877 (ribosomal protein L27 [Filobasidiella neoformans]). Based upon sequence similarity, vo26_l proteins and each similar protein or peptide may share at least some activity. The nucleotide sequence of vo26_l indicates that it may contain a Mir repeat.

Clone "VP23 1"

A polynucleotide of the present invention has been identified as clone "vp23_l". vp23_l was isolated from a human adult prostate cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vp23_l is a full-length clone, including the entire coding sequence of a secreted protein (also refened to herein as "vp23_l protein").

The nucleotide sequence of vp23_l as presently determined is reported in SEQ ID NO:79, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence ofthe vp23_l protein conesponding to the foregoing nucleotide sequence is reported in SEQ ID NO: 80. Amino acids 5 to 17 of SEQ ID NO: 80 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 18. Due to the hydrophobic nature ofthe predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vp23_l protein.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone vp23_l should be approximately 1220 bp. The nucleotide sequence disclosed herein for vp23_J was searched against the

GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vp23_l demonstrated at least some similarity with sequences identified as AL021578 (Human DNA sequence from clone 453C12 on chromosome 20ql2-13J2 Contains SDC4 (syndecan 4 (amphiglycan, ryudocan)), predicts a gene like the mouse transcription factor RBP-L). Based upon sequence similarity, vp23_l proteins and each similar protein or peptide may share at least some activity. The nucleotide sequence of vp23_l indicates that it may contain an Alu repetitive element.

Clone "vq7 1" A polynucleotide of the present invention has been identified as clone "vq7_J". vq7_l was isolated from a human adult lung cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence ofthe encoded protein. vq7_l is a full-length clone, including the entire coding sequence of a secreted protein (also refened to herein as "vq7_l protein"). The nucleotide sequence of vq7_l as presently determined is reported in SEQ ID

NO:81, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence ofthe vq7_l protein conesponding to the foregoing nucleotide sequence is reported in SEQ ID NO: 82. Amino acids 9 to 21 of SEQ ID NO:82 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 22. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vq7_l protein.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone vq7_l should be approximately 1326 bp. The nucleotide sequence disclosed herein for vq7_l was searched against the

GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vq7_l demonstrated at least some similarity with sequences identified as AA036918 (zk32e03.r 1 Soares pregnant uterus NbHPU Homo sapiens cDNA clone 484540 5', mRNA sequence). The predicted amino acid sequence disclosed herein for vq7_l was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vq7_l protein demonstrated at least some similarity to sequences identified as AF 142780 (butyrophilin-like protein [Mus musculus]). Butyrophilin is a glycoprotein of the immunoglobulin superfamily that is secreted in association with the milk-fat-globule membrane from mammary epithelial cells (Ogg et al., 1996, Mamm. Genome 7 (12): 900-905, which is incorporated by reference herein). Based upon sequence similarity, vq7_l proteins and each similar protein or peptide may share at least some activity. The nucleotide sequence of vq7_l indicates that it may contain a repetitive element.

Clone "vq8 1"

A polynucleotide of the present invention has been identified as clone "vq8_l". vq8_ 1 was isolated from a human adult lung cDN A library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence ofthe encoded protein. vq8_l is a full-length clone, including the entire coding sequence of a secreted protein (also refened to herein as "vq8_l protein").

The nucleotide sequence of vq8_l as presently determined is reported in SEQ ID NO: 83, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence ofthe vq8_l protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:84. Amino acids 10 to 22 of SEQ ID NO: 84 are apredicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 23. Due to the hydrophobic nature ofthe predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vq8_l protein.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone vq8_l should be approximately 695 bp.

The nucleotide sequence disclosed herein for vq8_l was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and

FASTA search protocols. vq8_l demonstrated at least some similarity with sequences identified as AA433968 (zw23f07.rl Soares ovary tumor NbHOT Homo sapiens cDNA clone 770149 5', mRNA sequence) and V69618 (Human secreted protein gene 8 clone HLHCM89). The predicted amino acid sequence disclosed herein for vq8_l was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vq8_l protein demonstrated at least some similarity to sequences identified as W83953 (Polypeptide encoded by gene 7 clone HJPDJ64). Based upon sequence similarity, vq8_l proteins and each similar protein or peptide may share at least some activity.

Clone "vq9 1" A polynucleotide of the present invention has been identified as clone "vq9_l". vq9_l was isolated from a human adult lung cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence ofthe encoded protein. vq9_l is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vq9_l protein"). The nucleotide sequence of vq9_l as presently determined is reported in SEQ ID

NO:85, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence ofthe vq9_l protein conesponding to the foregoing nucleotide sequence is reported in SEQ ID NO:86. Amino acids 5 to 17 of SEQ ID NO:86 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 18. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vq9_l protein.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone vq9_l should be approximately 1218 bp. The nucleotide sequence disclosed herein for vq9_l was searched against the

GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vq9_l demonstrated at least some similarity with sequences identified as AA769310 (nz39f03.sl NCI_CGAP_GCB 1 Homo sapiens cDNA clone IMAGE: 1290173, mRNA sequence). The predicted amino acid sequence disclosed herein for vq9_l was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vq9_l protein demonstrated at least some similarity to sequences identified as U79260 (unknown [Homo sapiens]) and W48351 (Human breast cancer related protein BCRB2). Based upon sequence similarity, vq9_J proteins and each similar protein or peptide may share at least some activity.

Clone "vqlO 1" A polynucleotide of the present invention has been identified as clone "vql0_l ". vql0_J was isolated from a human adult lung cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vqlO_J is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vql0_l protein"). The nucleotide sequence of vq 10_ 1 as presently determined is reported in SEQ ID

NO:87, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence ofthe vqlO_l protein conesponding to the foregoing nucleotide sequence is reported in SEQ ID NO: 88. Amino acids 6 to 18 of SEQ ID NO: 88 are apredicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 19. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vqlO_l protein.

Another potential reading frame, encoded by nucleotides 331 to 834 of SEQ ID NO:87, is reported as the amino acid sequence of SEQ ID NO: 190. Amino acids 29 to 41 of SEQ ID NO: 190 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 42. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the protein of SEQ ID NO: 190. If one nucleotide was deleted from the group of nucleotides at positions 330 and

331 of SEQ ID NO : 87 , another potential reading frame would be created from what would then be nucleotides 18 to 836, with a predicted amino acid sequence reported as SEQ ID NO: 191. Amino acids 6 to 18 of SEQ ID NO: 191 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 19. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the protein of SEQ ID NO: 191. The EcoRI/Notl restriction fragment obtainable from the deposit containing clone vqlO_l should be approximately 1516 bp.

The nucleotide sequence disclosed herein for vqlO_l was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vql0_l demonstrated at least some similarity with sequences identified as AA359702 (EST68843 Fetal lung II Homo sapiens cDNA 5' end similar to similar to pulmonary surfactant protein B, mRNA sequence), 108571 (Sequence 14 from Patent WO 8706588), and Q79287 (Human pulmonary surfactant protein B (SPB)). The predicted amino acid sequence disclosed herein for vql0_l was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vq 10_ 1 protein demonstrated at least some similarity to sequences identified as J02761 (pulmonary surfactant-associated protein SP-B [Homo sapiens]) and P70664 (6kd pulmonary surfactant protein). Pulmonary surfactant associated proteins such as SP- B promote alveolar stability by lowering the surface tension at the air-liquid interface in the peripheral air spaces. Based upon sequence similarity, vql0_l proteins and each similar protein or peptide may share at least some activity. The nucleotide sequence of vql0_l indicates that it may contain an Alu repetitive element.

Clone "vq!3 1" A polynucleotide of the present invention has been identified as clone "vql3_l ". vql3_l was isolated from a human adult lung cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vql3_l is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vql3_l protein"). The nucleotide sequence of vq 13_ 1 as presently determined is reported in SEQ ID

NO:89, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence ofthe vql3_l protein conesponding to the foregoing nucleotide sequence is reported in SEQ ID NO:90. Amino acids 10 to 22 of SEQ ED NO:90 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 23. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vql3_l protein. The EcoRI/Notl restriction fragment obtainable from the deposit containing clone vql3_l should be approximately 2284 bp.

The nucleotide sequence disclosed herein for vql3_l was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vql3_l demonstrated at least some similarity with sequences identified as AA928678 (on48e07.sl NCI_CGAP_Co8 Homo sapiens cDNA clone IMAGE 15599403', mRNA sequence), AB023187 (Homo sapiens mRNA for KIAA0970 protein, complete eds), and T 19039 (Human gene signature HUMGS00046). Based upon sequence similarity, vq 13_1 proteins and each similar protein or peptide may share at least some activity.

Clone "vq 16 1"

A polynucleotide of the present invention has been identified as clone "vql6_l". vql6_l was isolated from a human adult lung cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence ofthe encoded protein. vql6_l is a full-length clone, including the entire coding sequence of a secreted protein (also refened to herein as "vql6_l protein").

The nucleotide sequence of vql6_l as presently determined is reported in SEQ ID NO:91, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vq 16_ 1 protein conesponding to the foregoing nucleotide sequence is reported in SEQ ID NO:92. Amino acids 34 to 46 of SEQ ID NO:92 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 47. Due to the hydrophobic nature ofthe predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vql6_l protein.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone vql6_l should be approximately 1087 bp.

The nucleotide sequence disclosed herein for vql6_l was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vql6_l demonstrated at least some similarity with sequences identified as AA400700 (zu70gl l.rl Soares_testis_NHT Homo sapiens cDNA clone IMAGE:743396 5' similar to WP:R05D3.2 CE00281; mRNA sequence). The predicted amino acid sequence disclosed herein for vql6_l was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vql6_l protein demonstrated at least some similarity to sequences identified as AF05611 (unknown [Fugu rubripes]). Based upon sequence similarity, vql6_l proteins and each similar protein or peptide may share at least some activity. The TopPredll computer program predicts three additional potential transmembrane domains within the vql6_l protein sequence, centered around amino acids 90, 134, and 174 of SEQ ID NO:92, respectively.

Clone "vα 19 1"

A polynucleotide of the present invention has been identified as clone "vql9_l". vql9_l was isolated from a human adult lung cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vql9_l is a full-length clone, including the entire coding sequence of a secreted protein (also refened to herein as "vql9_l protein").

The nucleotide sequence of vql9_l as presently determined is reported in SEQ ID

NO:93, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence ofthe vql9_l protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:94. Amino acids 11 to 23 of SEQ ID NO:94 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 24. Due to the hydrophobic nature ofthe predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vql9_l protein.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone vql9_l should be approximately 1833 bp.

The nucleotide sequence disclosed herein for vql9_l was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vql9_l demonstrated at least some similarity with sequences identified as AA577696 (nn22h03.sl NCI_CGAP_Col2 Homo sapiens cDNA clone IMAGEJ084661 3' similar to contains Alu repetitive element; mRNA sequence. Based upon sequence similarity, vql9_l proteins and each similar protein or peptide may share at least some activity. The TopPredll computer program predicts an additional potential transmembrane domains within the vql9_l protein sequence centered around amino acid 214 of SEQ ID NO:94. The nucleotide sequence of vql9_l indicates that it may contain an Alu repetitive element.

Clone "vq20 1"

A polynucleotide of the present invention has been identified as clone "vq20_l". vq20_l was isolated from a human adult lung cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence ofthe encoded protein. vq20_l is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vq20_l protein").

The nucleotide sequence of vq20_l as presently determined is reported in SEQ ID

NO:95, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence ofthe vq20_l protein conesponding to the foregoing nucleotide sequence is reported in SEQ ID NO:96. Amino acids 10 to 22 of SEQ ID NO:96 are apredicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 23. Due to the hydrophobic nature ofthe predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vq20_l protein.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone vq20_l should be approximately 1275 bp.

The nucleotide sequence disclosed herein for vq20_l was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vq20_l demonstrated at least some similarity with sequences identified as AA826249 (ofl lc04.sl NCI_CGAP_Col2 Homo sapiens cDNA clone IMAGE 1420806 3' similar to TR Q13445 Q13445 PUTATIVE T1/ST2 RECEPTOR BINDING PROTEIN PRECURSOR; mRNA sequence), AI129838 (qc49hl l.xl Soares pregnant uterus NbHPU Homo sapiens cDNA clone IMAGEJ712997 3' similar to TR:Q13445 Q13445 PUTATIVE T1/ST2 RECEPTOR BINDING PROTEIN PRECURSOR; mRNA sequence), U41805 (Mus musculus putative T1/ST2 receptor binding protein precursor mRNA, partial eds), and V17729 (Human TI receptor-like ligand II cDNA). The predicted amino acid sequence disclosed herein for vq20_l was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vq20_J protein demonstrated at least some similarity to sequences identified as U41804 (putative T1/ST2 receptor binding protein precursor [Homo sapiens]) and W48335 (Human TI receptor-like ligand II). T1/ST2 is a receptor-like molecule homologous to the type I interleukin- 1 receptor (Gayle et al. , 1996, J. Biol. Chem. 271 (10): 5784-5789, which is incorporated by reference herein). Based upon sequence similarity, vq20_l proteins and each similar protein or peptide may share at least some activity. The TopPredll computer program predicts an additional potential transmembrane domain within the vq20_l protein sequence centered around amino acid 208 of SEQ ID NO:96.

Clone "vq21 1"

A polynucleotide of the present invention has been identified as clone "vq21_l". vq21_l was isolated from a human adult lung cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence ofthe encoded protein. vq21_l is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vq21_l protein").

The nucleotide sequence of vq21_l as presently determined is reported in SEQ ID

NO: 97, and includes a poly (A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence ofthe vq21_1 protein conesponding to the foregoing nucleotide sequence is reported in SEQ ID NO:98. Amino acids 16 to 28 of SEQ ID NO:98 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 29. Due to the hydrophobic nature ofthe predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vq21_l protein. The EcoRI Notl restriction fragment obtainable from the deposit containing clone vq21_l should be approximately 1230 bp.

The nucleotide sequence disclosed herein for vq21_l was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vq21_l demonstrated at least some similarity with sequences identified as AA149768 (zo01g05.sl Stratagene colon (#937204) Homo sapiens cDNA clone IMAGE 566456 3' similar to contains Alu repetitive element; mRNA sequence), AC005282 (Homo sapiens clone DJ0826E18, WORKING DRAFT SEQUENCE, 4 unordered pieces), T25413 (Human gene signature HUMGS07579). The predicted amino acid sequence disclosed herein for vq21_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vq21_ 1 protein demonstrated at least some similarity to sequences identified as U67577 (cell division protein FtsJ [Methanococcus jannaschii]). Based upon sequence similarity, vq21_J proteins and each similar protein or peptide may share at least some activity.

Clone "yr2 1"

A polynucleotide of the present invention has been identified as clone "vr2_J". vr2_l was isolated from a human adult lung cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vr2_l is a full-length clone, including the entire coding sequence of a secreted protein (also refened to herein as "vr2_l protein").

The nucleotide sequence of vr2_l as presently determined is reported in SEQ ID NO : 99. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vr2_l protein conesponding to the foregoing nucleotide sequence is reported in SEQ ID NO: 100.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone vr2_l should be approximately 1382 bp. The nucleotide sequence disclosed herein for vr2_l was searched against the

GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. No significant similarities were identified in the databases. The TopPredll computer program predicts a potential transmembrane domain within the vr2_l protein sequence centered around amino acid 85 of SEQ ID NO: 100. The nucleotide sequence of vr2_l indicates that it may contain one ore more of the following repetitive elements: Alu, MER2, MER4B.

Clone "vc69 1"

A polynucleotide of the present invention has been identified as clone "vc69_J". vc69_l was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vc69_l is a full-length clone, including the entire coding sequence of a secreted protein (also refened to herein as "vc69_l protein").

The nucleotide sequence of vc69_l as presently determined is reported in SEQ ID

NO: 101 , and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vc69_ 1 protein conesponding to the foregoing nucleotide sequence is reported in SEQ ID NO: 102. Amino acids 7 to 19 of SEQ ID NOJ 02 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 20. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vc69_l protein.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone • vc69_l should be approximately 1600 bp.

The nucleotide sequence disclosed herein for vc69_l was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vc69_l demonstrated at least some similarity with sequences identified as AB023138 (Homo sapiens mRNA for KIAA0921 protein, partial eds), and AI421941 (tf45c01.xl NCI_CGAP_Brn23 Homo sapiens cDNA clone IMAGE 2099136 3' similar to TR Q63376 Q63376 NEUREXIN II-BETA-A PRECURSOR; mRNA sequence). The predicted amino acid sequence disclosed herein for vc69_l was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vc69_l protein demonstrated at least some similarity to sequences identified as AB02313 (KIAA0921 protein [Homo sapiens]), and various isoforms of Rattus norvegicus neurexin II protein. Based upon sequence similarity, vc69_l proteins and each similar protein or peptide may share at least some activity.

Clone "vc71 1"

A polynucleotide of the present invention has been identified as clone "vc71_J". vc71_l was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vc71_l is a full-length clone, including the entire coding sequence of a secreted protein (also refened to herein as "vc71_l protein"). The nucleotide sequence of vc71_l as presently determined is reported in SEQ ID NOJ03, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence ofthe vc71_1 protein conesponding to the foregoing nucleotide sequence is reported in SEQ ID NO: 104. Amino acids 2 to 14 of SEQ ID NO: 104 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 15. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vc71_l protein. The EcoRI/Notl restriction fragment obtainable from the deposit containing clone vc71_J should be approximately 760 bp.

The nucleotide sequence disclosed herein for vc71_l was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vc71_l demonstrated at least some similarity with sequences identified as AI393859 (tg65f04.xl Soares_NhHMPu_S 1 Homo sapiens cDNA clone IMAGE 2113663 3', mRNA sequence) and AL050018 (Homo sapiens mRNA; cDNA DKFZp564B 116 (from clone DKFZp564B 116)). Based upon sequence similarity, vc71_1 proteins and each similar protein or peptide may share at least some activity.

Clone "vo27 1"

A polynucleotide of the present invention has been identified as clone "vo27_l ". vo27_l was isolated from a human adult pancreas cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence ofthe encoded protein. vo27_l is a full-length clone, including the entire coding sequence of a secreted protein (also refened to herein as "vo27_J protein").

The nucleotide sequence of vo27_l as presently determined is reported in SEQ ID NO: 105, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence ofthe vo27_l protein conesponding to the foregoing nucleotide sequence is reported in SEQ ID NO: 106. Amino acids 13 to 25 of SEQ ID NO: 106 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 26. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vo27_l protein.

Another potential reading frame, encoded by nucleotides 1665 to 1844 of SEQ ID NO.J05, is reported as the amino acid sequence of SEQ ID NO: 192. Amino acids 4 to 16 of SEQ ID NO: 192 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 17; amino acids 28 to 40 of SEQ ID NO: 192 are also a possible leader/signal sequence, with the predicted mature amino acid sequence beginning in that case at amino acid 41. Due to the hydrophobic nature of these predicted leader/signal sequences, each is likely to act as a transmembrane domain should it not be separated from the remainder of the protein of SEQ ID NO: 192.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone vo27_l should be approximately 2433 bp.

The nucleotide sequence disclosed herein for vo27_l was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vo27_l demonstrated at least some similarity with sequences identified as AC007621 (Homo sapiens clone RPCI11-757G14, WORKING DRAFT SEQUENCE, 142 unordered pieces), AI207832 (ao89gl 1.xl Schiller meningioma Homo sapiens cDNA clone IMAGE 1953092 3' similar to contains Alu repetitive element; mRNA sequence), and X80059 (Human PRO361 nucleotide sequence). Based upon sequence similarity, vo27_l proteins and each similar protein or peptide may share at least some activity. The TopPredll computer program predicts a potential transmembrane domain within the vo27_l protein sequence centered around amino acid 400 of SEQ ID NO: 106. The nucleotide sequence of vo27_l indicates that it may contain an Alu repetitive element.

Clone "vo31 1"

A polynucleotide of the present invention has been identified as clone "vo31_l". vo31_l was isolated from a human adult pancreas cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vo31_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vo31_1 protein"). The nucleotide sequence of vo31_1 as presently determined is reported in SEQ ID NOJ07, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence ofthe vo31_1 protein conesponding to the foregoing nucleotide sequence is reported in SEQ ID NO: 108. Amino acids 7 to 19 of SEQ ID NO: 108 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 20. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vo31_l protein. Another potential reading frame, encoded by nucleotides 1937 to 3007 of SEQ ID

NO: 107, is reported as the amino acid sequence of SEQ ID NO: 193.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone vo31_l should be approximately 3222 bp.

The nucleotide sequence disclosed herein for vo31_l was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vo31_l demonstrated at least some similarity with sequences identified as AF022147 (Rattus norvegicus uterus-ovary specific putative transmembrane protein (uo) mRNA, complete eds), AI417638 (tg80e01.xl Soares_NhHMPu_S 1 Homo sapiens cDNA clone IMAGE 2115096 3' similar to TR O35360 O35360 UTERUS- OVARY SPECIFIC PUTATIVE TRANSMEMBRANE PROTEIN; mRNA sequence), andX52248 (Protein PRO257 cDNA clone DNA35841-1173). The predicted amino acid sequence disclosed herein for vo31_ l was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vo31_1 protein demonstrated at least some similarity to sequences identified as AF02214 (uterus-ovary specific putative transmembrane protein [Rattus norvegicus]) and Y13377 (Amino acid sequence of protein PRO257). Based upon sequence similarity, vo31_l proteins and each similar protein or peptide may share at least some activity. The TopPredll computer program predicts a potential transmembrane domain within the protein sequence of SEQ ID NO: 193, centered around amino acid 328 of SEQ ID NO: 193. Hidden markov model analysis indicates the presence of Zona-pellucida-like domains at amino acids 26-115 and 146-273 of SEQ ID NO: 193. The nucleotide sequence of vo31_1 indicates that it may contain a Mer5a repetitive element. Clone "vo32 1"

A polynucleotide of the present invention has been identified as clone "vo32_l". vo32_l was isolated from a human adult pancreas cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vo32_l is a full-length clone, including the entire coding sequence of a secreted protein (also refened to herein as "vo32_l protein").

The nucleotide sequence of vo32_l as presently determined is reported in SEQ ID

NO: 109, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence ofthe vo32_l protein conesponding to the foregoing nucleotide sequence is reported in SEQ ID NO: 110. Amino acids 4 to 16 of SEQ ID NO: 110 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 17. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vo32_l protein.

The EcoRI Notl restriction fragment obtainable from the deposit containing clone vo32_l should be approximately 1868 bp.

The nucleotide sequence disclosed herein for vo32_l was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vo32_l demonstrated at least some similarity with sequences identified as AF028740 (Mus musculus olfactomedin mRNA, complete eds), AI078144 (oz30b06.xl Soares_total_fetus_Nb2HF8_9w Homo sapiens cDNA clone IMAGE 16768193' similar to TR Q99784 Q99784 NEURONAL OLFACTOMEDIN-RELATED ER LOCALIZED PROTEIN; mRNA sequence), AI869993 (wl63e09.xl NCI_CGAP Brn25 Homo sapiens cDNA clone IMAGE:2429608 3' similar to SW:NOMR_HUMAN

Q99784 NEURONAL OLFACTOMEDIN-RELATED ER LOCALIZED PROTEIN; mRNA sequence), and V34217 (Human secreted protein gene 64 clone HSLDJ95). The predicted amino acid sequence disclosed herein for vo32_l was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vo32_ 1 protein demonstrated at least some similarity to sequences identified as U03416 (neuronal olfactomedin-related ER localized protein [Rattus norvegicus]) and W75120 (Human secreted protein encoded by gene 64 clone HSLDJ95). Based upon sequence similarity, vo32_l proteins and each similar protein or peptide may share at least some activity.

Clone "vo33 1" A polynucleotide of the present invention has been identified as clone "vo33_l ". vo33_l was isolated from a human adult pancreas cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vo33_l is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vo33_l protein"). The nucleotide sequence of vo33_ 1 as presently determined is reported in SEQ ID

NO: 111, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence ofthe vo33_l protein conesponding to the foregoing nucleotide sequence is reported in SEQ ID NO: 112. Amino acids 5 to 17 of SEQ ID NO: 112 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 18. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vo33_l protein.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone vo33_l should be approximately 2879 bp.

The nucleotide sequence disclosed herein for vo33_l was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vo33_l demonstrated at least some similarity with sequences identified as AI225613 (ujl3e01.yl Sugano mouse kidney mkia Mus musculus cDNA clone IMAGE: 1907928 5' similar to TR:Q14624 Q14624 INTER-ALPHA-TRYPSIN INHIBITOR FAMILY HEAVY CHAIN-RELATED PROTEIN; mRNA sequence) and X80054 (Human PRO354 nucleotide sequence). The predicted amino acid sequence disclosed herein for vo33_l was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vo33_l protein demonstrated at least some similarity to sequences identified as D38535 (PK- 120 precursor

[Homo sapiens]), Y 11545 (inter-alpha-inhibitor heavy-chain H2 [Sus scrofa]), and the H2 proteins of several species, including Homo sapiens. Based upon sequence similarity, vo33_l proteins and each similar protein or peptide may share at least some activity. The TopPredll computer program predicts a potential transmembrane domain within the vo33_l protein sequence centered around amino acid 386 of SEQ ID NO: 112. The nucleotide sequence of vo33_l indicates that it may contain an Alu repetitive element.

Clone "vq23 1"

A polynucleotide of the present invention has been identified as clone "vq23_l". vq23_l was isolated from a human adult lung cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vq23_l is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vq23_l protein").

The nucleotide sequence of vq23_l as presently determined is reported in SEQ ID NO: 113, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence ofthe vq23_l protein conesponding to the foregoing nucleotide sequence is reported in SEQ ID NO: 114. Amino acids 18 to 30 of SEQ ID NOJ 14 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 31. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vq23_l protein.

Another potential reading frame, encoded by nucleotides 1012 to 1518 of SEQ ID NO: 113, is reported as the amino acid sequence of SEQ ID NO: 194. Amino acids 83 to 94 of SEQ ID NO: 194 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 95. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of protein of SEQ ID NO: 194.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone vq23_l should be approximately 1793 bp. The nucleotide sequence disclosed herein for vq23_l was searched against the

GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vq23_l demonstrated at least some similarity with sequences identified as AA625521 (af72f02.rl Soares_NhHMPu_S 1 Homo sapiens cDNA clone IMAGE 1047579 5', mRNA sequence) and AC002364 (Homo sapiens Xp22 Cosmids U15E4, U115H5, U132E12, U115B9 (Lawrence Livermore human cosmid library) complete sequence). Based upon sequence similarity, vq23_l proteins and each similar protein or peptide may share at least some activity. The nucleotide sequence of vq23_J indicates that it may contain an Alu repetitive element.

Clone "vq24 1"

A polynucleotide of the present invention has been identified as clone "vq24_l". vq24_J was isolated from a human adult lung cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vq24_l is a full-length clone, including the entire coding sequence of a secreted protein (also refened to herein as "vq24_l protein").

The nucleotide sequence of vq24_l as presently determined is reported in SEQ ID NO: 115, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence ofthe vq24_l protein conesponding to the foregoing nucleotide sequence is reported in SEQ ID NO: 116. Amino acids 5 to 17 of SEQ ID NO: 116 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 18. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vq24_l protein.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone vq24_l should be approximately 2168 bp. The nucleotide sequence disclosed herein for vq24_l was searched against the

GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vq24_l demonstrated at least some similarity with sequences identified as N29315 (yx43d06.rl Soares melanocyte 2NbHM Homo sapiens cDNA clone IMAGE:264491 5' similar to SP:SW:FCG1_HUMAN P12315 HIGH AFFINITY IMMUNOGLOBULIN GAMMA FC RECEPTOR I 'B FORM' PRECURSOR; mRNA sequence). The predicted amino acid sequence disclosed herein for vq24_l was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vq24_J protein demonstrated at least some similarity to sequences identified as AF14317 (high affinity immunoglobulin gamma Fc receptor I [Mus musculus]) and R12428 (Hybrid Fc(gamma)RII/I receptor). Based upon sequence similarity, vq24_l proteins and each similar protein or peptide may share at least some activity. Hidden markov model analysis detects immunoglobulin superfamily signatures in the vq24_l protein sequence from amino acid 92 to amino acid 145, and from amino acid 185 to amino acid 242, of SEQ ID NO: 116. The nucleotide sequence of vq24_l indicates that it may contain one or more of the following repetitive elements: Mer, MLTla.

Clone "vq26 1"

A polynucleotide of the present invention has been identified as clone "vq26_J". vq26_l was isolated from a human adult lung cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence ofthe encoded protein. vq26_l is a full-length clone, including the entire coding sequence of a secreted protein (also refened to herein as "vq26_l protein").

The nucleotide sequence of vq26_l as presently determined is reported in SEQ ID

NO: 117, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence ofthe vq26_l protein conesponding to the foregoing nucleotide sequence is reported in SEQ ID NO : 118. Amino acids 9 to 21 of SEQ ID NOJ 18 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 22. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vq26_l protein.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone vq26_l should be approximately 1419 bp.

The nucleotide sequence disclosed herein for vq26_J was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vq26_l demonstrated at least some similarity with sequences identified as AA191552 (zp82g04.s 1 Stratagene HeLa cell s3937216 Homo sapiens cDNA clone IMAGE 6267423', mRNA sequence) and AA573741 (nk07a05.s 1 NCI_CGAP_Co2 Homo sapiens cDNA clone IMAGE: 10127843', mRNA sequence). Based upon sequence similarity, vq26_l proteins and each similar protein or peptide may share at least some activity.

Deposit of Clones

Clones vc62_l,vpl0_l, vpl I_l,vpl3_l, vpl6_l,vp21_l,vp22_l, vq2_l, vq3_l, vq5_l, vq6_l, and vrl_l were deposited on February 17, 1999 with the ATCC (American Type Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and were given the accession number ATCC 207114, from which each clone comprising a particular polynucleotide is obtainable.

Clone vc63_l was deposited on February 17, 1999 with the ATCC (American Type

Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and was given the accession number ATCC 207115, from which the vc63_l clone comprising a particular polynucleotide is obtainable.

Clones vb25_l , vb27_l , vb28_l , vb29_l , vb30_l , vc67_l , vf4_l , vg3_l , vo2_l , vo3_l, vo5_l, vo6_l, and vo9_l were deposited on July 15, 1999 with the ATCC (American Type Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and were given the accession number PTA-362, from which each clone comprising a particular polynucleotide is obtainable.

Clones vol l_l, vol2_l, vol3_l, vol4_l, vol5_l, vol6_l, vol8_l, vol9_l, vo22_l, vo23_l, vo24_l, vo25_l, and vo26_l were deposited on July 15, 1999 with the ATCC (American Type Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and were given the accession number PTA-366, from which each clone comprising a particular polynucleotide is obtainable.

Clones Vp23_l, vq7_l, vq8_l, vq9_l, vql0_l, vql3_l,vql6_l, vql9_l, vq20_l, vq21_l, and vr2_l were deposited on July 15, 1999 with the ATCC (American Type

Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and were given the accession number PTA-368, from which each clone comprising a particular polynucleotide is obtainable.

Clones vc69_l, vc71_l, vo27_l, vo31_l, vo32_l, vo33_l, vq23_l, vq24_l, and vq26_l were deposited on December 21, 1999 with the ATCC (American Type Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and were given the accession number PTA-1075, from which each clone comprising a particular polynucleotide is obtainable. All restrictions on the availability to the public of the deposited material will be inevocably removed upon the granting ofthe patent, except for the requirements specified in 37 C.F.R. § 1.808(b), and the term of the deposit will comply with 37 C.F.R. § 1.806.

Each clone has been transfected into separate bacterial cells (E. coli) in these composite deposits. Each clone can be removed from the vector in which it was deposited by performing an EcoRI/Notl digestion (5' site, EcoRI; 3' site, Notl) to produce the appropriate fragment for such clone. Each clone was deposited in either the pED6 or pNOTs vector depicted in Figures IA and IB, respectively. The pED6dpc2 vector ("pED6") was derived from pEDόdpcl by insertion of a new polylinker to facilitate cDNA cloning (Kaufman et al., 1991, Nucleic Acids Res. 19: 4485-4490); the pNOTs vector was derived from pMT2 (Kaufman et al., 1989, Mol. Cell. Biol. 9: 946-958) by deletion of the DHFR sequences, insertion of a new polylinker, and insertion of the M13 origin of replication in the Clal site. In some instances, the deposited clone can become "flipped" (i.e., in the reverse orientation) in the deposited isolate. In such instances, the cDNA insert can still be isolated by digestion with EcoRI and Notl. However, Notl will then produce the 5' site and EcoRI will produce the 3' site for placement of the cDNA in proper orientation for expression in a suitable vector. The cDNA may also be expressed from the vectors in which they were deposited.

Bacterial cells containing a particular clone can be obtained from the composite deposit as follows:

An oligonucleotide probe or probes should be designed to the sequence that is known for that particular clone. This sequence can be derived from the sequences provided herein, or from a combination of those sequences. The sequence of an oligonucleotide probe that was used to isolate or to sequence each full-length clone is identified below, and should be most reliable in isolating the clone of interest. Clone Probe Sequence vc62_J SEQ ID NOJ 19 vplO_J SEQ ID NO: 120 vpl l_l SEQ ID NO: 121 vpl3_l SEQ ID NO: 122 vpl6_l SEQ ID NO: 123 vp21_l SEQ ID NO: 124 vp22_l SEQ ID NO: 125 vq2_l SEQ ID NO: 126 vq3_l SEQ ID NO: 127 vq5_l SEQ ID NO: 128 vq6_l SEQ ID NO: 129 vrl_l SEQ ID NO: 130 vc63_l SEQ ID NO: 131 vb25_l SEQ ID NO: 132 vb27_l SEQ ID NO: 133 vb28_l SEQ ID NO: 134 vb29_l SEQ ID NO: 135 vb30_l SEQ ID NO: 136 vc67_l SEQ ID NO: 137 vf4_l SEQ ID NO: 138 vg3_l SEQ ID NO: 139 vo2_l SEQ ID NO: 140 vo3_l SEQ ID NO: 141 vo5_l SEQ ID NO: 142 vo6_l SEQ ID NO: 143 vo9_l SEQ ID NO: 144 vol l_l SEQ ID NO: 145 vol2_J SEQ ID NO: 146 vol3_l SEQ ID NO: 147 vol4_l SEQ ID NO: 148 vol5_l SEQ ID NO: 149 vol6_l SEQ ID NO: 150 vol8_l SEQ ID NO: 151 vol9_l SEQ ID NO: 152 vo22_l SEQ ID NO: 153 vo23_l SEQ ID NO: 154 vo24_l SEQ ID NO: 155 vo25_l SEQ ID NO: 156 vo26_l SEQ ID NO: 157 vp23_l SEQ ID NO: 158 vq7_l SEQ ID NO: 159 vq8_l SEQ ID NO: 160 vq9_l SEQ ID NO: 161 vql0_l SEQ ID NO: 162 vql3_l SEQ ID NO: 163 vql6_l SEQ ID NO: 164 vql9_l SEQ ID NO: 165 vq20_l SEQ ID NO: 166 vq21_l SEQ ID NO: 167 vr2_l SEQ ID NO: 168

In the sequences listed above which include an N at position 2, that position is occupied in preferred probes/primers by a biotinylated phosphoaramidite residue rather than a nucleotide (such as, for example, that produced by use of biotin phosphoramidite (1- dimethoxytrityloxy-2-(N-biotinyl-4-aminobutyl)-propyl-3-O-(2-cyanoethyl)-(N,N- diisopropyl)-phosphoramadite) (Glen Research, cat. no. 10-1953)).

The design ofthe oligonucleotide probe should preferably follow these parameters:

(a) It should be designed to an area of the sequence which has the fewest ambiguous bases ("N's"), if any;

(b) It should be designed to have a T_m of approx. 80 ^° C (assuming 2° for each A or T and 4 degrees for each G or C).

The oligonucleotide should preferably be labeled with γ-³²P ATP (specific activity 6000 Ci/mmole) and T4 polynucleotide kinase using commonly employed techniques for labeling oligonucleotides. Other labeling techniques can also be used. Unincorporated label should preferably be removed by gel filtration chromatography or other established methods. The amount of radioactivity incorporated into the probe should be quantitated by measurement in a scintillation counter. Preferably, specific activity of the resulting probe should be approximately 4e+6 dpm/pmole.

The bacterial culture containing the pool of full-length clones should preferably be thawed and 100 μl of the stock used to inoculate a sterile culture flask containing 25 ml of sterile L-broth containing ampicillin at 100 μg/ml. The culture should preferably be grown to saturation at 37^°C, and the saturated culture should preferably be diluted in fresh L-broth. Aliquots of these dilutions should preferably be plated to determine the dilution and volume which will yield approximately 5000 distinct and well-separated colonies on solid bacteriological media containing L-broth containing ampicillin at 100 μg/ml and agar at 1.5% in a 150 mm petri dish when grown overnight at 37°C. Other known methods of obtaining distinct, well-separated colonies can also be employed. Standard colony hybridization procedures should then be used to transfer the colonies to nitrocellulose filters and lyse, denature and bake them.

The filter is then preferably incubated at 65 ^°C for 1 hour with gentle agitation in 6X SSC (20X stock is 175.3 g NaCl/liter, 88.2 g Na citrate/liter, adjusted to pH 7.0 with NaOH) containing 0.5% SDS, 100 μg/ml of yeast RNA, and 10 mM EDTA (approximately 10 mL per 150 mm filter). Preferably, the probe is then added to the hybridization mix at a concentration greater than or equal to le+6 dpm/mL. The filter is then preferably incubated at 65 °C with gentle agitation overnight. The filter is then preferably washed in 500 mL of 2X SSC/0.5% SDS at room temperature without agitation, preferably followed by 500 mL of 2X SSC/0J% SDS at room temperature with gentle shaking for 15 minutes. A third wash with 0. IX SSC/0.5% SDS at 65^°C for 30 minutes to 1 hour is optional. The filter is then preferably dried and subjected to autoradiography for sufficient time to visualize the positives on the X-ray film. Other known hybridization methods can also be employed.

The positive colonies are picked, grown in culture, and plasmid DNA isolated using standard procedures. The clones can then be verified by restriction analysis, hybridization analysis, or DNA sequencing. Fragments ofthe proteins ofthe present invention which are capable of exhibiting biological activity are also encompassed by the present invention. Fragments of the protein may be in linear form or they may be cyclized using known methods, for example, as described in H.U. Saragovi, et al, Bio/Technology 10, 773-778 (1992) and in R.S. McDowell, et al., J. Amer. Chem. Soc. U4, 9245-9253 (1992), both of which are incorporated herein by reference. Such fragments may be fused to carrier molecules such as immunoglobulins for many purposes, including increasing the valency of protein binding sites. For example, fragments of the protein may be fused through "linker" sequences to the Fc portion of an immunoglobulin. For a bivalent form of the protein, such a fusion could be to the Fc portion of an IgG molecule. Other immunoglobulin isotypes may also be used to generate such fusions. For example, a protein - IgM fusion would generate a decavalent form of the protein of the invention.

The present invention also provides both full-length and mature forms of the disclosed proteins. The full-length form of the such proteins is identified in the sequence listing by translation of the nucleotide sequence of each disclosed clone. The mature form(s) of such protein may be obtained by expression of the disclosed full-length polynucleotide (preferably those deposited with the ATCC) in a suitable mammalian cell or other host cell. The sequence(s) of the mature form(s) of the protein may also be determinable from the amino acid sequence of the full-length form. The present invention also provides genes conesponding to the polynucleotide sequences disclosed herein. "Conesponding genes" are the regions ofthe genome that are transcribed to produce the mRNAs from which cDNA polynucleotide sequences are derived and may include contiguous regions of the genome necessary for the regulated expression of such genes. Conesponding genes may therefore include but are not limited to coding sequences, 5' and 3' untranslated regions, alternatively spliced exons, introns, promoters, enhancers, and silencer or suppressor elements. The conesponding genes can be isolated in accordance with known methods using the sequence information disclosed herein. Such methods include the preparation of probes or primers from the disclosed sequence information for identification and/or amplification of genes in appropriate genomic libraries or other sources of genomic materials. An "isolated gene" is a gene that has been separated from the adjacent coding sequences, if any, present in the genome of the organism from which the gene was isolated. The chromosomal location conesponding to the polynucleotide sequences disclosed herein may also be determined, for example by hybridizing appropriately labeled polynucleotides of the present invention to chromosomes in situ. It may also be possible to determine the conesponding chromosomal location for a disclosed polynucleotide by identifying significantly similar nucleotide sequences in public databases, such as expressed sequence tags (ESTs), that have already been mapped to particular chromosomal locations. For at least some of the polynucleotide sequences disclosed herein, public database sequences having at least some similarity to the polynucleotide of the present invention have been listed by database accession number. Searches using the GenBank accession numbers of these public database sequences can then be performed at an Internet site provided by the National Center for Biotechnology Information having the address http://www.ncbi.nlm.nih.gov/UniGene/, in order to identify "UniGene clusters" of overlapping sequences. Many of the "UniGene clusters" so identified will already have been mapped to particular chromosomal sites. Organisms that have enhanced, reduced, or modified expression of the gene(s) corresponding to the polynucleotide sequences disclosed herein are provided. The desired change in gene expression can be achieved through the use of antisense polynucleotides or ribozymes that bind and or cleave the mRNA transcribed from the gene (Albert and Monis, 1994, Trends Pharmacol. Sci. 15(7): 250-254; Lavarosky et al, 1997, Biochem. Mol. Med. 62(1): 11-22; and Hampel, 1998, Prog. Nucleic Acid Res. Mol. Biol. 58: 1-39; all of which are incorporated by reference herein). The desired change in gene expression can also be achieved through the use of double-stranded ribonucleotide molecules having some complementarity to the mRNA transcribed from the gene, and which interfere with the transcription, stability, or expression ofthe mRNA ("RNA intereference" or "RNAi"; Fire etα/., 1998, Nature 391 (6669): 806-811; Montgomery etal, 1998, Proc. Natl. Acad. Sci. USA 95 (26): 15502-15507; and Sharp, 1999, Genes Dev. 13 (2): 139-141; all of which are incorporated by reference herein). Transgenic animals that have multiple copies ofthe gene(s) conesponding to the polynucleotide sequences disclosed herein, preferably produced by transformation of cells with genetic constructs that are stably maintained within the transformed cells and their progeny, are provided. Transgenic animals that have modified genetic control regions that increase or reduce gene expression levels, or that change temporal or spatial patterns of gene expression, are also provided (see European Patent No. 0 649 464 Bl, incoφorated by reference herein). In addition, organisms are provided in which the gene(s) conesponding to the polynucleotide sequences disclosed herein have been partially or completely inactivated, through insertion of extraneous sequences into the conesponding gene(s) or through deletion of all or part of the corresponding gene(s). Partial or complete gene inactivation can be accomplished through insertion, preferably followed by imprecise excision, of transposable elements (Plasterk, 1992, Bioessays 14(9): 629-633; Zwaal et al, 1993, Proc. Natl. Acad. Sci. USA 90(16): 7431 -7435 ; Clark et al , 1994, Proc. Natl. Acad. Sci. USA 91(2): 719-722; all of which are incorporated by reference herein), or through homologous recombination, preferably detected by positive/negative genetic selection strategies (Mansour et al, 1988, Nature 336: 348-352; U.S. Patent Nos. 5,464,764; 5,487,992; 5,627,059; 5,631,153; 5,614, 396; 5,616,491; and 5,679,523; all of which are incorporated by reference herein). These organisms with altered gene expression are preferably eukaryotes and more preferably are mammals. Such organisms are useful for the development of non-human models for the study of disorders involving the conesponding gene(s), and for the development of assay systems for the identification of molecules that interact with the protein product(s) ofthe conesponding gene(s).

Where the protein ofthe present invention is membrane-bound (e.g., is areceptor), the present invention also provides for soluble forms of such protein. In such forms, part or all of the intracellular and transmembrane domains of the protein are deleted such that the protein is fully secreted from the cell in which it is expressed. The intracellular and transmembrane domains of proteins ofthe invention can be identified in accordance with known techniques for determination of such domains from sequence information. For example, the TopPredll computer program can be used to predict the location of transmembrane domains in an amino acid sequence, domains which are described by the location ofthe center ofthe transmsmbrane domain, with at least ten transmembrane amino acids on each side of the reported central residue(s).

Proteins and protein fragments ofthe present invention include proteins with amino acid sequence lengths that are at least 25%(more preferably at least 50%, and most preferably at least 75%) of the length of a disclosed protein and have at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% or 95% identity) with that disclosed protein, where sequence identity is determined by comparing the amino acid sequences ofthe proteins when aligned so as to maximize overlap and identity while minimizing sequence gaps. Also included in the present invention are proteins and protein fragments that contain a segment preferably comprising 8 or more (more preferably 20 or more, most preferably 30 or more) contiguous amino acids that shares at least 75% sequence identity (more preferably, at least 85% identity; most preferably at least 95% identity) with any such segment of any of the disclosed proteins.

In particular, sequence identity may be determined using WU-BLAST (Washington University BLAST) version 2.0 software, which builds upon WU-BLAST version 1.4, which in turn is based on the public domain NCB I-B LAST version 1.4 (Altschul and Gish, 1996, Local alignment statistics, Doolittle ed., Methods in Enzymology 266: 460-480; Altschul etal, 1990, Basic local alignment search tool, Journal of Molecular Biology 215: 403-410; Gish and States, 1993, Identification of protein coding regions by database similarity search, Nature Genetics3: 266-272; Karlin and Altschul, 1993, Applications and statistics for multiple high-scoring segments in molecular sequences, Proc. Natl. Acad. Sci. USA 90: 5873-5877; all of which are incorporated by reference herein). WU-BLAST version 2.0 executable programs for several UNIX platforms can be downloaded from ftp://blast.wustl.edu/blast/executables. The complete suite of search programs (BLASTP, BLASTN, BLASTX, TBLASTN, and TBLASTX) is provided at that site, in addition to several support programs. WU-BLAST 2.0 is copyrighted and may not be sold or redistributed in any form or manner without the express written consent of the author; but the posted executables may otherwise be freely used for commercial, nonprofit, or academic purposes. In all search programs in the suite — BLASTP, BLASTN, BLASTX, TBLASTN and TBLASTX — the gapped alignment routines are integral to the database search itself, and thus yield much better sensitivity and selectivity while producing the more easily interpreted output. Gapping can optionally be turned off in all of these programs, if desired. The default penalty (Q) for a gap of length one is Q=9 for proteins and BLASTP, and Q=10 for BLASTN, but may be changed to any integer value including zero, one through eight, nine, ten, eleven, twelve through twenty, twenty-one through fifty, fifty-one through one hundred, etc. The default per-residue penalty for extending a gap (R) is R=2 for proteins and BLASTP, and R= 10 for BLASTN, but may be changed to any integer value including zero, one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve through twenty, twenty-one through fifty, fifty-one through one hundred, etc. Any combination of values for Q and R can be used in order to align sequences so as to maximize overlap and identity while minimizing sequence gaps. The default amino acid comparison matrix is BLOSUM62, but other amino acid comparison matrices such as PAM can be utilized. Species homologues of the disclosed polynucleotides and proteins are also provided by the present invention. As used herein, a "species homologue" is a protein or polynucleotide with a different species of origin from that of a given protein or polynucleotide, but with significant sequence similarity to the given protein or polynucleotide. Preferably, polynucleotide species homologues have at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% identity) with the given polynucleotide, and protein species homologues have at least 30% sequence identity (more preferably, at least 45% identity; most preferably at least 60% identity) with the given protein, where sequence identity is determined by comparing the nucleotide sequences of the polynucleotides or the amino acid sequences of the proteins when aligned so as to maximize overlap and identity while minimizing sequence gaps. Species homologues may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source from the desired species. Preferably, species homologues are those isolated from mammalian species. Most preferably, species homologues are those isolated from certain mammalian species such as, for example, Pan troglodytes, Gorilla gorilla, Pongo pygmaeus, Hylobates concolor, Macaca mulatta, Papio papio, Papio hamadryas, Cercopithecus aethiops, Cebus capucinus, Aotus trivirgatus, Sanguinus oedipus, Microcebus murinus, Mus musculus, Rattus norvegicus, Cricetulus griseus, Felis catus, Mustela vison, Canisfamiliaris, Oryctolagus cuniculus, Bos taurus, Ovis aries, Sus scrofa, and Equus caballus, for which genetic maps have been created allowing the identification of syntenic relationships between the genomic organization of genes in one species and the genomic organization ofthe related genes in another species (O'Brien and Seuanez, 1988, Ann. Rev. Genet. 22: 323-351; O'Brien et al, 1993, Nature Genetics 3: 103-112; Johansson et al, 1995, Genomics 25: 682-690; Lyons et al., 1997, Nature Genetics 15: 47-56; O'Brien et al, 1997, Trends in Genetics 13(10): 393-399; Carver and Stubbs, 1997, Genome Research 7: 1123- 1137; all of which are incorporated by reference herein). The invention also encompasses allelic variants of the disclosed polynucleotides or proteins; that is, naturally-occuning alternative forms of the isolated polynucleotides which also encode proteins which are identical or have significantly similar sequences to those encoded by the disclosed polynucleotides. Preferably, allelic variants have at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% identity) with the given polynucleotide, where sequence identity is determined by comparing the nucleotide sequences of the polynucleotides when aligned so as to maximize overlap and identity while minimizing sequence gaps. Allelic variants may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source from individuals of the appropriate species.

The invention also includes polynucleotides with sequences complementary to those of the polynucleotides disclosed herein.

The present invention also includes polynucleotides that hybridize under reduced stringency conditions, more preferably stringent conditions, and most preferably highly stringent conditions, to polynucleotides described herein. Examples of stringency conditions are shown in the table below: highly stringent conditions are those that are at least as stringent as, for example, conditions A-F; stringent conditions are at least as stringent as, for example, conditions G-L; and reduced stringency conditions are at least as stringent as, for example, conditions M-R.

* The hybπd length is that anticipated for the hybndized regιon(s) of the hybndizing polynucleotides When hybπdizing a polynucleotide to a target polynucleotide of unknown sequence, the hybπd length is assumed to be that of the hybndizing polynucleotide When polynucleotides of known sequence are hybndized, the hybnd length can be determined by aligning the sequences ofthe polynucleotides and identifying the region or regions of optimal sequence complementanty

* SSPE (lxSSPE is 0 15M NaCl, lOmM NaH₂P0₄, and 1 25mM EDTA, pH 7 4) can be substituted for SSC (lxSSC is 0 15M NaCl and 15mM sodium citrate) in the hybπdization and wash buffers, washes are performed for 15 minutes after hybndization is complete

*T_B - T_R The hybπdization temperature for hybnds anticipated to be less than 50 base pairs in length should be 5-10°C less than the melting temperature (T_m) of the hybrid, where T_m is determined according to the following equations For hybnds less than 18 base pairs in length, T .°C) = 2(# of A + T bases) + 4(# of G + C bases) For hybnds between 18 and 49 base pairs in length, T_m(°C) = 81 5 + 16 6(log₁₀[Na⁺]) + 041(%G+C) - (600/N), where N is the number of bases in the hybπd, and [Na⁺] is the concentration of sodium ions in the hybndization buffer ([Na⁺] for lxSSC = 0 165 M) Additional examples of stringency conditions for polynucleotide hybridization are provided in Sambrook, J., E.F. Fritsch, and T. Maniatis, 1989, Molecular Cloning: A

Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, chapters 9 and 11, and Current Protocols in Molecular Biology , 1995, F.M. Ausubel et al., eds., John Wiley & Sons, Inc., sections 2.10 and 6.3-6.4, incorporated herein by reference.

Preferably, each such hybridizing polynucleotide has a length that is at least 25%(more preferably at least 50%, and most preferably at least 75%) of the length of the polynucleotide of the present invention to which it hybridizes, and has at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% or 95% identity) with the polynucleotide of the present invention to which it hybridizes, where sequence identity is determined by comparing the sequences of the hybridizing polynucleotides when aligned so as to maximize overlap and identity while minimizing sequence gaps.

The isolated polynucleotide endcoing the protein ofthe invention may be operably linked to an expression control sequence such as the pMT2 or pED expression vectors disclosed in Kaufman etal, Nucleic Acids Res. 19, 4485-4490 (1991), in order to produce the protein recombinantly. Many suitable expression control sequences are known in the art. General methods of expressing recombinant proteins are also known and are exemplified in R. Kaufman, Methods in Enzymology 185. 537-566 (1990). As defined herein "operably linked" means that the isolated polynucleotide of the invention and an expression control sequence are situated within a vector or cell in such a way that the protein is expressed by a host cell which has been transformed (transfected) with the ligated polynucleotide/expression control sequence.

A number of types of cells may act as suitable host cells for expression of the protein. Mammalian host cells include, for example, monkey COS cells, Chinese Hamster Ovary (CHO) cells, human kidney 293 cells, human epidermal A431 cells, human Colo205 cells, 3T3 cells, CV-1 cells, other transformed primate cell lines, normal diploid cells, cell strains derived from in vitro culture of primary tissue, primary explants, HeLa cells, mouse L cells, BHK, HL-60, U937, HaK or Jurkat cells.

Alternatively, it may be possible to produce the protein in lower eukaryotes such as yeast or in prokaryotes such as bacteria. Potentially suitable yeast strains include

Saccharomyces cerevisiae, Schizosaccharomyces pombe, Kluyveromyces strains, Candida, or any yeast strain capable of expressing heterologous proteins. Potentially suitable bacterial strains include Escherichia coli, Bacillus subtilis, Salmonella typhimurium, or any bacterial strain capable of expressing heterologous proteins. If the protein is made in yeast or bacteria, it may be necessary to modify the protein produced therein, for example by phosphorylation or glycosylation of the appropriate sites, in order to obtain the functional protein. Such covalent attachments may be accomplished using known chemical or enzymatic methods.

The protein may also be produced by operably linking the isolated polynucleotide ofthe invention to suitable control sequences in one or more insect expression vectors, and employing an insect expression system. Materials and methods for baculovirus/insect cell expression systems are commercially available in kit form from, e.g., Invitrogen, San Diego, California, U.S.A. (the MaxBac® kit), and such methods are well known in the art, as described in Summers and Smith, Texas Agricultural Experiment Station Bulletin No. 1555 (1987), incorporated herein by reference. As used herein, an insect cell capable of expressing a polynucleotide of the present invention is "transformed." The protein of the invention may be prepared by culturing transformed host cells under culture conditions suitable to express the recombinant protein. The resulting expressed protein may then be purified from such culture (i.e., from culture medium or cell extracts) using known purification processes, such as gel filtration and ion exchange chromatography. The purification of the protein may also include an affinity column containing agents which will bind to the protein; one or more column steps over such affinity resins as concanavalin A-agarose, heparin-toyopearl® or Cibacrom blue 3GA Sepharose®; one or more steps involving hydrophobic interaction chromatography using such resins as phenyl ether, butyl ether, or propyl ether; or immunoaffmity chromatography. Alternatively, the protein of the invention may also be expressed in a form which will facilitate purification. For example, it may be expressed as a fusion protein, such as those of maltose binding protein (MBP), glutathione-S -transferase (GST) or thioredoxin (TRX). Kits for expression and purification of such fusion proteins are commercially available from New England BioLabs (Beverly, MA), Pharmacia (Piscataway, NJ) and Invitrogen Corporation (Carlsbad, CA), respectively. The protein can also be tagged with an epitope and subsequently purified by using a specific antibody directed to such epitope. One such epitope ("Flag") is commercially available from the Eastman Kodak Company (New Haven, CT).

Finally, one or more reverse-phase high performance liquid chromatography (RP- HPLC) steps employing hydrophobic RP-HPLC media, e.g., silica gel having pendant methyl or other aliphatic groups, can be employed to further purify the protein. Some or all of the foregoing purification steps, in various combinations, can also be employed to provide a substantially homogeneous isolated recombinant protein. The protein thus purified is substantially free of other mammalian proteins and is defined in accordance with the present invention as an "isolated protein." The protein of the invention may also be expressed as a product of transgenic animals, e.g., as a component ofthe milk of transgenic cows, goats, pigs, or sheep which are characterized by somatic or germ cells containing a nucleotide sequence encoding the protein.

The protein may also be produced by known conventional chemical synthesis. Methods for constructing the proteins of the present invention by synthetic means are known to those skilled in the art. The synthetically-constructed protein sequences, by virtue of sharing primary, secondary or tertiary structural and/or conformational characteristics with proteins may possess biological properties in common therewith, including protein activity. Thus, they may be employed as biologically active or immunological substitutes for natural, purified proteins in screening of therapeutic compounds and in immunological processes for the development of antibodies.

The proteins provided herein also include proteins characterized by amino acid sequences similar to those of purified proteins but into which modification are naturally provided or deliberately engineered. For example, modifications in the peptide or DNA sequences can be made by those skilled in the art using known techniques. Modifications of interest in the protein sequences may include the alteration, substitution, replacement, insertion or deletion of a selected amino acid residue in the coding sequence. For example, one or more of the cysteine residues may be deleted or replaced with another amino acid to alter the conformation of the molecule. Techniques for such alteration, substitution, replacement, insertion or deletion are well known to those skilled in the art (see, e.g., U.S.

Patent No.4,518,584). Preferably, such alteration, substitution, replacement, insertion or deletion retains the desired activity of the protein. Other fragments and derivatives of the sequences of proteins which would be expected to retain protein activity in whole or in part and may thus be useful for screening or other immunological methodologies may also be easily made by those skilled in the art given the disclosures herein. Such modifications are believed to be encompassed by the present invention.

USES AND BIOLOGICAL ACTIVITY

The polynucleotides and proteins of the present invention are expected to exhibit one or more of the uses or biological activities (including those associated with assays cited herein) identified below. Uses or activities described for proteins of the present invention may be provided by administration or use of such proteins or by administration or use of polynucleotides encoding such proteins (such as, for example, in gene therapies or vectors suitable for introduction of DNA).

Research Uses and Utilities

The polynucleotides provided by the present invention can be used by the research community for various purposes. The polynucleotides can be used to express recombinant protein for analysis, characterization or therapeutic use; as markers for tissues in which the conesponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in disease states); as molecular weight markers on Southern gels; as chromosome markers or tags (when labeled) to identify chromosomes or to map related gene positions; to compare with endogenous DNA sequences in patients to identify potential genetic disorders; as probes to hybridize and thus discover novel, related DNA sequences; as a source of information to derive PCR primers for genetic fingerprinting; as a probe to "subtract-out" known sequences in the process of discovering other novel polynucleotides; for selecting and making oligomers for attachment to a "gene chip" or other support, including for examination of expression patterns; to raise anti-protein antibodies using DNA immunization techniques; and as an antigen to raise anti-DNA antibodies or elicit another immune response. Where the polynucleotide encodes a protein which binds or potentially binds to another protein (such as, for example, in a receptor-ligand interaction), the polynucleotide can also be used in interaction trap assays (such as, for example, those described in Gyuris et al, 1993, Cell 75: 791-803 and in Rossi et al, 1997, Proc. Natl. Acad. Sci. USA 94: 8405-8410, all of which are incorporated by reference herein) to identify polynucleotides encoding the other protein with which binding occurs or to identify inhibitors of the binding interaction.

The proteins provided by the present invention can similarly be used in assay to determine biological activity, including in a panel of multiple proteins for high-throughput screening; to raise antibodies or to elicit another immune response; as a reagent (including the labeled reagent) in assays designed to quantitatively determine levels ofthe protein (or its receptor) in biological fluids; as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in a disease state); and, of course, to isolate conelative receptors or ligands. Where the protein binds or potentially binds to another protein (such as, for example, in a receptor-ligand interaction), the protein can be used to identify the other protein with which binding occurs or to identify inhibitors ofthe binding interaction. Proteins involved in these binding interactions can also be used to screen for peptide or small molecule inhibitors or agonists of the binding interaction.

Any or all of these research utilities are capable of being developed into reagent grade or kit format for commercialization as research products.

Methods for performing the uses listed above are well known to those skilled in the art. References disclosing such methods include without limitation "Molecular Cloning: A Laboratory Manual", 2d ed., Cold Spring Harbor Laboratory Press, Sambrook, J., E.F. Fritsch and T. Maniatis eds., 1989, and "Methods in Enzymology: Guide to Molecular Cloning Techniques", Academic Press, Berger, S.L. and A.R. Kimmel eds., 1987.

Nutritional Uses Polynucleotides and proteins ofthe present invention can also be used as nutritional sources or supplements. Such uses include without limitation use as a protein or amino acid supplement, use as a carbon source, use as a nitrogen source and use as a source of carbohydrate. In such cases the protein or polynucleotide of the invention can be added to the feed of a particular organism or can be administered as a separate solid or liquid preparation, such as in the form of powder, pills, solutions, suspensions or capsules. In the case of microorganisms, the protein or polynucleotide ofthe invention can be added to the medium in or on which the microorganism is cultured. Cytokine and Cell Proliferation/Differentiation Activity

A protein of the present invention may exhibit cytokine, cell proliferation (either inducing or inhibiting) or cell differentiation (either inducing or inhibiting) activity or may induce production of other cytokines in certain cell populations. Many protein factors discovered to date, including all known cytokines, have exhibited activity in one or more factor-dependent cell proliferation assays, and hence the assays serve as a convenient confirmation of cytokine activity. The activity of a protein of the present invention is evidenced by any one of a number of routine factor dependent cell proliferation assays for cell lines including, without limitation, 32D, DA2, DA1G, T10, B9, B9/11, BaF3, MC9/G, M+ (preB M+), 2E8, RB5, DAI, 123, T1165, HT2, CTLL2, TF-1, Mo7e and CMK.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Assays for T-cell or thymocyte proliferation include without limitation those described in: Cunent Protocols in Immunology, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley- Interscience (Chapter 3 , In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Takai et al., J. Immunol. 137:3494-3500, 1986; Bertagnolli et al., J. Immunol. 145:1706-1712, 1990; Bertagnolli et al., Cellular Immunology 133:327-341, 1991; Bertagnolli, et al., J. Immunol. 149:3778-3783, 1992; Bowman et al., J. Immunol. 152: 1756-1761, 1994.

Assays for cytokine production and/or proliferation of spleen cells, lymph node cells or thymocytes include, without limitation, those described in: Polyclonal T cell stimulation, Kruisbeek, A.M. and Shevach, E.M. In Current Protocols in Immunology. J.E.e.a. Coligan eds. Vol 1 pp. 3.12.1-3.12.14, John Wiley and Sons, Toronto. 1994; and Measurement of mouse and human Interferon γ, Schreiber, R.D. In Current Protocols in

Immunology. J.E.e.a. Coligan eds. Vol 1 pp. 6.8.1-6.8.8, John Wiley and Sons, Toronto. 1994.

Assays for proliferation and differentiation of hematopoietic and lymphopoietic cells include, without limitation, those described in: Measurement of Human and Murine Interleukin 2 and Interleukin 4, Bottomly, K., Davis, L.S. and Lipsky, P.E. In Current

Protocols in Immunology. J.E.e.a. Coligan eds. Vol 1 pp. 6.3.1-6.3.12, John Wiley and Sons, Toronto. 1991; deVries et al., J. Exp. Med. 173: 1205-1211, 1991; Moreau et al., Nature 336:690-692, 1988; Greenberger et al., Proc. Natl. Acad. Sci. U.S.A.80:2931-2938, 1983; Measurement of mouse and human interleukin 6 - Nordan, R. In Current Protocols in Immunology. J.E.e.a. Coligan eds. Vol 1 pp.6.6.1-6.6.5, John Wiley and Sons, Toronto. 1991; Smith et al, Proc. Natl. Acad. Sci. U.S.A. 83:1857-1861, 1986; Measurement of human Interleukin 11 - Bennett, F., Giannotti, J., Clark, S.C. and Turner, K. J. In Current Protocols in Immunology. J.E.e.a. Coligan eds. Vol 1 pp. 6.15.1 John Wiley and Sons, Toronto. 1991; Measurement of mouse and human Interleukin 9 - Ciarletta, A., Giannotti, J., Clark, S.C. and Turner, K.J. In Current Protocols in Immunology. J.E.e.a. Coligan eds. Vol 1 pp. 6.13.1, John Wiley and Sons, Toronto. 1991. Assays for T-cell clone responses to antigens (which will identify, among others, proteins that affect APC-T cell interactions as well as direct T-cell effects by measuring proliferation and cytokine production) include, without limitation, those described in: Cunent Protocols in Immunology, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function; Chapter 6, Cytokines and their cellular receptors; Chapter 7, Immunologic studies in Humans); Weinberger et al., Proc. Natl. Acad. Sci. USA 77:6091-6095, 1980; Weinberger et al., Eur. J. Immun. 11:405-411, 1981; Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988.

Immune Stimulating or Suppressing Activity

A protein of the present invention may also exhibit immune stimulating or immune suppressing activity, including without limitation the activities for which assays are described herein. A protein may be useful in the treatment of various immune deficiencies and disorders (including severe combined immunodeficiency (SCID)), e.g., in regulating

(up or down) growth and proliferation of T and/or B lymphocytes, as well as effecting the cytolytic activity of NK cells and other cell populations. These immune deficiencies may be genetic or be caused by viral (e.g., HIV) as well as bacterial or fungal infections, or may result from autoimmune disorders. More specifically, infectious diseases causes by viral, bacterial, fungal or other infection may be treatable using a protein of the present invention, including infections by HIV, hepatitis viruses, herpesviruses, mycobacteria, Leishmania spp., malaria spp. and various fungal infections such as candidiasis. Of course, in this regard, a protein of the present invention may also be useful where a boost to the immune system generally may be desirable, i.e., in the treatment of cancer.

Autoimmune disorders which may be treated using a protein of the present invention include, for example, connective tissue disease, multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain- Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes mellitis, myasthenia gravis, graft-versus-host disease and autoimmune inflammatory eye disease. Such a protein of the present invention may also to be useful in the treatment of allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems. Other conditions, in which immune suppression is desired (including, for example, organ transplantation), may also be treatable using a protein of the present invention.

Using the proteins of the invention it may also be possible to regulate immune responses in a number of ways. Down regulation may be in the form of inhibiting or blocking an immune response already in progress or may involve preventing the induction of an immune response. The functions of activated T cells may be inhibited by suppressing T cell responses or by inducing specific tolerance in T cells, or both. Immunosuppression of T cell responses is generally an active, non-antigen-specific, process which requires continuous exposure of the T cells to the suppressive agent. Tolerance, which involves inducing non-responsiveness or anergy in T cells, is distinguishable from immunosuppression in that it is generally antigen-specific and persists after exposure to the tolerizing agent has ceased. Operationally, tolerance can be demonstrated by the lack of a T cell response upon reexposure to specific antigen in the absence of the tolerizing agent.

Down regulating or preventing one or more antigen functions (including without limitation B lymphocyte antigen functions (such as , for example, B7)), e.g., preventing high level lymphokine synthesis by activated T cells, will be useful in situations of tissue, skin and organ transplantation and in graft-versus-host disease (GVHD). For example, blockage of T cell function should result in reduced tissue destruction in tissue transplantation. Typically, in tissue transplants, rejection of the transplant is initiated through its recognition as foreign by T cells, followed by an immune reaction that destroys the transplant. The administration of a molecule which inhibits or blocks interaction of a B7 lymphocyte antigen with its natural ligand(s) on immune cells (such as a soluble, monomeric form of a peptide having B7-2 activity alone or in conjunction with a monomeric form of apeptide having an activity of another B lymphocyte antigen (e.g., B7- 1, B7-3) or blocking antibody), prior to transplantation can lead to the binding of the molecule to the natural ligand(s) on the immune cells without transmitting the corresponding costimulatory signal. Blocking B lymphocyte antigen function in this matter prevents cytokine synthesis by immune cells, such as T cells, and thus acts as an immunosuppressant. Moreover, the lack of costimulation may also be sufficient to anergize the T cells, thereby inducing tolerance in a subject. Induction of long-term tolerance by B lymphocyte antigen-blocking reagents may avoid the necessity of repeated administration of these blocking reagents. To achieve sufficient immunosuppression or tolerance in a subject, it may also be necessary to block the function of a combination of B lymphocyte antigens.

The efficacy of particular blocking reagents in preventing organ transplant rejection or GVHD can be assessed using animal models that are predictive of efficacy in humans. Examples of appropriate systems which can be used include allogeneic cardiac grafts in rats and xenogeneic pancreatic islet cell grafts in mice, both of which have been used to examine the immunosuppressive effects of CTLA4Ig fusion proteins in vivo as described in Lenschow et al, Science 257:789-792 (1992) and Turka et al, Proc. Natl. Acad. Sci USA, 89:11102-11105 (1992). In addition, murine models of GVHD (see Paul ed., Fundamental Immunology, Raven Press, New York, 1989, pp. 846-847) can be used to determine the effect of blocking B lymphocyte antigen function in vivo on the development of that disease.

Blocking antigen function may also be therapeutically useful for treating autoimmune diseases. Many autoimmune disorders are the result of inappropriate activation of T cells that are reactive against self tissue and which promote the production of cytokines and autoantibodies involved in the pathology ofthe diseases. Preventing the activation of autoreactive T cells may reduce or eliminate disease symptoms. Administration of reagents which block costimulation of T cells by disrupting receptoπligand interactions of B lymphocyte antigens can be used to inhibit T cell activation and prevent production of autoantibodies or T cell-derived cytokines which may be involved in the disease process. Additionally, blocking reagents may induce antigen- specific tolerance of autoreactive T cells which could lead to long-term relief from the disease. The efficacy of blocking reagents in preventing or alleviating autoimmune disorders can be determined using a number of well-characterized animal models of human autoimmune diseases. Examples include murine experimental autoimmune encephalitis, systemic lupus erythmatosis in MRL/lpr/lpr mice or NZB hybrid mice, murine autoimmune collagen arthritis, diabetes mellitus in NOD mice and BB rats, and murine experimental myasthenia gravis (see Paul ed., Fundamental Immunology, Raven Press, New York, 1989, pp. 840-856).

Upregulation of an antigen function (preferably a B lymphocyte antigen function), as a means of up regulating immune responses, may also be useful in therapy. Upregulation of immune responses may be in the form of enhancing an existing immune response or eliciting an initial immune response. For example, enhancing an immune response through stimulating B lymphocyte antigen function may be useful in cases of viral infection. In addition, systemic viral diseases such as influenza, the common cold, and encephalitis might be alleviated by the administration of stimulatory forms of B lymphocyte antigens systemically.

Alternatively, anti-viral immune responses may be enhanced in an infected patient by removing T cells from the patient, costimulating the T cells in vitro with viral antigen- pulsed APCs either expressing a peptide of the present invention or together with a stimulatory form of a soluble peptide ofthe present invention and reintroducing the in vitro activated T cells into the patient. Another method of enhancing anti-viral immune responses would be to isolate infected cells from a patient, transfect them with a nucleic acid encoding a protein of the present invention as described herein such that the cells express all or a portion ofthe protein on their surface, and reintroduce the transfected cells into the patient. The infected cells would now be capable of delivering a costimulatory signal to, and thereby activate, T cells in vivo.

In another application, up regulation or enhancement of antigen function (preferably B lymphocyte antigen function) may be useful in the induction of tumor immunity. Tumor cells (e.g., sarcoma, melanoma, lymphoma, leukemia, neuroblastoma, carcinoma) transfected with a nucleic acid encoding at least one peptide of the present invention can be administered to a subject to overcome tumor-specific tolerance in the subject. If desired, the tumor cell can be transfected to express a combination of peptides. For example, tumor cells obtained from a patient can be transfected ex vivo with an expression vector directing the expression of a peptide having B7-2-like activity alone, or in conjunction with a peptide having B7-l-like activity and/or B7-3-like activity. The transfected tumor cells are returned to the patient to result in expression ofthe peptides on the surface of the transfected cell. Alternatively, gene therapy techniques can be used to target a tumor cell for transfection in vivo.

The presence of the peptide of the present invention having the activity of a B lymphocyte antigen(s) on the surface of the tumor cell provides the necessary costimulation signal to T cells to induce a T cell mediated immune response against the transfected tumor cells. In addition, tumor cells which lack MHC class I or MHC class II molecules, or which fail to reexpress sufficient amounts of MHC class I or MHC class II molecules, can be transfected with nucleic acid encoding all or a portion of (e.g., a cytoplasmic-domain truncated portion) of an MHC class I α chain protein and β₂ microglobulin protein or an MHC class II α chain protein and an MHC class II β chain protein to thereby express MHC class I or MHC class II proteins on the cell surface. Expression of the appropriate class I or class II MHC in conjunction with a peptide having the activity of aB lymphocyte antigen (e.g., B7-1, B7-2, B7-3) induces a T cell mediated immune response against the transfected tumor cell. Optionally, a gene encoding an antisense construct which blocks expression of an MHC class II associated protein, such as the invariant chain, can also be cotransfected with a DNA encoding a peptide having the activity of a B lymphocyte antigen to promote presentation of tumor associated antigens and induce tumor specific immunity. Thus, the induction of a T cell mediated immune response in a human subject may be sufficient to overcome tumor-specific tolerance in the subject.

Suitable assays for thymocyte or splenocyte cytotoxicity include, without limitation, those described in: Cunent Protocols in Immunology, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Herrmann et al., Proc. Natl. Acad. Sci. USA 78:2488-2492, 1981; Herrmann et al., J. Immunol. 128:1968-1974, 1982; Handa et al., J. Immunol. 135: 1564-1572, 1985; Takai et al., J. Immunol. 137:3494-3500, 1986; Takai etal., JJmmunol. 140:508-512, 1988; Herrmann etal., Proc. Natl. Acad. Sci. USA 78:2488-2492, 1981; Herrmann et al., J. Immunol. 128:1968-1974, 1982; Handa et al., J. Immunol. 135:1564-1572, 1985; Takai et al., j. Immunol. 137:3494-3500, 1986; Bowmanet al., J. Virology 61: 1992-1998; Takai et al., j. Immunol. 140:508-512, 1988; Bertagnolli et al., Cellular Immunology 133:327-341, 1991; Brown et al., J. Immunol. 153:3079-3092, 1994.

Assays for T-cell-dependent immunoglobulin responses and isotype switching (which will identify, among others, proteins that modulate T-cell dependent antibody responses and that affect Thl Th2 profiles) include, without limitation, those described in: Maliszewski, J. Immunol. 144:3028-3033, 1990; and Assays for B cell function: In vitro antibody production, Mond, J.J. and Brunswick, M. In Current Protocols in Immunology. J.E.e.a. Coligan eds. Vol 1 pp. 3.8.1-3.8.16, John Wiley and Sons, Toronto. 1994.

Mixed lymphocyte reaction (MLR) assays (which will identify, among others, proteins that generate predominantly Thl and CTL responses) include, without limitation, those described in: Cunent Protocols in Immunology, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1- 3.19; Chapter 7, Immunologic studies in Humans); Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988; Bertagnolli et al., J. Immunol. 149:3778-3783, 1992.

Dendritic cell-dependent assays (which will identify, among others, proteins expressed by dendritic cells that activate naive T-cells) include, without limitation, those described in: Guery et al., J. Immunol. 134:536-544, 1995; Inaba et al., Journal of Experimental Medicine 173:549-559, 1991; Macatonia et al., Journal of Immunology 154:5071-5079, 1995; Porgador et al., Journal of Experimental Medicine 182:255-260, 1995; Nair et al., Journal of Virology 67:4062-4069, 1993; Huang et al., Science 264:961-965, 1994; Macatonia et al., Journal of Experimental Medicine 169:1255-1264, 1989; Bhardwaj et al., Journal of Clinical Investigation 94:797-807, 1994; and Inaba et al., Journal of Experimental Medicine 172:631-640, 1990. Assays for lymphocyte survival/apoptosis (which will identify, among others, proteins that prevent apoptosis after superantigen induction and proteins that regulate lymphocyte homeostasis) include, without limitation, those described in: Darzynkiewicz etal., Cytometry 13:795-808, 1992; Gorczycaetal.,Leukemia7:659-670, 1993; Gorczyca et al., Cancer Research 53:1945-1951, 1993; Itoh et al., Cell 66:233-243, 1991; Zacharchuk, Journal of Immunology 145:4037-4045, 1990; Zamai et al., Cytometry 14:891-897, 1993; Gorczyca et al, International Journal of Oncology 1:639-648, 1992. Assays for proteins that influence early steps of T-cell commitment and development include, without limitation, those described in: Antica et al., Blood 84:111-117, 1994; Fine etal., Cellular Immunology 155:111-122, 1994; Galy etal., Blood 85:2770-2778, 1995; Toki et al., Proc. Nat. Acad Sci. USA 88:7548-7551, 1991.

Hematopoiesis Regulating Activity

A protein of the present invention may be useful in regulation of hematopoiesis and, consequently, in the treatment of myeloid or lymphoid cell deficiencies. Even marginal biological activity in support of colony forming cells or of factor-dependent cell lines indicates involvement in regulating hematopoiesis, e.g. in supporting the growth and proliferation of erythroid progenitor cells alone or in combination with other cytokines, thereby indicating utility, for example, in treating various anemias or for use in conjunction with irradiation chemotherapy to stimulate the production of erythroid precursors and/or erythroid cells; in supporting the growth and proliferation of myeloid cells such as granulocytes and monocytes/macrophages (i.e., traditional CSF activity) useful, for example, in conjunction with chemotherapy to prevent or treat consequent myelo- suppression; in supporting the growth and proliferation of megakaryocytes and consequently of platelets thereby allowing prevention or treatment of various platelet disorders such as thrombocytopenia, and generally for use in place of or complimentary to platelet transfusions; and/or in supporting the growth and proliferation of hematopoietic stem cells which are capable of maturing to any and all of the above-mentioned hematopoietic cells and therefore find therapeutic utility in various stem cell disorders (such as those usually treated with transplantation, including, without limitation, aplastic anemia and paroxysmal nocturnal hemoglobinuria), as well as in repopulating the stem cell compartment post irradiation/chemotherapy, either in-vivo or ex-vivo (i.e., in conjunction with bone marrow transplantation or with peripheral progenitor cell transplantation

(homologous or heterologous)) as normal cells or genetically manipulated for gene therapy. The activity of a protein of the invention may, among other means, be measured by the following methods:

Suitable assays for proliferation and differentiation of various hematopoietic lines are cited above. Assays for embryonic stem cell differentiation (which will identify, among others, proteins that influence embryonic differentiation hematopoiesis) include, without limitation, those described in: Johansson et al. Cellular Biology 15:141-151, 1995; Keller et al., Molecular and Cellular Biology 13:473-486, 1993; McClanahan et al., Blood 81:2903-2915, 1993. Assays for stem cell survival and differentiation (which will identify, among others, proteins that regulate lympho-hematopoiesis) include, without limitation, those described in: Methylcellulose colony forming assays, Freshney, M.G. In Culture of Hematopoietic Cells. R.I. Freshney, etal eds. Vol pp. 265-268, Wiley-Liss, Inc., New York, NY. 1994; Hirayama et al., Proc. Natl. Acad. Sci. USA 89:5907-5911, 1992; Primitive hematopoietic colony forming cells with high proliferative potential, McNiece, LK. and Briddell, R.A. In Culture of Hematopoietic Cells. R.I. Freshney, et al. eds. Vol pp. 23-39, Wiley-Liss, Inc., New York, NY. 1994; Neben et al., Experimental Hematology 22:353-359, 1994; Cobblestone area forming cell assay, Ploemacher, R.E. In Culture of Hematopoietic Cells. R.I. Freshney, etal. eds. Vol pp. 1-21, Wiley-LissJnc, New York, NY. 1994; Long term bone manow cultures in the presence of stromal cells, Spooncer, E. , Dexter, M. and Allen,

T. In Culture of Hematopoietic Cells. R.L Freshney, et al. eds. Vol pp. 163-179, Wiley-Liss, Inc., New York, NY. 1994; Long term culture initiating cell assay, Sutherland, H.J. In Culture of Hematopoietic Cells. R.L Freshney, et al. eds. Vol pp. 139-162, Wiley-Liss, Inc., New York, NY. 1994.

Tissue Growth Activity

A protein of the present invention also may have utility in compositions used for bone, cartilage, tendon, ligament and/or nerve tissue growth or regeneration, as well as for wound healing and tissue repair and replacement, and in the treatment of burns, incisions and ulcers.

A protein ofthe present invention, which induces cartilage and/or bone growth in circumstances where bone is not normally formed, has application in the healing of bone fractures and cartilage damage or defects in humans and other animals. Such a preparation employing a protein ofthe invention may have prophylactic use in closed as well as open fracture reduction and also in the improved fixation of artificial joints. De novo bone formation induced by an osteogenic agent contributes to the repair of congenital, trauma induced, or oncologic resection induced craniofacial defects, and also is useful in cosmetic plastic surgery.

A protein of this invention may also be used in the treatment of periodontal disease, and in other tooth repair processes. Such agents may provide an environment to attract bone-forming cells, stimulate growth of bone-forming cells or induce differentiation of progenitors of bone-forming cells. A protein of the invention may also be useful in the treatment of osteoporosis or osteoarthritis, such as through stimulation of bone and/or cartilage repair or by blocking inflammation or processes of tissue destruction (collagenase activity, osteoclast activity, etc.) mediated by inflammatory processes.

Another category of tissue regeneration activity that may be attributable to the protein of the present invention is tendon/ligament formation. A protein of the present invention, which induces tendon/ligament-like tissue or other tissue formation in circumstances where such tissue is not normally formed, has application in the healing of tendon or ligament tears, deformities and other tendon or ligament defects in humans and other animals. Such a preparation employing a tendon/ligament-like tissue inducing protein may have prophylactic use in preventing damage to tendon or ligament tissue, as well as use in the improved fixation of tendon or ligament to bone or other tissues, and in repairing defects to tendon or ligament tissue. De novo tendon/ligament-like tissue formation induced by a composition of the present invention contributes to the repair of congenital, trauma induced, or other tendon or ligament defects of other origin, and is also useful in cosmetic plastic surgery for attachment or repair of tendons or ligaments. The compositions of the present invention may provide an environment to attract tendon- or ligament-forming cells, stimulate growth of tendon- or ligament-forming cells, induce differentiation of progenitors of tendon- or ligament-forming cells, or induce growth of tendon/ligament cells or progenitors ex vivo for return in vivo to effect tissue repair. The compositions of the invention may also be useful in the treatment of tendinitis, carpal tunnel syndrome and other tendon or ligament defects. The compositions may also include an appropriate matrix and/or sequestering agent as a canier as is well known in the art. The protein ofthe present invention may also be useful for proliferation of neural cells and for regeneration of nerve and brain tissue, i.e. for the treatment of central and peripheral nervous system diseases and neuropathies, as well as mechanical and traumatic disorders, which involve degeneration, death or trauma to neural cells or nerve tissue. More specifically, a protein may be used in the treatment of diseases of the peripheral nervous system, such as peripheral nerve injuries, peripheral neuropathy and localized neuropathies, and central nervous system diseases, such as Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome. Further conditions which may be treated in accordance with the present invention include mechanical and traumatic disorders, such as spinal cord disorders, head trauma and cerebrovascular diseases such as stroke. Peripheral neuropathies resulting from chemotherapy or other medical therapies may also be treatable using a protein of the invention.

Proteins of the invention may also be useful to promote better or faster closure of non-healing wounds, including without limitation pressure ulcers, ulcers associated with vascular insufficiency, surgical and traumatic wounds, and the like.

It is expected that a protein of the present invention may also exhibit activity for generation or regeneration of other tissues, such as organs (including, for example, pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac) and vascular (including vascular endothelium) tissue, or for promoting the growth of cells comprising such tissues. Part ofthe desired effects may be by inhibition or modulation of fibrotic scarring to allow normal tissue to regenerate. A protein ofthe invention may also exhibit angiogenic activity.

A protein of the present invention may also be useful for gut protection or regeneration and treatment of lung or liver fibrosis, reperfusion injury in various tissues, and conditions resulting from systemic cytokine damage.

A protein of the present invention may also be useful for promoting or inhibiting differentiation of tissues described above from precursor tissues or cells; or for inhibiting the growth of tissues described above. The activity of a protein of the invention may, among other means, be measured by the following methods: Assays for tissue generation activity include, without limitation, those described in: International Patent Publication No. WO95/16035 (bone, cartilage, tendon); International Patent Publication No. WO95/05846 (nerve, neuronal); International Patent Publication No. WO91/07491 (skin, endothelium ). Assays for wound healing activity include, without limitation, those described in:

Winter, Epidermal Wound Healing, pps.71-112 (Maibach, HI and Rovee, DT, eds.), Year Book Medical Publishers, Inc., Chicago, as modified by Eaglstein and Mertz, J. Invest. Dermatol 71:382-84 (1978).

Activin Inhibin Activity

A protein of the present invention may also exhibit activin- or inhibin-related activities. Inhibins are characterized by their ability to inhibit the release of follicle stimulating hormone (FSH), while activins and are characterized by their ability to stimulate the release of follicle stimulating hormone (FSH). Thus, aprotein ofthe present invention, alone or in heterodimers with a member of the inhibin family, may be useful as a contraceptive based on the ability of inhibins to decrease fertility in female mammals and decrease spermatogenesis in male mammals. Administration of sufficient amounts of other inhibins can induce infertility in these mammals. Alternatively, the protein of the invention, as a homodimer or as a heterodimer with other protein subunits ofthe inhibin-β group, may be useful as a fertility inducing therapeutic, based upon the ability of activin molecules in stimulating FSH release from cells ofthe anterior pituitary. See, for example, United States Patent 4,798,885. A protein of the invention may also be useful for advancement ofthe onset of fertility in sexually immature mammals, so as to increase the lifetime reproductive performance of domestic animals such as cows, sheep and pigs. The activity of a protein of the invention may, among other means, be measured by the following methods:

Assays for activin/inhibin activity include, without limitation, those described in: Vale et al., Endocrinology 91:562-572, 1972; Ling et al., Nature 321:779-782, 1986; Vale et al., Nature 321:776-779, 1986; Mason et al., Nature 318:659-663, 1985; Forage et al., Proc. Natl. Acad. Sci. USA 83:3091-3095, 1986.

Chemotactic/Chemokinetic Activity A protein ofthe present invention may have chemotactic or chemokinetic activity (e.g., act as a chemokine) for mammalian cells, including, for example, monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells. Chemotactic and chemokinetic proteins can be used to mobilize or attract a desired cell population to a desired site of action. Chemotactic or chemokinetic proteins provide particular advantages in treatment of wounds and other trauma to tissues, as well as in treatment of localized infections. For example, attraction of lymphocytes, monocytes or neutrophils to tumors or sites of infection may result in improved immune responses against the tumor or infecting agent. A protein or peptide has chemotactic activity for a particular cell population if it can stimulate, directly or indirectly, the directed orientation or movement of such cell population. Preferably, the protein or peptide has the ability to directly stimulate directed movement of cells. Whether a particular protein has chemotactic activity for a population of cells can be readily determined by employing such protein or peptide in any known assay for cell chemotaxis.

Assays for chemotactic activity (which will identify proteins that induce or prevent chemotaxis) consist of assays that measure the ability of a protein to induce the migration of cells across a membrane as well as the ability of a protein to induce the adhesion of one cell population to another cell population. Suitable assays for movement and adhesion include, without limitation, those described in: Cunent Protocols in Immunology, Ed by J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W.Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 6J2, Measurement of alpha and beta Chemokines 6.12.1-6.12.28; Taub et al. J. Clin. Invest. 95:1370-1376, 1995; Lind et al. APMIS 103: 140-146, 1995; Muller et al Eur. J. Immunol. 25: 1744-1748; Gruber et al. J. of Immunol. 152:5860-5867, 1994; Johnston etal. J. of Immunol. 153: 1762-1768, 1994.

Hemostatic and Thrombolvtic Activity A protein of the invention may also exhibit hemostatic or thrombolytic activity.

As a result, such a protein is expected to be useful in treatment of various coagulation disorders (including hereditary disorders, such as hemophilias) or to enhance coagulation and other hemostatic events in treating wounds resulting from trauma, surgery or other causes. A protein of the invention may also be useful for dissolving or inhibiting formation of thromboses and for treatment and prevention of conditions resulting therefrom (such as, for example, infarction of cardiac and central nervous system vessels (e.g., stroke).

Assay for hemostatic and thrombolytic activity include, without limitation, those described in: Linet et al., J. Clin. Pharmacol.26: 131-140, 1986; Burdick et al., Thrombosis Res. 45:413-419, 1987; Humphrey et al., Fibrinolysis 5:71-79 (1991); Schaub, Prostaglandins 35:467-474, 1988.

Receptor/Ligand Activity

A protein of the present invention may also demonstrate activity as receptors, receptor ligands or inhibitors or agonists of receptor/ligand interactions. Examples of such receptors and ligands include, without limitation, cytokine receptors and their ligands, receptor kinases and their ligands, receptor phosphatases and their ligands, receptors involved in cell-cell interactions and their ligands (including without limitation, cellular adhesion molecules (such as selectins, integrins and their ligands) and receptor/ligand pairs involved in antigen presentation, antigen recognition and development of cellular and humoral immune responses). Receptors and ligands are also useful for screening of potential peptide or small molecule inhibitors of the relevant receptor/ligand interaction. A protein of the present invention (including, without limitation, fragments of receptors and ligands) may themselves be useful as inhibitors of receptor/ligand interactions. The activity of a protein of the invention may, among other means, be measured by the following methods:

Suitable assays for receptor-ligand activity include without limitation those described in:Current Protocols in Immunology, Ed by J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W.Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 7.28, Measurement of Cellular Adhesion under static conditions 7.28.1-7.28.22), Takai et al., Proc. Natl. Acad. Sci. USA 84:6864-6868, 1987; Bierer et al., J. Exp. Med. 168:1145-1156, 1988; Rosenstein et al., J. Exp. Med. 169:149-160 1989; Stoltenborg et al., J. Immunol. Methods 175:59-68, 1994; Stittetal., Cell 80:661-670, 1995.

Anti-Inflammatory Activity Proteins of the present invention may also exhibit anti-inflammatory activity. The anti-inflammatory activity may be achieved by providing a stimulus to cells involved in the inflammatory response, by inhibiting or promoting cell-cell interactions (such as, for example, cell adhesion), by inhibiting or promoting chemotaxis of cells involved in the inflammatory process, inhibiting or promoting cell extravasation, or by stimulating or suppressing production of other factors which more directly inhibit or promote an inflammatory response. Proteins exhibiting such activities can be used to treat inflammatory conditions including chronic or acute conditions), including without limitation inflammation associated with infection (such as septic shock, sepsis or systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine-induced lung injury, inflammatory bowel disease, Crohn's disease or resulting from over production of cytokines such as TNF or IL- 1. Proteins of the invention may also be useful to treat anaphylaxis and hypersensitivity to an antigenic substance or material.

Cadherin/Tumor Invasion Suppressor Activity

Cadherins are calcium-dependent adhesion molecules that appear to play major roles during development, particularly in defining specific cell types. Loss or alteration of normal cadherin expression can lead to changes in cell adhesion properties linked to tumor growth and metastasis. Cadherin malfunction is also implicated in other human diseases, such as pemphigus vulgaris and pemphigus foliaceus (auto-immune blistering skin diseases), Crohn's disease, and some developmental abnormalities.

The cadherin superfamily includes well over forty members, each with a distinct pattern of expression. All members of the superfamily have in common conserved extracellular repeats (cadherin domains), but structural differences are found in other parts of the molecule. The cadherin domains bind calcium to form their tertiary structure and thus calcium is required to mediate their adhesion. Only a few amino acids in the first cadherin domain provide the basis for homophilic adhesion; modification of this recognition site can change the specificity of a cadherin so that instead of recognizing only itself, the mutant molecule can now also bind to a different cadherin. In addition, some cadherins engage in heterophilic adhesion with other cadherins.

E-cadherin, one member ofthe cadherin superfamily, is expressed in epithelial cell types. Pathologically, if E-cadherin expression is lost in a tumor, the malignant cells become invasive and the cancer metastasizes. Transfection of cancer cell lines with polynucleotides expressing E- cadherin has reversed cancer-associated changes by returning altered cell shapes to normal, restoring cells' adhesiveness to each other and to their substrate, decreasing the cell growth rate, and drastically reducing anchorage-independent cell growth. Thus, reintroducing E-cadherin expression reverts carcinomas to a less advanced stage. It is likely that other cadherins have the same invasion suppressor role in carcinomas derived from other tissue types. Therefore, proteins of the present invention with cadherin activity, and polynucleotides of the present invention encoding such proteins, can be used to treat cancer. Introducing such proteins or polynucleotides into cancer cells can reduce or eliminate the cancerous changes observed in these cells by providing normal cadherin expression. Cancer cells have also been shown to express cadherins of a different tissue type than their origin, thus allowing these cells to invade and metastasize in a different tissue in the body. Proteins of the present invention with cadherin activity, and polynucleotides of the present invention encoding such proteins, can be substituted in these cells for the inappropriately expressed cadherins, restoring normal cell adhesive properties and reducing or eliminating the tendency of the cells to metastasize.

Additionally, proteins ofthe present invention with cadherin activity, and polynucleotides of the present invention encoding such proteins, can used to generate antibodies recognizing and binding to cadherins. Such antibodies can be used to block the adhesion of inappropriately expressed tumor-cell cadherins, preventing the cells from forming a tumor elsewhere. Such an anti-cadherin antibody can also be used as a marker for the grade, pathological type, and prognosis of a cancer, i.e. the more progressed the cancer, the less cadherin expression there will be, and this decrease in cadherin expression can be detected by the use of a cadherin-binding antibody.

Fragments of proteins of the present invention with cadherin activity, preferably a polypeptide comprising a decapeptide of the cadherin recognition site, and poly-nucleotides of the present invention encoding such protein fragments, can also be used to block cadherin function by binding to cadherins and preventing them from binding in ways that produce undesirable effects. Additionally, fragments of proteins of the present invention with cadherin activity, preferably truncated soluble cadherin fragments which have been found to be stable in the circulation of cancer patients, and polynucleotides encoding such protein fragments, can be used to disturb proper cell-cell adhesion.

Assays for cadherin adhesive and invasive suppressor activity include, without limitation, those described in: Hortsch et al. J Biol Chem 270 (32): 18809-18817, 1995; Miyaki et al. Oncogene 11: 2547-2552, 1995; Ozawa et al. Cell 63: 1033-1038, 1990.

Tumor Inhibition Activity

In addition to the activities described above for immunological treatment or prevention of tumors, a protein of the invention may exhibit other anti-tumor activities. A protein may inhibit tumor growth directly or indirectly (such as, for example, via antibody-dependent cell-mediated cytotoxicity (ADCC)). A protein may exhibit its tumor inhibitory activity by acting on tumor tissue or tumor precursor tissue, by inhibiting formation of tissues necessary to support tumor growth (such as, for example, by inhibiting angiogenesis), by causing production of other factors, agents or cell types which inhibit tumor growth, or by suppressing, eliminating or inhibiting factors, agents or cell types which promote tumor growth.

Other Activities

A protein ofthe invention may also exhibit one or more ofthe following additional activities or effects: inhibiting the growth, infection or function of, or killing, infectious agents, including, without limitation, bacteria, viruses, fungi and other parasites; effecting (suppressing or enhancing) bodily characteristics, including, without limitation, height, weight, hair color, eye color, skin, fat to lean ratio or other tissue pigmentation, or organ or body part size or shape (such as, for example, breast augmentation or diminution, change in bone form or shape); effecting biorhythms or caricadic cycles or rhythms; effecting the fertility of male or female subjects; effecting the metabolism, catabolism, anabolism, processing, utilization, storage or elimination of dietary fat, lipid, protein, carbohydrate, vitamins, minerals, cofactors or other nutritional factors or component(s); effecting behavioral characteristics, including, without limitation, appetite, libido, stress, cognition (including cognitive disorders), depression (including depressive disorders) and violent behaviors; providing analgesic effects or other pain reducing effects; promoting differentiation and growth of embryonic stem cells in lineages other than hematopoietic lineages; hormonal or endocrine activity; in the case of enzymes, conecting deficiencies of the enzyme and treating deficiency-related diseases; treatment of hyperproliferative disorders (such as, for example, psoriasis); immunoglobulin-like activity (such as, for example, the ability to bind antigens or complement); and the ability to act as an antigen in a vaccine composition to raise an immune response against such protein or another material or entity which is cross-reactive with such protein.

ADMINISTRATION AND DOSING

A protein of the present invention (from whatever source derived, including without limitation from recombinant and non-recombinant sources) may be used in a pharmaceutical composition when combined with a pharmaceutically acceptable carrier. Such a composition may also contain (in addition to protein and a carrier) diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials well known in the art. The term "pharmaceutically acceptable" means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredient(s). The characteristics of the carrier will depend on the route of administration. The pharmaceutical composition ofthe invention may also contain cytokines, lymphokines, or other hematopoietic factors such as M-CSF, GM-CSF, TNF, IL-1, IL-2, IL-3, E -4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IFN, TNFO, TNF1, TNF2, G-CSF, Meg-CSF, thrombopoietin, stem cell factor, and erythropoietin. The pharmaceutical composition may further contain other agents which either enhance the activity ofthe protein or compliment its activity or use in treatment. Such additional factors and/or agents may be included in the pharmaceutical composition to produce a synergistic effect with protein of the invention, or to minimize side effects. Conversely, protein of the present invention may be included in formulations of the particular cytokine, lymphokine, other hematopoietic factor, thrombolytic or anti-thrombotic factor, or anti-inflammatory agent to minimize side effects of the cytokine, lymphokine, other hematopoietic factor, thrombolytic or anti- thrombotic factor, or anti-inflammatory agent.

A protein of the present invention may be active in mul timers (e.g., heterodimers or homodimers) or complexes with itself or other proteins. As a result, pharmaceutical compositions ofthe invention may comprise a protein ofthe invention in such multimeric or complexed form. The pharmaceutical composition ofthe invention may be in the form of a complex of the protein(s) of present invention along with protein or peptide antigens. The protein and/or peptide antigen will deliver a stimulatory signal to both B and T lymphocytes. B lymphocytes will respond to antigen through their surface immunoglobulin receptor. T lymphocytes will respond to antigen through the T cell receptor (TCR) following presentation of the antigen by MHC proteins. MHC and structurally related proteins including those encoded by class I and class II MHC genes on host cells will serve to present the peptide antigen(s) to T lymphocytes. The antigen components could also be supplied as purified MHC-peptide complexes alone or with co-stimulatory molecules that can directly signal T cells. Alternatively antibodies able to bind surface immunolgobulin and other molecules on B cells as well as antibodies able to bind the TCR and other molecules on T cells can be combined with the pharmaceutical composition of the invention.

The pharmaceutical composition ofthe invention may be in the form of a liposome in which protein of the present invention is combined, in addition to other pharmaceutically acceptable carriers, with amphipathic agents such as lipids which exist in aggregated form as micelles, insoluble monolayers, liquid crystals, or lamellar layers in aqueous solution. Suitable lipids for liposomal formulation include, without limitation, monoglycerides, diglycerides, sulfatides, lysolecithin, phospholipids, saponin, bile acids, and the like. Preparation of such liposomal formulations is within the level of skill in the art, as disclosed, for example, in U.S. Patent No. 4,235,871; U.S. Patent No. 4,501,728; U.S. Patent No. 4,837,028; and U.S. Patent No. 4,737,323, all of which are incorporated herein by reference.

As used herein, the term "therapeutically effective amount" means the total amount of each active component of the pharmaceutical composition or method that is sufficient to show a meaningful patient benefit, i.e., treatment, healing, prevention or amelioration of the relevant medical condition, or an increase in rate of treatment, healing, prevention or amelioration of such conditions. When applied to an individual active ingredient, administered alone, the term refers to that ingredient alone. When applied to a combination, the term refers to combined amounts of the active ingredients that result in the therapeutic effect, whether administered in combination, serially or simultaneously. In practicing the method of treatment or use of the present invention, a therapeutically effective amount of protein of the present invention is administered to a mammal having a condition to be treated. Protein of the present invention may be administered in accordance with the method ofthe invention either alone or in combination with other therapies such as treatments employing cytokines, lymphokines or other hematopoietic factors. When co-administered with one or more cytokines, lymphokines or other hematopoietic factors, protein ofthe present invention may be administered either simultaneously with the cytokine(s), lymphokine(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors, or sequentially. If administered sequentially, the attending physician will decide on the appropriate sequence of administering protein ofthe present invention in combination with cytokine(s), lymphokine(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors.

Administration of protein of the present invention used in the pharmaceutical composition or to practice the method of the present invention can be carried out in a variety of conventional ways, such as oral ingestion, inhalation, topical application or cutaneous, subcutaneous, intraperitoneal, parenteral or intravenous injection. Intravenous administration to the patient is preferred.

When a therapeutically effective amount of protein of the present invention is administered orally, protein ofthe present invention will be in the form of a tablet, capsule, powder, solution or elixir. When administered in tablet form, the pharmaceutical composition of the invention may additionally contain a solid carrier such as a gelatin or an adjuvant. The tablet, capsule, and powder contain from about 5 to 95% protein of the present invention, and preferably from about 25 to 90% protein of the present invention. When administered in liquid form, a liquid carrier such as water, petroleum, oils of animal or plant origin such as peanut oil, mineral oil, soybean oil, or sesame oil, or synthetic oils may be added. The liquid form of the pharmaceutical composition may further contain physiological saline solution, dextrose or other saccharide solution, or glycols such as ethylene glycol, propylene glycol or polyethylene glycol. When administered in liquid form, the pharmaceutical composition contains from about 0.5 to 90% by weight of protein of the present invention, and preferably from about 1 to 50% protein of the present invention. When a therapeutically effective amount of protein of the present invention is administered by intravenous, cutaneous or subcutaneous injection, protein of the present invention will be in the form of a pyrogen-free, parenterally acceptable aqueous solution. The preparation of such parenterally acceptable protein solutions, having due regard to pH, isotonicity, stability, and the like, is within the skill in the art. A preferred pharmaceutical composition for intravenous, cutaneous, or subcutaneous injection should contain, in addition to protein of the present invention, an isotonic vehicle such as Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, Lactated Ringer's Injection, or other vehicle as known in the art. The pharmaceutical composition of the present invention may also contain stabilizers, preservatives, buffers, antioxidants, or other additives known to those of skill in the art.

The amount of protein ofthe present invention in the pharmaceutical composition of the present invention will depend upon the nature and severity of the condition being treated, and on the nature of prior treatments which the patient has undergone. Ultimately, the attending physician will decide the amount of protein of the present invention with which to treat each individual patient. Initially, the attending physician will administer low doses of protein of the present invention and observe the patient's response. Larger doses of protein ofthe present invention may be administered until the optimal therapeutic effect is obtained for the patient, and at that point the dosage is not increased further. It is contemplated that the various pharmaceutical compositions used to practice the method of the present invention should contain about 0.01 μg to about 100 mg (preferably about OJng to about 10 mg, more preferably about 0J μg to about 1 mg) of protein of the present invention per kg body weight.

The duration of intravenous therapy using the pharmaceutical composition of the present invention will vary, depending on the severity of the disease being treated and the condition and potential idiosyncratic response of each individual patient. It is contemplated that the duration of each application of the protein of the present invention will be in the range of 12 to 24 hours of continuous intravenous administration. Ultimately the attending physician will decide on the appropriate duration of intravenous therapy using the pharmaceutical composition of the present invention.

Protein ofthe invention may also be used to immunize animals to obtain polyclonal and monoclonal antibodies which specifically react with the protein. As used herein, the term "antibody" includes without limitation a polyclonal antibody, a monoclonal antibody, a chimeric antibody, a single-chain antibody, a CDR-grafted antibody, a humanized antibody, or fragments thereof which bind to the indicated protein. Such term also includes any other species derived from an antibody or antibody sequence which is capable of binding the indicated protein.

Antibodies to a particular protein can be produced by methods well known to those skilled in the art. For example, monoclonal antibodies can be produced by generation of antibody-producing hybridomas in accordance with known methods (see for example, Goding, 1983, Monoclonal antibodies: principles and practice, Academic Press Inc., New York; and Yokoyama, 1992, "Production of Monoclonal Antibodies" in Current Protocols in Immunology, Unit 2.5, Greene Publishing Assoc. and John Wiley & Sons). Polyclonal sera and antibodies can be produced by inoculation of a mammalian subject with the relevant protein or fragments thereof in accordance with known methods. Fragments of antibodies, receptors, or other reactive peptides can be produced from the corresponding antibodies by cleavage of and collection of the desired fragments in accordance with known methods (see for example, Goding, supra; and Andrew et al., 1992, "Fragmentation of Immunoglobulins" in Current Protocols in Immunology, Unit 2.8, Greene Publishing Assoc. and John Wiley & Sons). Chimeric antibodies and single chain antibodies can also be produced in accordance with known recombinant methods (see for example, 5, 169,939, 5,194,594, and 5,576,184). Humanized antibodies can also be made from conesponding murine antibodies in accordance with well known methods (see for example, U.S. Patent Nos. 5,530,101, 5,585,089, and 5,693,762). Additionally, human antibodies may be produced in non-human animals such as mice that have been genetically altered to express human antibody molecules (see for example Fishwild et al, 1996, Nature Biotechnology 14: 845-851 ; Mendez et al. , 1997, Nature Genetics 15: 146- 156 (erratum Nature Genetics 16: 410); and U.S. Patents 5,877,397 and 5,625,126). Such antibodies may be obtained using either the entire protein or fragments thereof as an immunogen. The peptide immunogens additionally may contain a cysteine residue at the carboxyl terminus, and are conjugated to a hapten such as keyhole limpet hemocyanin (KLH). Methods for synthesizing such peptides are known in the art, for example, as in R.P. Menifield, J.

Amer.Chem.Soc. 85, 2149-2154 (1963); J.L. Krstenansky, et al, FEBS Lett. 21J, 10 (1987). Monoclonal antibodies binding to the protein of the invention may be useful diagnostic agents for the immunodetection of the protein. Neutralizing monoclonal antibodies binding to the protein may also be useful therapeutics for both conditions associated with the protein and also in the treatment of some forms of cancer where abnormal expression of the protein is involved. In the case of cancerous cells or leukemic cells, neutralizing monoclonal antibodies against the protein may be useful in detecting and preventing the metastatic spread of the cancerous cells, which may be mediated by the protein.

For compositions of the present invention which are useful for bone, cartilage, tendon or ligament regeneration, the therapeutic method includes administering the composition topically, systematically, or locally as an implant or device. When administered, the therapeutic composition for use in this invention is, of course, in a pyrogen-free, physiologically acceptable form. Further, the composition may desirably be encapsulated or injected in a viscous form for delivery to the site of bone, cartilage or tissue damage. Topical administration may be suitable for wound healing and tissue repair. Therapeutically useful agents other than a protein ofthe invention which may also optionally be included in the composition as described above, may alternatively or additionally, be administered simultaneously or sequentially with the composition in the methods ofthe invention. Preferably for bone and/or cartilage formation, the composition would include a matrix capable of delivering the protein-containing composition to the site of bone and/or cartilage damage, providing a structure for the developing bone and cartilage and optimally capable of being resorbed into the body. Such matrices may be formed of materials presently in use for other implanted medical applications.

The choice of matrix material is based on biocompatibility, biodegradability, mechanical properties, cosmetic appearance and interface properties. The particular application ofthe compositions will define the appropriate formulation. Potential matrices for the compositions may be biodegradable and chemically defined calcium sulfate, tricalciumphosphate, hydroxyapatite, polylactic acid, polyglycolic acid and poly anhydrides . Other potential materials are biodegradable and biologically well-defined, such as bone or dermal collagen. Further matrices are comprised of pure proteins or extracellular matrix components. Other potential matrices are nonbiodegradable and chemically defined, such as sintered hydroxapatite, bioglass, aluminates, or other ceramics. Matrices may be comprised of combinations of any of the above mentioned types of material, such as polylactic acid and hydroxyapatite or collagen and tricalciumphosphate. The bioceramics may be altered in composition, such as in calcium-aluminate-phosphate and processing to alter pore size, particle size, particle shape, and biodegradability. Presently prefened is a 50:50 (mole weight) copolymer of lactic acid and glycolic acid in the form of porous particles having diameters ranging from 150 to 800 microns. In some applications, it will be useful to utilize a sequestering agent, such as carboxymethyl cellulose or autologous blood clot, to prevent the protein compositions from disassociating from the matrix. A preferred family of sequestering agents is cellulosic materials such as alkylcelluloses (including hydroxyalkylcelluloses), including methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropyl- methylcellulose, and carboxymethylcellulose, the most preferred being cationic salts of carboxymethylcellulose (CMC). Other prefened sequestering agents include hyaluronic acid, sodium alginate, poly(ethylene glycol), polyoxyethylene oxide, carboxy vinyl polymer and poly(vinyl alcohol). The amount of sequestering agent useful herein is 0.5-20 wt%, preferably 1-10 wt% based on total formulation weight, which represents the amount necessary to prevent desorbtion of the protein from the polymer matrix and to provide appropriate handling of the composition, yet not so much that the progenitor cells are prevented from infiltrating the matrix, thereby providing the protein the opportunity to assist the osteogenic activity of the progenitor cells.

In further compositions, proteins of the invention may be combined with other agents beneficial to the treatment of the bone and/or cartilage defect, wound, or tissue in question. These agents include various growth factors such as epidermal growth factor (EGF), platelet derived growth factor (PDGF), transforming growth factors (TGF-α and

TGF-β), and insulin-like growth factor (IGF).

The therapeutic compositions are also presently valuable for veterinary applications. Particularly domestic animals and thoroughbred horses, in addition to humans, are desired patients for such treatment with proteins of the present invention. The dosage regimen of a protein-containing pharmaceutical composition to be used in tissue regeneration will be determined by the attending physician considering various factors which modify the action ofthe proteins, e.g., amount of tissue weight desired to be formed, the site of damage, the condition of the damaged tissue, the size of a wound, type of damaged tissue (e.g., bone), the patient's age, sex, and diet, the severity of any infection, time of administration and other clinical factors. The dosage may vary with the type of matrix used in the reconstitution and with inclusion of other proteins in the pharmaceutical composition. For example, the addition of other known growth factors, such as IGF I (insulin like growth factor I), to the final composition, may also effect the dosage. Progress can be monitored by periodic assessment of tissue/bone growth and/or repair, for example, X-rays, histomorphometric determinations and tetracycline labeling.

Polynucleotides ofthe present invention can also be used for gene therapy. Such polynucleotides can be introduced either in vivo or ex vivo into cells for expression in a mammalian subject. Polynucleotides of the invention may also be administered by other known methods for introduction of nucleic acid into a cell or organism (including, without limitation, in the form of viral vectors or naked DNA).

Cells may also be cultured ex vivo in the presence of proteins of the present invention in order to proliferate or to produce a desired effect on or activity in such cells. Treated cells can then be introduced in vivo for therapeutic purposes.

Patent and literature references cited herein are incorporated by reference as if fully set forth.

Claims

What is claimed is:

1. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO: 1 ;

(b) the nucleotide sequence of SEQ ID NO: 1 from nucleotide 27 to nucleotide 260;

(c) the nucleotide sequence of SEQ ID NO: 1 from nucleotide 72 to nucleotide 260;

(d) the nucleotide sequence of the full-length protein coding sequence of clone vc62_l deposited with the ATCC under accession number 207114;

(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vc62_l deposited with the ATCC under accession number 207114;

(f) the nucleotide sequence of a mature protein coding sequence of clone vc62_l deposited with the ATCC under accession number 207114;

(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vc62_l deposited with the ATCC under accession number 207114;

(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:2;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2, the fragment comprising eight contiguous amino acids of SEQ ID NO:2;

(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one ofthe polynucleotides specified by (a)-(g); and

(k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one ofthe polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO: 1.

2. The polynucleotide of claim 1 wherein said polynucleotide is operably linked to at least one expression control sequence.

3. A host cell transformed with the polynucleotide of claim 2.

4. The host cell of claim 3, wherein said cell is a mammalian cell.

5. A process for producing a protein encoded by the polynucleotide of claim 2, which process comprises:

(a) growing a culture of a host cell in a suitable culture medium, wherein the host cell has been transformed with the polynucleotide of claim 2; and

(b) purifying said protein from the culture.

6. A protein produced according to the process of claim 5.

7. An isolated polynucleotide encoding the protein of claim 6.

8. The polynucleotide of claim 7, wherein the polynucleotide comprises the cDNA insert of clone vc62_l deposited with the ATCC under accession number 207114.

9. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:2;

(b) a fragment of the amino acid sequence of SEQ ID NO:2, the fragment comprising eight contiguous amino acids of SEQ ID NO:2; and

(c) the amino acid sequence encoded by the cDNA insert of clone vc62_l deposited with the ATCC under accession number 207114; the protein being substantially free from other mammalian proteins.

10. The protein of claim 9, wherein said protein comprises the amino acid sequence of SEQ ID NO:2.

11. A composition comprising the protein of claim 9 and a pharmaceutically acceptable carrier.

12. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO: 3;

(b) the nucleotide sequence of SEQ ID NO:3 from nucleotide 6 to nucleotide 1325;

(c) the nucleotide sequence of SEQ ID NO: 3 from nucleotide 99 to nucleotide 1325;

(d) the nucleotide sequence of the full-length protein coding sequence of clone vpl0_l deposited with the ATCC under accession number 207114;

(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vpl0_l deposited with the ATCC under accession number 207114;

(f) the nucleotide sequence of a mature protein coding sequence of clone vpl0_l deposited with the ATCC under accession number 207114;

(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vpl0_l deposited with the ATCC under accession number 207114;

(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:4;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4, the fragment comprising eight contiguous amino acids of SEQ ID NO:4;

(k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one ofthe polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:3.

13. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:4;

(b) a fragment of the amino acid sequence of SEQ ID NOJ, the fragment comprising eight contiguous amino acids of SEQ ID NOJ; and

(c) the amino acid sequence encoded by the cDNA insert of clone vpl0_l deposited with the ATCC under accession number 207114; the protein being substantially free from other mammalian proteins.

14. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO:5;

(b) the nucleotide sequence of SEQ ID NO:5 from nucleotide 149 to nucleotide 322;

(c) the nucleotide sequence of SEQ ID NO:5 from nucleotide 200 to nucleotide 322;

(d) the nucleotide sequence of the full-length protein coding sequence of clone vpl 1_1 deposited with the ATCC under accession number 207114;

(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vpl l_l deposited with the ATCC under accession number 207114;

(f) the nucleotide sequence of a mature protein coding sequence of clone vpl 1_1 deposited with the ATCC under accession number 207114;

(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vpl 1_1 deposited with the ATCC under accession number 207114;

(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:6;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6, the fragment comprising eight contiguous amino acids of SEQ ID NO:6; (j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one ofthe polynucleotides specified by (a)-(g); and

(k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one ofthe polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:5.

15. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:6;

(b) a fragment of the amino acid sequence of SEQ ID NO: 6, the fragment comprising eight contiguous amino acids of SEQ ID NO: 6; and

(c) the amino acid sequence encoded by the cDNA insert of clone vpl 1_1 deposited with the ATCC under accession number 207114; the protein being substantially free from other mammalian proteins.

16. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO:7;

(b) the nucleotide sequence of SEQ ID NO:7 from nucleotide 288 to nucleotide 629;

(c) the nucleotide sequence of SEQ ID NO: 7 from nucleotide 363 to nucleotide 629;

(d) the nucleotide sequence of the full-length protein coding sequence of clone vpl3_l deposited with the ATCC under accession number 207114;

(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vpl3_l deposited with the ATCC under accession number 207114;

(f) the nucleotide sequence of a mature protein coding sequence of clone vpl3_l deposited with the ATCC under accession number 207114; (g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vpl3_l deposited with the ATCC under accession number 207114;

(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO: 8;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8, the fragment comprising eight contiguous amino acids of SEQ ID NO: 8;

(k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one ofthe polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:7.

17. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:8;

(b) a fragment of the amino acid sequence of SEQ ID NO:8, the fragment comprising eight contiguous amino acids of SEQ ID NO: 8; and

(c) the amino acid sequence encoded by the cDNA insert of clone vpl3_l deposited with the ATCC under accession number 207114; the protein being substantially free from other mammalian proteins.

18. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO:9;

(b) the nucleotide sequence of SEQ ID NO:9 from nucleotide 11 to nucleotide 298;

(c) the nucleotide sequence of SEQ ID NO:9 from nucleotide 149 to nucleotide 298; (d) the nucleotide sequence of the full-length protein coding sequence of clone vpl6_l deposited with the ATCC under accession number 207114;

(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vpl6_l deposited with the ATCC under accession number 207114;

(f) the nucleotide sequence of a mature protein coding sequence of clone vpl6_l deposited with the ATCC under accession number 207114;

(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vpl6_l deposited with the ATCC under accession number 207114;

(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO: 10;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NOJ0, the fragment comprising eight contiguous amino acids of SEQ ID NO: 10;

(k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one ofthe polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:9.

19. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO: 10;

(b) a fragment of the amino acid sequence of SEQ ID NO: 10, the fragment comprising eight contiguous amino acids of SEQ ID NO: 10; and

(c) the amino acid sequence encoded by the cDNA insert of clone vpl6_l deposited with the ATCC under accession number 207114; the protein being substantially free from other mammalian proteins.

20. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO: 11 ;

(b) the nucleotide sequence of SEQ ID NO: 11 from nucleotide 257 to nucleotide 607;

(c) the nucleotide sequence of SEQ ID NO: 11 from nucleotide 479 to nucleotide 607;

(d) the nucleotide sequence of the full-length protein coding sequence of clone vp21_l deposited with the ATCC under accession number 207114;

(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vp21_l deposited with the ATCC under accession number 207114;

(f) the nucleotide sequence of a mature protein coding sequence of clone vp21_l deposited with the ATCC under accession number 207114;

(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vp21_l deposited with the ATCC under accession number 207114;

(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO: 12;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 12, the fragment comprising eight contiguous amino acids of SEQ ID NO: 12;

(k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one ofthe polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO: 11.

21. A protein comprising an amino acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ID NO: 12;

(c) the amino acid sequence encoded by the cDNA insert of clone vp21_l deposited with the ATCC under accession number 207114; the protein being substantially free from other mammalian proteins.

22. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO: 13;

(b) the nucleotide sequence of SEQ ID NO: 13 from nucleotide 163 to nucleotide 477;

(c) the nucleotide sequence of SEQ ID NO: 13 from nucleotide 238 to nucleotide 477;

(d) the nucleotide sequence of the full-length protein coding sequence of clone vp22_l deposited with the ATCC under accession number 207114;

(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vp22_l deposited with the ATCC under accession number 207114;

(f) the nucleotide sequence of a mature protein coding sequence of clone vp22_l deposited with the ATCC under accession number 207114;

(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vp22_l deposited with the ATCC under accession number 207114;

(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO: 14;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 14, the fragment comprising eight contiguous amino acids of SEQ ID NO: 14;

(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one ofthe polynucleotides specified by (a)-(g); and (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one ofthe polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO: 13.

23. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO: 14;

(b) a fragment of the amino acid sequence of SEQ ID NO: 14, the fragment comprising eight contiguous amino acids of SEQ ID NO: 14; and

(c) the amino acid sequence encoded by the cDNA insert of clone vp22_l deposited with the ATCC under accession number 207114; the protein being substantially free from other mammalian proteins.

24. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO: 15;

(b) the nucleotide sequence of SEQ ID NOJ 5 from nucleotide 58 to nucleotide 624;

(c) the nucleotide sequence of SEQ ID NOJ 5 from nucleotide 106 to nucleotide 624;

(d) the nucleotide sequence of the full-length protein coding sequence of clone vq2_l deposited with the ATCC under accession number 207114;

(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vq2_l deposited with the ATCC under accession number 207114;

(f) the nucleotide sequence of a mature protein coding sequence of clone vq2_l deposited with the ATCC under accession number 207114;

(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vq2_l deposited with the ATCC under accession number 207114; (h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO: 16;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 16, the fragment comprising eight contiguous amino acids of SEQ ID NO: 16;

(k) the nucleotide. sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one ofthe polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO: 15.

25. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO: 16;

(c) the amino acid sequence encoded by the cDNA insert of clone vq2_l deposited with the ATCC under accession number 207114; the protein being substantially free from other mammalian proteins.

26. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO: 17;

(b) the nucleotide sequence of SEQ ID NO: 17 from nucleotide 773 to nucleotide 1090;

(c) the nucleotide sequence of SEQ ID NO: 17 from nucleotide 842 to nucleotide 1090;

(d) the nucleotide sequence of the full-length protein coding sequence of clone vq3_l deposited with the ATCC under accession number 207114; (e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vq3_l deposited with the ATCC under accession number 207114;

(f) the nucleotide sequence of a mature protein coding sequence of clone vq3_J deposited with the ATCC under accession number 207114;

(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vq3_J deposited with the ATCC under accession number 207114;

(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO: 18;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 18, the fragment comprising eight contiguous amino acids of SEQ ID NO: 18;

(k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one ofthe polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO: 17.

27. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO: 18;

(b) a fragment of the amino acid sequence of SEQ ID NO: 18, the fragment comprising eight contiguous amino acids of SEQ ID NO: 18; and

(c) the amino acid sequence encoded by the cDNA insert of clone vq3_l deposited with the ATCC under accession number 207114; the protein being substantially free from other mammalian proteins.

28. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of: (a) the nucleotide sequence of SEQ ID NO: 19;

(b) the nucleotide sequence of SEQ ID NO: 19 from nucleotide 96 to nucleotide 275;

(c) the nucleotide sequence of SEQ ID NO: 19 from nucleotide 159 to nucleotide 275;

(d) the nucleotide sequence of the full-length protein coding sequence of clone vq5_l deposited with the ATCC under accession number 207114;

(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vq5_ l deposited with the ATCC under accession number 207114;

(f) the nucleotide sequence of a mature protein coding sequence of clone vq5_l deposited with the ATCC under accession number 207114;

(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vq5_l deposited with the ATCC under accession number 207114;

(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:20;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:20, the fragment comprising eight contiguous amino acids of SEQ ID NO:20;

(k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one ofthe polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO: 19.

29. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO: 20; (b) a fragment of the amino acid sequence of SEQ ID NO:20, the fragment comprising eight contiguous amino acids of SEQ ID NO:20; and

(c) the amino acid sequence encoded by the cDNA insert of clone vq5_J deposited with the ATCC under accession number 207114; the protein being substantially free from other mammalian proteins.

30. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO:21 ;

(b) the nucleotide sequence of SEQ ID NO:21 from nucleotide 176 to nucleotide 340;

(c) the nucleotide sequence of SEQ ID NO:21 from nucleotide 230 to nucleotide 340;

(d) the nucleotide sequence of the full-length protein coding sequence of clone vq6_l deposited with the ATCC under accession number 207114;

(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vq6_l deposited with the ATCC under accession number 207114;

(f) the nucleotide sequence of a mature protein coding sequence of clone vq6_l deposited with the ATCC under accession number 207114;

(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vq6_l deposited with the ATCC under accession number 207114;

(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:22;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:22, the fragment comprising eight contiguous amino acids of SEQ ID NO:22;

(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one ofthe polynucleotides specified by (a)-(g); and (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one ofthe polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:21.

31. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:22;

(b) a fragment of the amino acid sequence of SEQ ID NO:22, the fragment comprising eight contiguous amino acids of SEQ ID NO: 22; and

(c) the amino acid sequence encoded by the cDNA insert of clone vq6_l deposited with the ATCC under accession number 207114; the protein being substantially free from other mammalian proteins.

32. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO:23;

(b) the nucleotide sequence of SEQ ID NO:23 from nucleotide 29 to nucleotide 1111;

(c) the nucleotide sequence of SEQ ID NO: 23 from nucleotide 167 to nucleotide 1111;

(d) the nucleotide sequence of the full-length protein coding sequence of clone vrl_l deposited with the ATCC under accession number 207114;

(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vrl_l deposited with the ATCC under accession number 207114;

(f) the nucleotide sequence of a mature protein coding sequence of clone vrl_l deposited with the ATCC under accession number 207114;

(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vrl_l deposited with the ATCC under accession number 207114; (h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:24;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:24, the fragment comprising eight contiguous amino acids of SEQ ID NO: 24;

(k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one ofthe polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:23.

33. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:24;

(c) the amino acid sequence encoded by the cDNA insert of clone vrl_l deposited with the ATCC under accession number 207114; the protein being substantially free from other mammalian proteins.

34. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO:25;

(b) the nucleotide sequence of SEQ ID NO:25 from nucleotide 13 to nucleotide 513;

(c) the nucleotide sequence of the full-length protein coding sequence of clone vc63_J deposited with the ATCC under accession number 207115;

(d) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vc63_l deposited with the ATCC under accession number 207115; (e) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:26;

(f) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:26, the fragment comprising eight contiguous amino acids of SEQ ID NO:26;

(g) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one ofthe polynucleotides specified by (a)-(d); and

(h) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one ofthe polynucleotides specified by (a)-(d), and that has a length that is at least 25% of the length of SEQ ID NO:25.

35. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:26;

(c) the amino acid sequence encoded by the cDNA insert of clone vc63_l deposited with the ATCC under accession number 207115; the protein being substantially free from other mammalian proteins.

36. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO: 27;

(b) the nucleotide sequence of SEQ ID NO:27 from nucleotide 79 to nucleotide 345;

(c) the nucleotide sequence of SEQ ID NO: 27 from nucleotide 130 to nucleotide 345;

(d) the nucleotide sequence of the full-length protein coding sequence of clone vb25_l deposited with the ATCC under accession number PTA-362; (e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vb25_l deposited with the ATCC under accession number PTA-362;

(f) the nucleotide sequence of a mature protein coding sequence of clone vb25_l deposited with the ATCC under accession number PTA-362;

(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vb25_l deposited with the ATCC under accession number PTA-362;

(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:28;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:28, the fragment comprising eight contiguous amino acids of SEQ ID NO:28;

(k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one ofthe polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:27.

37. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:28;

(b) a fragment of the amino acid sequence of SEQ ID NO:28, the fragment comprising eight contiguous amino acids of SEQ ID NO:28; and

(c) the amino acid sequence encoded by the cDNA insert of clone vb25_l deposited with the ATCC under accession number PTA-362; the protein being substantially free from other mammalian proteins.

38. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of: (a) the nucleotide sequence of SEQ ID NO:29;

(b) the nucleotide sequence of SEQ ID NO:29 from nucleotide 72 to nucleotide 236;

(c) the nucleotide sequence of SEQ ID NO:29 from nucleotide 150 to nucleotide 236;

(d) the nucleotide sequence of the full-length protein coding sequence of clone vb27_l deposited with the ATCC under accession number PTA-362;

(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vb27_l deposited with the ATCC under accession number PTA-362;

(f) the nucleotide sequence of a mature protein coding sequence of clone vb27_J deposited with the ATCC under accession number PTA-362;

(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vb27_l deposited with the ATCC under accession number PTA-362;

(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO: 30;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:30, the fragment comprising eight contiguous amino acids of SEQ ID NO:30;

(k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one ofthe polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:29.

39. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:30; (b) a fragment of the amino acid sequence of SEQ ID NO:30, the fragment comprising eight contiguous amino acids of SEQ ID NO:30; and

(c) the amino acid sequence encoded by the cDNA insert of clone vb27_l deposited with the ATCC under accession number PTA-362; the protein being substantially free from other mammalian proteins.

40. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO:31 ;

(b) the nucleotide sequence of SEQ ID NO:31 from nucleotide 135 to nucleotide 884;

(c) the nucleotide sequence of SEQ ID NO: 31 from nucleotide 183 to nucleotide 884;

(d) the nucleotide sequence of the full-length protein coding sequence of clone vb28_l deposited with the ATCC under accession number PTA-362;

(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vb28_l deposited with the ATCC under accession number PTA-362;

(f) the nucleotide sequence of a mature protein coding sequence of clone vb28_l deposited with the ATCC under accession number PTA-362;

(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vb28_l deposited with the ATCC under accession number PTA-362;

(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:32;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:32, the fragment comprising eight contiguous amino acids of SEQ ID NO:32;

(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one ofthe polynucleotides specified by (a)-(g); and (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one ofthe polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:31.

41. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:32;

(b) a fragment of the amino acid sequence of SEQ ID NO:32, the fragment comprising eight contiguous amino acids of SEQ ID NO:32; and

(c) the amino acid sequence encoded by the cDNA insert of clone vb28_l deposited with the ATCC under accession number PTA-362; the protein being substantially free from other mammalian proteins.

42. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO:33;

(b) the nucleotide sequence of SEQ ID NO:33 from nucleotide 42 to nucleotide 206;

(c) the nucleotide sequence of SEQ ID NO: 33 from nucleotide 111 to nucleotide 206;

(d) the nucleotide sequence of the full-length protein coding sequence of clone vb29_l deposited with the ATCC under accession number PTA-362;

(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vb29_l deposited with the ATCC under accession number PTA-362;

(f) the nucleotide sequence of a mature protein coding sequence of clone vb29_l deposited with the ATCC under accession number PTA-362;

(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vb29_l deposited with the ATCC under accession number PTA-362; (h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:34;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:34, the fragment comprising eight contiguous amino acids of SEQ ID NO:34;

(k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one ofthe polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:33.

43. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:34;

(b) a fragment of the amino acid sequence of SEQ ID NO:34, the fragment comprising eight contiguous amino acids of SEQ ID NO: 34; and

(c) the amino acid sequence encoded by the cDNA insert of clone vb29_l deposited with the ATCC under accession number PTA-362; the protein being substantially free from other mammalian proteins.

44. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:35;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:35 from nucleotide 98 to nucleotide 253; (d) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone vb30_l deposited with the ATCC under accession number PTA-362;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vb30_l deposited with the ATCC under accession number PTA-362;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vb30_l deposited with the ATCC under accession number PTA-362;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vb30_l deposited with the ATCC under accession number PTA- 362;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:36;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:35.

45. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:36;

(b) a fragment of the amino acid sequence of SEQ ID NO:36, the fragment comprising eight contiguous amino acids of SEQ ID NO:36; and (c) the amino acid sequence encoded by the cDNA insert of clone vb30_l deposited with the ATCC under accession number PTA-362; the protein being substantially free from other mammalian proteins.

46. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO: 37;

(b) the nucleotide sequence of SEQ ID NO:37 from nucleotide 68 to nucleotide 424;

(c) the nucleotide sequence ofthe full-length protein coding sequence of clone vc67_l deposited with the ATCC under accession number PTA-362;

(d) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vc67_l deposited with the ATCC under accession number PTA-362;

(e) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:38;

(f) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:38, the fragment comprising eight contiguous amino acids of SEQ ID NO:38;

(h) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one ofthe polynucleotides specified by (a)-(d), and that has a length that is at least 25% of the length of SEQ ID NO:37.

47. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:38;

(b) a fragment of the amino acid sequence of SEQ ID NO:38, the fragment comprising eight contiguous amino acids of SEQ ID NO:38; and (c) the amino acid sequence encoded by the cDNA insert of clone vc67_J deposited with the ATCC under accession number PTA-362; the protein being substantially free from other mammalian proteins.

48. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO:39;

(b) the nucleotide sequence of SEQ ID NO:39 from nucleotide 103 to nucleotide 261;

(c) the nucleotide sequence of SEQ ID NO:39 from nucleotide 154 to nucleotide 261;

(d) the nucleotide sequence of the full-length protein coding sequence of clone vf4_l deposited with the ATCC under accession number PTA-362;

(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vf4_l deposited with the ATCC under accession number PTA-362;

(f) the nucleotide sequence of a mature protein coding sequence of clone vf4_l deposited with the ATCC under accession number PTA-362;

(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vf4_l deposited with the ATCC under accession number PTA-362;

(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:40;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:40, the fragment comprising eight contiguous amino acids of SEQ ID NO:40;

(k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one ofthe polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:39.

49. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:40;

(b) a fragment of the amino acid sequence of SEQ ID NO:40, the fragment comprising eight contiguous amino acids of SEQ ID NO:40; and

(c) the amino acid sequence encoded by the cDNA insert of clone vf4_l deposited with the ATCC under accession number PTA-362; the protein being substantially free from other mammalian proteins.

50. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO:41 ;

(b) the nucleotide sequence of SEQ ID NO:41 from nucleotide 1575 to nucleotide 3038;

(c) the nucleotide sequence of SEQ ID NO :41 from nucleotide 1650 to nucleotide 3038;

(d) the nucleotide sequence of the full-length protein coding sequence of clone vg3_l deposited with the ATCC under accession number PTA-362;

(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vg3_l deposited with the ATCC under accession number PTA-362;

(f) the nucleotide sequence of a mature protein coding sequence of clone vg3_l deposited with the ATCC under accession number PTA-362;

(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vg3_l deposited with the ATCC under accession number PTA-362;

(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:42; (i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:42, the fragment comprising eight contiguous amino acids of SEQ ID NO:42;

(k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one ofthe polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:41.

51. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:42;

(c) the amino acid sequence encoded by the cDNA insert of clone vg3_l deposited with the ATCC under accession number PTA-362; the protein being substantially free from other mammalian proteins.

52. An isolated polynucleotide comprising anucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO:43;

(b) the nucleotide sequence of SEQ ID NO:43 from nucleotide 2112 to nucleotide 2363;

(c) the nucleotide sequence of the full-length protein coding sequence of clone vo2_l deposited with the ATCC under accession number PTA-362;

(d) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vo2_l deposited with the ATCC under accession number PTA-362;

(e) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:44; (f) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:44, the fragment comprising eight contiguous amino acids of SEQ ID NO:44;

(h) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one ofthe polynucleotides specified by (a)-(d), and that has a length that is at least 25% of the length of SEQ ID NO:43.

53. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:44;

(b) a fragment of the amino acid sequence of SEQ ID NO:44, the fragment comprising eight contiguous amino acids of SEQ ID NO:44; and

(c) the amino acid sequence encoded by the cDNA insert of clone vo2_l deposited with the ATCC under accession number PTA-362; the protein being substantially free from other mammalian proteins.

54. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO:45;

(b) the nucleotide sequence of SEQ ID NO:45 from nucleotide 36 to nucleotide 707;

(c) the nucleotide sequence of SEQ ID NO:45 from nucleotide 393 to nucleotide 707;

(d) the nucleotide sequence of the full-length protein coding sequence of clone vo3_l deposited with the ATCC under accession number PTA-362;

(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vo3_l deposited with the ATCC under accession number PTA-362; (f) the nucleotide sequence of a mature protein coding sequence of clone vo3_l deposited with the ATCC under accession number PTA-362;

(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vo3_l deposited with the ATCC under accession number PTA-362;

(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:46;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:46, the fragment comprising eight contiguous amino acids of SEQ ID NO:46;

(k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one ofthe polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:45.

55. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:46;

(b) a fragment of the amino acid sequence of SEQ ID NO:46, the fragment comprising eight contiguous amino acids of SEQ ID NO:46; and

(c) the amino acid sequence encoded by the cDNA insert of clone vo3_l deposited with the ATCC under accession number PTA-362; the protein being substantially free from other mammalian proteins.

56. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO:47;

(b) the nucleotide sequence of SEQ ID NO:47 from nucleotide 74 to nucleotide 295; (c) the nucleotide sequence of SEQ ID NO:47 from nucleotide 134 to nucleotide 295;

(d) the nucleotide sequence of the full-length protein coding sequence of clone vo5_l deposited with the ATCC under accession number PTA-362;

(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vo5_l deposited with the ATCC under accession number PTA-362;

(f) the nucleotide sequence of a mature protein coding sequence of clone vo5_l deposited with the ATCC under accession number PTA-362;

(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vo5_J deposited with the ATCC under accession number PTA-362;

(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:48;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:48, the fragment comprising eight contiguous amino acids of SEQ ID NO:48;

(k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one ofthe polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:47.

57. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO: 48;

(c) the amino acid sequence encoded by the cDNA insert of clone vo5_l deposited with the ATCC under accession number PTA-362; the protein being substantially free from other mammalian proteins.

58. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO:49;

(b) the nucleotide sequence of SEQ ID NO:49 from nucleotide 45 to nucleotide 383;

(c) the nucleotide sequence of SEQ ID NO:49 from nucleotide 312 to nucleotide 383;

(d) the nucleotide sequence of the full-length protein coding sequence of clone vo6_l deposited with the ATCC under accession number PTA-362;

(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vo6_l deposited with the ATCC under accession number PTA-362;

(f) the nucleotide sequence of a mature protein coding sequence of clone vo6_l deposited with the ATCC under accession number PTA-362;

(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vo6_l deposited with the ATCC under accession number PTA-362;

(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:50;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:50, the fragment comprising eight contiguous amino acids of SEQ ID NO:50;

(k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one ofthe polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:49.

59. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:50;

(b) a fragment of the amino acid sequence of SEQ ID NO:50, the fragment comprising eight contiguous amino acids of SEQ ID NO:50; and

(c) the amino acid sequence encoded by the cDNA insert of clone vo6_l deposited with the ATCC under accession number PTA-362; the protein being substantially free from other mammalian proteins.

60. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO:51 ;

(b) the nucleotide sequence of SEQ ID NO: 51 from nucleotide 186 to nucleotide 1739;

(c) the nucleotide sequence of SEQ ID NO:51 from nucleotide 288 to nucleotide 1739;

(d) the nucleotide sequence of the full-length protein coding sequence of clone vo9_J deposited with the ATCC under accession number PTA-362;

(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vo9_J deposited with the ATCC under accession number PTA-362;

(f) the nucleotide sequence of a mature protein coding sequence of clone vo9_l deposited with the ATCC under accession number PTA-362;

(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vo9_l deposited with the ATCC under accession number PTA-362;

(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:52;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:52, the fragment comprising eight contiguous amino acids of SEQ ID NO:52; (j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one ofthe polynucleotides specified by (a)-(g); and

(k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one ofthe polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:51.

61. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO: 52;

(b) a fragment of the amino acid sequence of SEQ ID NO:52, the fragment comprising eight contiguous amino acids of SEQ ID NO:52; and

(c) the amino acid sequence encoded by the cDNA insert of clone vo9_l deposited with the ATCC under accession number PTA-362; the protein being substantially free from other mammalian proteins.

62. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO:53;

(b) the nucleotide sequence of SEQ ID NO:53 from nucleotide 440 to nucleotide 835;

(c) the nucleotide sequence of SEQ ID NO:53 from nucleotide 632 to nucleotide 835;

(d) the nucleotide sequence of the full-length protein coding sequence of clone vol l_l deposited with the ATCC under accession number PTA-366;

(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vol l_l deposited with the ATCC under accession number PTA-366;

(f) the nucleotide sequence of a mature protein coding sequence of clone vol 1_1 deposited with the ATCC under accession number PTA-366; (g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vol 1_1 deposited with the ATCC under accession number PTA-366;

(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:54;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 54, the fragment comprising eight contiguous amino acids of SEQ ID NO:54;

(k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one ofthe polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:53.

63. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:54;

(b) a fragment of the amino acid sequence of SEQ ID NO:54, the fragment comprising eight contiguous amino acids of SEQ ID NO:54; and

(c) the amino acid sequence encoded by the cDNA insert of clone vol 1_1 deposited with the ATCC under accession number PTA-366; the protein being substantially free from other mammalian proteins.

64. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO:55;

(b) the nucleotide sequence of SEQ ID NO:55 from nucleotide 72 to nucleotide 329;

(c) the nucleotide sequence of SEQ ID NO: 55 from nucleotide 120 to nucleotide 329; (d) the nucleotide sequence of the full-length protein coding sequence of clone vol2_l deposited with the ATCC under accession number PTA-366;

(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vol2_l deposited with the ATCC under accession number PTA-366;

(f) the nucleotide sequence of a mature protein coding sequence of clone vol2_l deposited with the ATCC under accession number PTA-366;

(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vol2_l deposited with the ATCC under accession number PTA-366;

(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:56;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:56, the fragment comprising eight contiguous amino acids of SEQ ID NO:56;

(k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one ofthe polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:55.

65. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:56;

(c) the amino acid sequence encoded by the cDNA insert of clone vol2_l deposited with the ATCC under accession number PTA-366; the protein being substantially free from other mammalian proteins.

66. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO:57;

(b) the nucleotide sequence of SEQ ID NO:57 from nucleotide 227 to nucleotide 439;

(c) the nucleotide sequence of SEQ ID NO:57 from nucleotide 287 to nucleotide 439;

(d) the nucleotide sequence of the full-length protein coding sequence of clone vol3_l deposited with the ATCC under accession number PTA-366;

(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vol3_l deposited with the ATCC under accession number PTA-366;

(f) the nucleotide sequence of a mature protein coding sequence of clone vol3_l deposited with the ATCC under accession number PTA-366;

(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vol3_l deposited with the ATCC under accession number PTA-366;

(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:58;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:58, the fragment comprising eight contiguous amino acids of SEQ ID NO: 58;

(k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one ofthe polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:57.

67. A protein comprising an amino acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ID NO:58;

(b) a fragment of the amino acid sequence of SEQ ID NO:58, the fragment comprising eight contiguous amino acids of SEQ ID NO:58; and

(c) the amino acid sequence encoded by the cDNA insert of clone vol3_l deposited with the ATCC under accession number PTA-366; the protein being substantially free from other mammalian proteins.

68. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO:59;

(b) the nucleotide sequence of SEQ ID NO:59 from nucleotide 96 to nucleotide 341;

(c) the nucleotide sequence of SEQ ID NO: 59 from nucleotide 174 to nucleotide 341;

(d) the nucleotide sequence of the full-length protein coding sequence of clone vol4_l deposited with the ATCC under accession number PTA-366;

(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vol4_l deposited with the ATCC under accession number PTA-366;

(f) the nucleotide sequence of a mature protein coding sequence of clone vol4_l deposited with the ATCC under accession number PTA-366;

(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vol4_l deposited with the ATCC under accession number PTA-366;

(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:60;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:60, the fragment comprising eight contiguous amino acids of SEQ ID NO:60;

(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one ofthe polynucleotides specified by (a)-(g); and (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one ofthe polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:59.

69. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:60;

(b) a fragment of the amino acid sequence of SEQ ID NO:60, the fragment comprising eight contiguous amino acids of SEQ ID NO:60; and

(c) the amino acid sequence encoded by the cDNA insert of clone vol4_l deposited with the ATCC under accession number PTA-366; the protein being substantially free from other mammalian proteins.

70. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO : 61 ;

(b) the nucleotide sequence of SEQ ID NO: 61 from nucleotide 90 to nucleotide 599;

(c) the nucleotide sequence of SEQ ID NO: 61 from nucleotide 165 to nucleotide 599;

(d) the nucleotide sequence of the full-length protein coding sequence of clone vol5_l deposited with the ATCC under accession number PTA-366;

(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vol5_l deposited with the ATCC under accession number PTA-366;

(f) the nucleotide sequence of a mature protein coding sequence of clone vol5_l deposited with the ATCC under accession number PTA-366;

(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vol5_l deposited with the ATCC under accession number PTA-366; (h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:62;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:62, the fragment comprising eight contiguous amino acids of SEQ ID NO:62;

(k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one ofthe polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:61.

71. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:62;

(b) a fragment of the amino acid sequence of SEQ ID NO:62, the fragment comprising eight contiguous amino acids of SEQ ID NO:62; and

(c) the amino acid sequence encoded by the cDNA insert of clone vol5_l deposited with the ATCC under accession number PTA-366; the protein being substantially free from other mammalian proteins.

72. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO: 63;

(b) the nucleotide sequence of SEQ ID NO: 63 from nucleotide 209 to nucleotide 451 ;

(c) the nucleotide sequence of SEQ ID NO:63 from nucleotide 398 to nucleotide 451 ;

(d) the nucleotide sequence of the full-length protein coding sequence of clone vol6_l deposited with the ATCC under accession number PTA-366; (e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vol6_l deposited with the ATCC under accession number PTA-366;

(f) the nucleotide sequence of a mature protein coding sequence of clone vol6_l deposited with the ATCC under accession number PTA-366;

(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vol6_l deposited with the ATCC under accession number PTA-366;

(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:64;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:64, the fragment comprising eight contiguous amino acids of SEQ ID NO: 64;

(k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one ofthe polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:63.

73. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:64;

(b) a fragment of the amino acid sequence of SEQ ID NO: 64, the fragment comprising eight contiguous amino acids of SEQ ID NO:64; and

(c) the amino acid sequence encoded by the cDNA insert of clone vol6_l deposited with the ATCC under accession number PTA-366; the protein being substantially free from other mammalian proteins.

74. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of: (a) the nucleotide sequence of SEQ ID NO:65;

(b) the nucleotide sequence of SEQ ID NO:65 from nucleotide 31 to nucleotide 231 ;

(c) the nucleotide sequence of SEQ ID NO:65 from nucleotide 97 to nucleotide 231 ;

(d) the nucleotide sequence of the full-length protein coding sequence of clone vol8_l deposited with the ATCC under accession number PTA-366;

(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vol8_l deposited with the ATCC under accession number PTA-366;

(f) the nucleotide sequence of a mature protein coding sequence of clone vol8_l deposited with the ATCC under accession number PTA-366;

(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vol8_l deposited with the ATCC under accession number PTA-366;

(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:66;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:66, the fragment comprising eight contiguous amino acids of SEQ ID NO:66;

(k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one ofthe polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:65.

75. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:66; (b) a fragment of the amino acid sequence of SEQ ID NO:66, the fragment comprising eight contiguous amino acids of SEQ ID NO:66; and

(c) the amino acid sequence encoded by the cDNA insert of clone vol8_l deposited with the ATCC under accession number PTA-366; the protein being substantially free from other mammalian proteins.

76. An isolated polynucleotide comprising anucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO:67;

(b) the nucleotide sequence of SEQ ID NO: 67 from nucleotide 23 to nucleotide 736;

(c) the nucleotide sequence of SEQ ID NO: 67 from nucleotide 83 to nucleotide 736;

(d) the nucleotide sequence of the full-length protein coding sequence of clone vol9_l deposited with the ATCC under accession number PTA-366;

(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vol9_l deposited with the ATCC under accession number PTA-366;

(f) the nucleotide sequence of a mature protein coding sequence of clone vol9_l deposited with the ATCC under accession number PTA-366;

(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vol9_l deposited with the ATCC under accession number PTA-366;

(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:68;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:68, the fragment comprising eight contiguous amino acids of SEQ ID NO:68;

(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one ofthe polynucleotides specified by (a)-(g); and (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one ofthe polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:67.

77. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO: 68;

(b) a fragment of the amino acid sequence of SEQ ID NO: 68, the fragment comprising eight contiguous amino acids of SEQ ID NO:68; and

(c) the amino acid sequence encoded by the cDNA insert of clone vol9_l deposited with the ATCC under accession number PTA-366; the protein being substantially free from other mammalian proteins.

78. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO:69;

(b) the nucleotide sequence of SEQ ID NO: 69 from nucleotide 104 to nucleotide 1399;

(c) the nucleotide sequence of SEQ ID NO: 69 from nucleotide 158 to nucleotide 1399;

(d) the nucleotide sequence of the full-length protein coding sequence of clone vo22_l deposited with the ATCC under accession number PTA-366;

(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vo22_l deposited with the ATCC under accession number PTA-366;

(f) the nucleotide sequence of a mature protein coding sequence of clone vo22_l deposited with the ATCC under accession number PTA-366;

(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vo22_l deposited with the ATCC under accession number PTA-366; (h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:70;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:70, the fragment comprising eight contiguous amino acids of SEQ ID NO:70;

(k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one ofthe polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:69.

79. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:70;

(b) a fragment of the amino acid sequence of SEQ ID NO:70, the fragment comprising eight contiguous amino acids of SEQ ID NO: 70; and

(c) the amino acid sequence encoded by the cDNA insert of clone vo22_l deposited with the ATCC under accession number PTA-366; the protein being substantially free from other mammalian proteins.

80. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO:71 ;

(b) the nucleotide sequence of SEQ ID NO: 71 from nucleotide 174 to nucleotide 1595;

(c) the nucleotide sequence of the full-length protein coding sequence of clone vo23_l deposited with the ATCC under accession number PTA-366;

(d) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vo23_l deposited with the ATCC under accession number PTA-366; (e) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:72;

(f) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:72, the fragment comprising eight contiguous amino acids of SEQ ID NO: 72;

(h) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one ofthe polynucleotides specified by (a)-(d), and that has a length that is at least 25% of the length of SEQ ID NO:71.

81. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:72;

(b) a fragment of the amino acid sequence of SEQ ID NO:72, the fragment comprising eight contiguous amino acids of SEQ ID NO: 72; and

(c) the amino acid sequence encoded by the cDNA insert of clone vo23_l deposited with the ATCC under accession number PTA-366; the protein being substantially free from other mammalian proteins.

82. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO:73;

(b) the nucleotide sequence of SEQ ID NO:73 from nucleotide 129 to nucleotide 311;

(c) the nucleotide sequence of SEQ ID NO:73 from nucleotide 195 to nucleotide 311;

(d) the nucleotide sequence of the full-length protein coding sequence of clone vo24_l deposited with the ATCC under accession number PTA-366; (e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vo24_l deposited with the ATCC under accession number PTA-366;

(f) the nucleotide sequence of a mature protein coding sequence of clone vo24_l deposited with the ATCC under accession number PTA-366;

(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vo24_l deposited with the ATCC under accession number PTA-366;

(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:74;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:74, the fragment comprising eight contiguous amino acids of SEQ ID NO: 74;

(k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one ofthe polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:73.

83. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:74;

(b) a fragment of the amino acid sequence of SEQ ID NO:74, the fragment comprising eight contiguous amino acids of SEQ ID NO:74; and

(c) the amino acid sequence encoded by the cDNA insert of clone vo24_l deposited with the ATCC under accession number PTA-366; the protein being substantially free from other mammalian proteins.

84. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of: (a) the nucleotide sequence of SEQ ID NO:75;

(b) the nucleotide sequence of SEQ ID NO:75 from nucleotide 73 to nucleotide 798;

(c) the nucleotide sequence of SEQ ID NO:75 from nucleotide 142 to nucleotide 798;

(d) the nucleotide sequence of the full-length protein coding sequence of clone vo25_l deposited with the ATCC under accession number PTA-366;

(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vo25_l deposited with the ATCC under accession number PTA-366;

(f) the nucleotide sequence of a mature protein coding sequence of clone vo25_l deposited with the ATCC under accession number PTA-366;

(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vo25_l deposited with the ATCC under accession number PTA-366;

(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:76;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:76, the fragment comprising eight contiguous amino acids of SEQ ID NO:76;

(k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one ofthe polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:75.

85. A protein comprising an amino acid sequence selected from the group consisting of:

(c) the amino acid sequence encoded by the cDNA insert of clone vo25_l deposited with the ATCC under accession number PTA-366; the protein being substantially free from other mammalian proteins.

86. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO:27;

(b) the nucleotide sequence of SEQ ID NO: 27 from nucleotide 26 to nucleotide 307;

(c) the nucleotide sequence of SEQ ID NO:27 from nucleotide 101 to nucleotide 307;

(d) the nucleotide sequence of the full-length protein coding sequence of clone vo26_l deposited with the ATCC under accession number PTA-366;

(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vo26_l deposited with the ATCC under accession number PTA-366;

(f) the nucleotide sequence of a mature protein coding sequence of clone vo26_l deposited with the ATCC under accession number PTA-366;

(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vo26_l deposited with the ATCC under accession number PTA-366;

(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:78;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:78, the fragment comprising eight contiguous amino acids of SEQ ID NO:78;

(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one ofthe polynucleotides specified by (a)-(g); and (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one ofthe polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:27.

87. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:78;

(b) a fragment of the amino acid sequence of SEQ ID NO:78, the fragment comprising eight contiguous amino acids of SEQ ID NO:78; and

(c) the amino acid sequence encoded by the cDNA insert of clone vo26_l deposited with the ATCC under accession number PTA-366; the protein being substantially free from other mammalian proteins.

88. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO:79;

(b) the nucleotide sequence of SEQ ID NO:79 from nucleotide 43 to nucleotide 228;

(c) the nucleotide sequence of SEQ ID NO:79 from nucleotide 94 to nucleotide 228;

(d) the nucleotide sequence of the full-length protein coding sequence of clone vp23_l deposited with the ATCC under accession number PTA-368;

(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vp23_l deposited with the ATCC under accession number PTA-368;

(f) the nucleotide sequence of a mature protein coding sequence of clone vp23_l deposited with the ATCC under accession number PTA-368;

(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vp23_l deposited with the ATCC under accession number PTA-368; (h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:80;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 80, the fragment comprising eight contiguous amino acids of SEQ ID NO:80;

(k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one ofthe polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:79.

89. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:80;

(c) the amino acid sequence encoded by the cDNA insert of clone vp23_l deposited with the ATCC under accession number PTA-368; the protein being substantially free from other mammalian proteins.

90. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO: 81 ;

(b) the nucleotide sequence of SEQ ID NO: 81 from nucleotide 245 to nucleotide 427;

(c) the nucleotide sequence of SEQ ID NO:81 from nucleotide 308 to nucleotide 427;

(d) the nucleotide sequence of the full-length protein coding sequence of clone vq7_l deposited with the ATCC under accession number PTA-368; (e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vq7_l deposited with the ATCC under accession number PTA-368;

(f) the nucleotide sequence of a mature protein coding sequence of clone vq7_l deposited with the ATCC under accession number PTA-368;

(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vq7_l deposited with the ATCC under accession number PTA-368;

(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:82;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:82, the fragment comprising eight contiguous amino acids of SEQ ID NO:82;

(k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one ofthe polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:81.

91. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO: 82;

(b) a fragment of the amino acid sequence of SEQ ID NO:82, the fragment comprising eight contiguous amino acids of SEQ ID NO:82; and

(c) the amino acid sequence encoded by the cDNA insert of clone vq7_l deposited with the ATCC under accession number PTA-368; the protein being substantially free from other mammalian proteins.

92. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of: (a) the nucleotide sequence of SEQ ID NO:83;

(b) the nucleotide sequence of SEQ ID NO:83 from nucleotide 119 to nucleotide 475;

(c) the nucleotide sequence of SEQ ID NO:83 from nucleotide 185 to nucleotide 475;

(d) the nucleotide sequence of the full-length protein coding sequence of clone vq8_l deposited with the ATCC under accession number PTA-368;

(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vq8_l deposited with the ATCC under accession number PTA-368;

(f) the nucleotide sequence of a mature protein coding sequence of clone vq8_l deposited with the ATCC under accession number PTA-368;

(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vq8_l deposited with the ATCC under accession number PTA-368;

(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO: 84;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 84, the fragment comprising eight contiguous amino acids of SEQ ID NO: 84;

(k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one ofthe polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:83.

93. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:84; (b) a fragment of the amino acid sequence of SEQ ID NO:84, the fragment comprising eight contiguous amino acids of SEQ ID NO:84; and

(c) the amino acid sequence encoded by the cDNA insert of clone vq8_l deposited with the ATCC under accession number PTA-368; the protein being substantially free from other mammalian proteins.

94. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO:85;

(b) the nucleotide sequence of SEQ ID NO:85 from nucleotide 90 to nucleotide 323;

(c) the nucleotide sequence of SEQ ID NO: 85 from nucleotide 141 to nucleotide 323;

(d) the nucleotide sequence of the full-length protein coding sequence of clone vq9_l deposited with the ATCC under accession number PTA-368;

(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vq9_l deposited with the ATCC under accession number PTA-368;

(f) the nucleotide sequence of a mature protein coding sequence of clone vq9_l deposited with the ATCC under accession number PTA-368;

(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vq9_l deposited with the ATCC under accession number PTA-368;

(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:86;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:86, the fragment comprising eight contiguous amino acids of SEQ ID NO: 86;

(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one ofthe polynucleotides specified by (a)-(g); and (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one ofthe polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO: 85.

95. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:86;

(b) a fragment of the amino acid sequence of SEQ ID NO: 86, the fragment comprising eight contiguous amino acids of SEQ ID NO: 86; and

(c) the amino acid sequence encoded by the cDNA insert of clone vq9_J deposited with the ATCC under accession number PTA-368; the protein being substantially free from other mammalian proteins.

96. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO: 87;

(b) the nucleotide sequence of SEQ ID NO:87 from nucleotide 18 to nucleotide 452;

(c) the nucleotide sequence of SEQ ID NO: 87 from nucleotide 72 to nucleotide 452;

(d) the nucleotide sequence of the full-length protein coding sequence of clone vql0_l deposited with the ATCC under accession number PTA-368;

(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vql0_l deposited with the ATCC under accession number PTA-368;

(f) the nucleotide sequence of a mature protein coding sequence of clone vql0_l deposited with the ATCC under accession number PTA-368;

(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vql0_l deposited with the ATCC under accession number PTA-368; (h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:88;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:88, the fragment comprising eight contiguous amino acids of SEQ ID NO:88;

(k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one ofthe polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:87.

97. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:88;

(b) a fragment of the amino acid sequence of SEQ ID NO:88, the fragment comprising eight contiguous amino acids of SEQ ID NO:88; and

(c) the amino acid sequence encoded by the cDNA insert of clone vql0_l deposited with the ATCC under accession number PTA-368; the protein being substantially free from other mammalian proteins.

98. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO: 89;

(b) the nucleotide sequence of SEQ ID NO: 89 from nucleotide 196 to nucleotide 378;

(c) the nucleotide sequence of SEQ ID NO:89 from nucleotide 262 to nucleotide 378;

(d) the nucleotide sequence of the full-length protein coding sequence of clone vql3_l deposited with the ATCC under accession number PTA-368; (e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vql3_l deposited with the ATCC under accession number PTA-368;

(f) the nucleotide sequence of a mature protein coding sequence of clone vql3_l deposited with the ATCC under accession number PTA-368;

(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vql3_l deposited with the ATCC under accession number PTA-368;

(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:90;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:90, the fragment comprising eight contiguous amino acids of SEQ ID NO: 90;

(k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one ofthe polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:89.

99. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:90;

(b) a fragment of the amino acid sequence of SEQ ID NO:90, the fragment comprising eight contiguous amino acids of SEQ ID NO:90; and

(c) the amino acid sequence encoded by the cDNA insert of clone vql3_l deposited with the ATCC under accession number PTA-368; the protein being substantially free from other mammalian proteins.

100. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of: (a) the nucleotide sequence of SEQ ID NO:91 ;

(b) the nucleotide sequence of SEQ ID NO:91 from nucleotide 35 to nucleotide 718;

(c) the nucleotide sequence of SEQ ID NO:91 from nucleotide 173 to nucleotide 718;

(d) the nucleotide sequence of the full-length protein coding sequence of clone vql6_l deposited with the ATCC under accession number PTA-368;

(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone yql6_l deposited with the ATCC under accession number PTA-368;

(f) the nucleotide sequence of a mature protein coding sequence of clone vql6_l deposited with the ATCC under accession number PTA-368;

(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vql6_l deposited with the ATCC under accession number PTA-368;

(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:92;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:92, the fragment comprising eight contiguous amino acids of SEQ ID NO: 92;

(k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one ofthe polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:91.

101. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:92; (b) a fragment of the amino acid sequence of SEQ ID NO:92, the fragment comprising eight contiguous amino acids of SEQ ID NO:92; and

(c) the amino acid sequence encoded by the cDNA insert of clone vql6_l deposited with the ATCC under accession number PTA-368; the protein being substantially free from other mammalian proteins.

102. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide. sequence of SEQ ID NO: 93;

(b) the nucleotide sequence of SEQ ID NO:93 from nucleotide 1 to nucleotide 762;

(c) the nucleotide sequence of SEQ ID NO:93 from nucleotide 70 to nucleotide 762;

(d) the nucleotide sequence of the full-length protein coding sequence of clone vql9_l deposited with the ATCC under accession number PTA-368;

(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vql9_l deposited with the ATCC under accession number PTA-368;

(f) the nucleotide sequence of a mature protein coding sequence of clone vql9_l deposited with the ATCC under accession number PTA-368;

(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vql9_l deposited with the ATCC under accession number PTA-368;

(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:94;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:94, the fragment comprising eight contiguous amino acids of SEQ ID NO: 94;

(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one ofthe polynucleotides specified by (a)-(g); and (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one ofthe polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:93.

103. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:94;

(c) the amino acid sequence encoded by the cDNA insert of clone vql9_l deposited with the ATCC under accession number PTA-368; the protein being substantially free from other mammalian proteins.

104. An isolated polynucleotide comprising anucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO: 95;

(b) the nucleotide sequence of SEQ ID NO:95 from nucleotide 106 to nucleotide 792;

(c) the nucleotide sequence of SEQ ID NO:95 from nucleotide 172 to nucleotide 792;

(d) the nucleotide sequence of the full-length protein coding sequence of clone vq20_l deposited with the ATCC under accession number PTA-368;

(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vq20_l deposited with the ATCC under accession number PTA-368;

(f) the nucleotide sequence of a mature protein coding sequence of clone vq20_J deposited with the ATCC under accession number PTA-368;

(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vq20_l deposited with the ATCC under accession number PTA-368; (h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:96;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:96, the fragment comprising eight contiguous amino acids of SEQ ID NO:96;

(k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one ofthe polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:95.

105. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:96;

(c) the amino acid sequence encoded by the cDNA insert of clone vq20_l deposited with the ATCC under accession number PTA-368; the protein being substantially free from other mammalian proteins.

106. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO:97;

(b) the nucleotide sequence of SEQ ID NO:97 from nucleotide 40 to nucleotide 315;

(c) the nucleotide sequence of SEQ ID NO:97 from nucleotide 124 to nucleotide 315;

(d) the nucleotide sequence of the full-length protein coding sequence of clone vq21_J deposited with the ATCC under accession number PTA-368; (e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vq21_l deposited with the ATCC under accession number PTA-368;

(f) the nucleotide sequence of a mature protein coding sequence of clone vq21_l deposited with the ATCC under accession number PTA-368;

(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vq21_ l deposited with the ATCC under accession number PTA-368;

(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:98;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:98, the fragment comprising eight contiguous amino acids of SEQ ID NO:98;

(k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one ofthe polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:97.

107. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:98;

(b) a fragment of the amino acid sequence of SEQ ID NO:98, the fragment comprising eight contiguous amino acids of SEQ ID NO:98; and

(c) the amino acid sequence encoded by the cDNA insert of clone vq21_l deposited with the ATCC under accession number PTA-368; the protein being substantially free from other mammalian proteins.

108. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of: (a) the nucleotide sequence of SEQ ID NO:99;

(b) the nucleotide sequence of SEQ ID NO:99 from nucleotide 70 to nucleotide 699;

(c) the nucleotide sequence of the full-length protein coding sequence of clone vr2_l deposited with the ATCC under accession number PTA-368;

(d) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vr2_l deposited with the ATCC under accession number PTA-368;

(e) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO: 100;

(f) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 100, the fragment comprising eight contiguous amino acids of SEQ ID NO: 100;

(h) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one ofthe polynucleotides specified by (a)-(d), and that has a length that is at least 25% of the length of SEQ ID NO:99.

109. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO: 100;

(b) a fragment of the amino acid sequence of SEQ ID NO: 100, the fragment comprising eight contiguous amino acids of SEQ ID NO: 100; and

(c) the amino acid sequence encoded by the cDNA insert of clone vr2_l deposited with the ATCC under accession number PTA-368; the protein being substantially free from other mammalian proteins.

110. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of: (a) the nucleotide sequence of SEQ ID NO : 101 ;

(b) the nucleotide sequence of SEQ ID NO: 101 from nucleotide 170to nucleotide 394;

(c) the nucleotide sequence ofSEQ ID NOJOl from nucleotide 227 to nucleotide 394;

(d) the nucleotide sequence of the full-length protein coding sequence of clone PTA- 1075 deposited with the ATCC under accession number PTA- 1075 ;

(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vc69_l deposited with the ATCC under accession number PTA-1075;

(f) the nucleotide sequence of a mature protein coding sequence of clone vc69_l deposited with the ATCC under accession number PTA-1075;

(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vc69_l deposited with the ATCC under accession number PTA-1075;

(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO: 102;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 102, the fragment comprising eight contiguous amino acids of SEQ ID NO: 102;

(k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one ofthe polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO: 101.

111. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO: 102; (b) a fragment of the amino acid sequence of SEQ ID NO: 102, the fragment comprising eight contiguous amino acids of SEQ ID NO: 102; and

(c) the amino acid sequence encoded by the cDNA insert of clone vc69_l deposited with the ATCC under accession number PTA-1075; the protein being substantially free from other mammalian proteins.

112. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO: 103;

(b) the nucleotide sequence of SEQ ID NO: 103 from nucleotide 43 to nucleotide 198;

(c) the nucleotide sequence of SEQ ID NO: 103 from nucleotide 85 to nucleotide 198;

(d) the nucleotide sequence of the full-length protein coding sequence of clone vc71_l deposited with the ATCC under accession number PTA-1075;

(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vc71_l deposited with the ATCC under accession number PTA-1075;

(f) the nucleotide sequence of a mature protein coding sequence of clone vc71_l deposited with the ATCC under accession number PTA-1075;

(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vc71_l deposited with the ATCC under accession number PTA-1075;

(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO: 104;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 104, the fragment comprising eight contiguous amino acids of SEQ ID NO: 104;

(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one ofthe polynucleotides specified by (a)-(g); and (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one ofthe polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NOJ 03.

113. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO: 104;

(b) a fragment of the amino acid sequence of SEQ ID NO: 104, the fragment comprising eight contiguous amino acids of SEQ ID NOJ04; and

(c) the amino acid sequence encoded by the cDNA insert of clone vc71_l deposited with the ATCC under accession number PTA-1075; the protein being substantially free from other mammalian proteins.

114. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO: 105;

(b) the nucleotide sequence ofSEQ IDNOJ05 from nucleotide 260 to nucleotide 1552;

(c) the nucleotide sequence of SEQ ID NO: 105 from nucleotide 335 to nucleotide 1552;

(d) the nucleotide sequence of the full-length protein coding sequence of clone vo27_l deposited with the ATCC under accession number PTA-1075;

(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vo27_l deposited with the ATCC under accession number PTA-1075;

(f) the nucleotide sequence of a mature protein coding sequence of clone vo27_l deposited with the ATCC under accession number PTA-1075;

(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vo27_l deposited with the ATCC under accession number PTA-1075; (h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO: 106;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 106, the fragment comprising eight contiguous amino acids of SEQ ID NO: 106;

(k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one ofthe polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO: 105.

115. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO: 106;

(b) a fragment of the amino acid sequence of SEQ ID NO: 106, the fragment comprising eight contiguous amino acids of SEQ ID NO: 106; and

(c) the amino acid sequence encoded by the cDNA insert of clone vo27_l deposited with the ATCC under accession number PTA-1075; the protein being substantially free from other mammalian proteins.

116. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO: 107;

(b) the nucleotide sequence of SEQ ID NO: 107 from nucleotide 15 to nucleotide 320;

(c) the nucleotide sequence of SEQ ID NO: 107 from nucleotide 72 to nucleotide 320;

(d) the nucleotide sequence of the full-length protein coding sequence of clone vo31_l deposited with the ATCC under accession number PTA-1075; (e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vo31_J deposited with the ATCC under accession number PTA-1075;

(f) the nucleotide sequence of a mature protein coding sequence of clone vo31_l deposited with the ATCC under accession number PTA-1075;

(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vo31_1 deposited with the ATCC under accession number PTA-1075;

(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO: 108;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 108, the fragment comprising eight contiguous amino acids of SEQ ID NO: 108;

(k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one ofthe polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO: 107.

117. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO: 108;

(b) a fragment of the amino acid sequence of SEQ ID NO: 108, the fragment comprising eight contiguous amino acids of SEQ ID NO: 108; and

(c) the amino acid sequence encoded by the cDNA insert of clone vo31_l deposited with the ATCC under accession number PTA-1075; the protein being substantially free from other mammalian proteins.

118. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of: (a) the nucleotide sequence of SEQ ID NO: 109;

(b) the nucleotide sequence of SEQ ID NO: 109 from nucleotide 38 to nucleotide 1255;

(c) the nucleotide sequence of SEQ ID NO: 109 from nucleotide 86 to nucleotide 1255;

(d) the nucleotide sequence of the full-length protein coding sequence of clone vo32_l deposited with the ATCC under accession number PTA-1075;

(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vo32_l deposited with the ATCC under accession number PTA-1075;

(f) the nucleotide sequence of a mature protein coding sequence of clone vo32_l deposited with the ATCC under accession number PTA-1075;

(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vo32_l deposited with the ATCC under accession number PTA-1075;

(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO: 110;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 110, the fragment comprising eight contiguous amino acids of SEQ ID NO: 110;

(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or4X SSC at 42 degrees C with 50% formamide, to any one ofthe polynucleotides specified by (a)-(g); and

(k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one ofthe polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO: 109.

119. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO: 110; (b) a fragment of the amino acid sequence of SEQ ID NO: 110, the fragment comprising eight contiguous amino acids of SEQ ID NOJ 10; and

(c) the amino acid sequence encoded by the cDNA insert of clone vo32_l deposited with the ATCC under accession number PTA-1075; the protein being substantially free from other mammalian proteins.

120. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO: 111;

(b) the nucleotide sequence of SEQ ID NO: 111 from nucleotide 80 to nucleotide 1276;

(c) the nucleotide sequence of SEQ ID NO: 111 from nucleotide 131 to nucleotide 1276;

(d) the nucleotide sequence of the full-length protein coding sequence of clone vo33_l deposited with the ATCC under accession number PTA-1075;

(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vo33_l deposited with the ATCC under accession number PTA- 1075;

(f) the nucleotide sequence of a mature protein coding sequence of clone vo33_l deposited with the ATCC under accession number PTA-1075;

(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vo33_l deposited with the ATCC under accession number PTA-1075;

(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO: 112;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 112, the fragment comprising eight contiguous amino acids of SEQ ID NO: 112;

(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one ofthe polynucleotides specified by (a)-(g); and (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one ofthe polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO: 111.

121. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO: 112;

(b) a fragment of the amino acid sequence of SEQ ID NO: 112, the fragment comprising eight contiguous amino acids of SEQ ID NO: 112; and

(c) the amino acid sequence encoded by the cDNA insert of clone vo33_l deposited with the ATCC under accession number PTA-1075; the protein being substantially free from other mammalian proteins.

122. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO: 113;

(b) the nucleotide sequence of SEQ ID NO: 113 from nucleotide 202 to nucleotide 429;

(c) the nucleotide sequence of SEQ ID NO : 113 from nucleotide 292 to nucleotide 429;

(d) the nucleotide sequence of the full-length protein coding sequence of clone vq23_l deposited with the ATCC under accession number PTA-1075;

(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vq23_l deposited with the ATCC under accession number PTA-1075;

(f) the nucleotide sequence of a mature protein coding sequence of clone vq23_l deposited with the ATCC under accession number PTA-1075;

(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vq23_l deposited with the ATCC under accession number PTA-1075; (h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NOJ 14;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 114, the fragment comprising eight contiguous amino acids of SEQ ID NO: 114;

(k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one ofthe polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO: 113.

123. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO: 114;

(b) a fragment of the amino acid sequence of SEQ ID NO: 114, the fragment comprising eight contiguous amino acids of SEQ ID NOJ 14; and

(c) the amino acid sequence encoded by the cDNA insert of clone vq23_l deposited with the ATCC under accession number PTA-1075; the protein being substantially free from other mammalian proteins.

124. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO: 115;

(b) the nucleotide sequence of SEQ ID NO: 115 from nucleotide 37 to nucleotide 1113;

(c) the nucleotide sequence of SEQ ID NO: 115 from nucleotide 88 to nucleotide 1113;

(d) the nucleotide sequence of the full-length protein coding sequence of clone vq24_l deposited with the ATCC under accession number PTA-1075; (e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vq24_l deposited with the ATCC under accession number PTA-1075;

(f) the nucleotide sequence of a mature protein coding sequence of clone vq24_l deposited with the ATCC under accession number PTA-1075;

(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vq24_l deposited with the ATCC under accession number PTA-1075;

(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO: 116;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 116, the fragment comprising eight contiguous amino acids of SEQ ID NO: 116;

(k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one ofthe polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO: 115.

125. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO: 116;

(b) a fragment of the amino acid sequence of SEQ ID NOJ 16, the fragment comprising eight contiguous amino acids of SEQ ID NO: 116; and

(c) the amino acid sequence encoded by the cDNA insert of clone vq24_l deposited with the ATCC under accession number PTA-1075; the protein being substantially free from other mammalian proteins.

126. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of: (a) the nucleotide sequence of SEQ ID NO: 117;

(b) the nucleotide sequence of SEQ ID NO: 117 from nucleotide 40 to nucleotide 207;

(c) the nucleotide sequence of SEQ ID NO: 117 from nucleotide 103 to nucleotide 207;

(d) the nucleotide sequence of the full-length protein coding sequence of clone vq26_l deposited with the ATCC under accession number PTA-1075;

(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vq26_l deposited with the ATCC under accession number PTA- 1075;

(f) the nucleotide sequence of a mature protein coding sequence of clone vq26_l deposited with the ATCC under accession number PTA-1075;

(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vq26_l deposited with the ATCC under accession number PTA-1075;

(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO: 118 ;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 118, the fragment comprising eight contiguous amino acids of SEQ ID NO: 118;

(k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one ofthe polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO: 117.

127. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO: 118; (b) a fragment of the amino acid sequence of SEQ ID NOJ 18, the fragment comprising eight contiguous amino acids of SEQ ID NOJ 18; and

(c) the amino acid sequence encoded by the cDNA insert of clone vq26_l deposited with the ATCC under accession number PTA-1075; the protein being substantially free from other mammalian proteins.